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Airway resident cells like epithelia and fibroblasts function not only as physical 
barriers for tissue integrity, but also regulators of airway pathophysiology. Pulmonary 
diseases such as asthma, chronic obstructive pulmonary disease, acute lung injury and 
respiratory viral infection are associated with airway resident cell activation, 
contributing to airway immunity, inflammation and remodeling.  
 
The present study investigated global protein profilings of normal human bronchial 
epithelial cells (NHBE) and normal human lung fibroblasts (NHLF) stimulated with 
pro-inflammatory cytokines tumor necrosis factor (TNF)-a and/or interferon (IFN)-g. 
Total proteins from cell lysates and culture media were separated by two-dimensional 
gel electrophoresis (2-DE), and differentially expressed proteins were identified by 
matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass 
spectrometry (MS) and MS/MS.  
 
TNF-a was found for the first time to alter the expression levels of myxovirus 
resistance protein A (MxA), interferon-stimulated gene (ISG)-15, plasminogen 
activator inhibitor (PAI)-2, lysyl hydroxylase 2 (isoform a) and prolyl 4-hydroxylase 
(a subunit) in human lung fibroblasts. In particular, dendritic cell-derived 
IFN-g-induced protein (DCIP) was up-regulated by TNF-a in lung fibroblasts, and its 
biological function is at present unknown. In addition, we found that TNF-a-induced 
DCIP expression is dependent on the transcription factor interferon regulatory factor 
 ix 
(IRF)-1. DCIP-selective antisense oligodeoxynucleotide (ASO) inhibited the 
expression of TNF-a-responsive gene targets including VCAM-1, ICAM-1, IL-6, 
IL-8, IP-10 and thymic stromal lymphopoietin. Lastly, in a LPS-induced and an 
influenza A virus-infected lung injury mouse model, DCIP mRNA level was elevated 
together with that of TNF-a.  
 
NHBE cells treated with either TNF-a or IFN-g alone did not show any significant 
cell loss even after 72 h. To our surprise, IFN-g showed more substantial effects on 
the proteome alteration of NHBE cells as compared with TNF-a. Several proteins 
were identified for the first time to be altered by IFN-g in NHBE cells in our 
proteomics study, which include metastasis suppressor N-myc downstream-regulated 
gene-1 (NDRG-1), serine protease inhibitor, clade B, member 1 (SERPINB1), 
cytoskeleton protein keratin10, tropomyosin 3 isoform 2 and g-actin. Interestingly, 
apolipoprotein L2 (apoL2) was found for the first time ever to be up-regulated by 
IFN-g in epithelial cells. In addition, we found almost the whole apoL family 
members except apoL5 were dramatically up-regulated by IFN-g using RT-PCR 
analysis. Furthermore, bronchial epithelial cell number significantly decreased in 
response to TNF-a or IFN-g, respectively, only when the cells were pretreated with 
apoL2 siRNA, but not apoL1, 3 or 4 siRNAs. Lastly, we verified the increased mRNA 
expressions of mouse apoL2, 3 and 6, SERPINB1a, NDRG-1, WARS and tapasin in 
an influenza A virus-infected mouse lung injury model. 
 
 x 
In summary, these studies not only reveal that proteomics is an efficient way to study 
the underlying molecular mechanisms after cytokine stimulation, but also demonstrate 
for the first time that DCIP is up-regulated by TNF-a and mediates TNF-a 
stimulation of human lung fibroblasts; and apoL2 is stimulated by IFN-g, which in 
turn affects TNF-a or IFN-g regulation of human bronchial epithelial cell 
proliferation, leading to airway immunity, inflammation and remodeling. 
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The upper and lower airways of the lungs represent the largest area of epithelial 
surface exposed to the outside environment. The inspired air is an indispensable 
source of oxygen, but gas exchange also introduces a great deal of polluted particles, 
toxic gases, microorganisms (e.g. bacteria and viruses), allergens, and so on, which 
can damage the respiratory system. The upper airways can provide the respiratory 
system the first defense with their anatomical barriers, together with cough reflex and 
mucociliary apparatus, which prevent the inspired particles and pathogens from 
entering distal respiratory units. However, this kind of mechanical defense is not 
always effective enough in filtering out all potential pathogens. Therefore, the airways 
are under constant surveillance by the pulmonary immune system. 
 
1.1. Lung Structural Cells in Pulmonary Immune Response 
Epithelium and the subepithelial fibroblast are the main structural cells that secrete 
extracellular matrix (ECM) components for the maintenance of tissue integrity. 
Traditionally, airway epithelium and fibroblast are considered as physical barriers 
between the external environment and the inner tissues of the lung. However, the 
repertoire of mediators that they can produce, both basally and upon stimulation, 
indicates that besides being physical barriers, they also play a central role in 
modulating pulmonary immune processes (Knight and Holgate, 2003).  
 
First of all, the epithelial barrier represents a critical line of defense against the 
environment, so airway epithelial cells are likely designed to be refractory to a 
 3 
number of potential apoptotic stimuli, including pro-inflammatory cytokine interferon 
(IFN)-g, which is highly induced under viral infection, and cell death receptor 
activators such as tumor necrosis factor (TNF)-a and Fas ligand during bacterial 
infection. Many studies have shown that T lymphocytes, neutrophils, and eosinophils 
undergo cell death in massive numbers within 3-6 h after stimulation with death 
agonists (Tong et al., 2006; Uller et al., 2005). However, only 5-15% of airway 
epithelial cells undergo cell death even after 24 h exposure to cell death agonists 
(Nakamura et al., 2004; Shi, et al., 2002; Trautmann et al., 2002), suggesting the 
epithelial cells have developed some mechanisms to pretect them from death. The 
relative resistance of airway epithelial cells to apoptosis is likely helpful to maintain 
the integrity of epithelial barrier when immune cells secrete detrimental mediators 
into the airways which are intended for eliminating the invading agents. This 
characteristics may be the inherent properties of the airway epithelium, which is a 
stable mucosal surface with relatively low rates of cell proliferation under normal 
conditions (Tesfaigzi, 2006).  
 
In addition, airway epithelium is potentially exposed to a diverse array of non-specific 
triggers like respiratory viruses and pollutants. It has been shown that the activation of 
signal transducer and activator of transcription (STAT)-1 pathway, often by IFN-g, 
leads to the synthesis of nitric oxide (NO), a pivotal anti-viral immune defense in the 
bronchial epithelium (Xu, et al., 2006). Reduced activation of STAT-1 signaling and 
impaired airway epithelial nitric oxide synthase (NOS)-2 have been reported in the 
airway epithelial cells of cystic fibrosis (CF) patients, who are more susceptible to 
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respiratory viral infection (Zheng et al., 2004; Xu, et al., 2006).  
 
Until recently, fibroblasts have been considered as important sentinel cells in immune 
system (Buckley et al., 2001). Located just below bronchial epithelial cells, airway 
fibroblasts are also the initial sites of entry for many respiratory pathogens such as 
viruses. In response to reovirus and influenza virus, these cells generate abundant type 
I interferon, mainly IFN-b (Hamamdzic et al., 2001), which further induces the 
anti-viral factors such as interferon stimulated gene 15 (ISG15) (Ritchie et al., 2004), 
and myxovirus resistance protein A (MxA) (Rautsi et al., 2007; Holzinger et al., 
2007). In addition, airway resident cells respond to inhaled substances by increasing 
the production of reactive oxygen species (ROS), which are important in many 
physiological processes but can also have detrimental effects on airway cells and 
tissues when produced in high quantities or during the absence of sufficient amounts 
of anti-oxidants (Henricks and Nijkamp, 2001). Airway epithelial cells and fibroblasts 
are important sources of anti-oxidants like manganese superoxide dismutase (MnSOD) 
(Kiningham et al., 2001; Rogers et al., 2001), which is impaired in some pulmonary 
diseases suffering from severe oxidative stress such as asthma (Comhair et al., 2005). 
 
1.2. Lung Structural Cells in Airway Inflammation 
Inappropriate activation of immune system often leads to inflammation. The five 
ancient signs of inflammation are redness (rubor), swelling (tumour), heat (calor), 
pain (dolor) and deranged function (functio laesa) (Lucignani, 2007). These clinical 
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signs of inflammation are the macroscopic manifestation of thousands of molecular 
and cellular processes, many of which have been well defined and demonstrated 
experimentally.  
 
Pulmonary inflammatory responses differ depending not only on the type but also on 
the phase of inflammation. Neutrophils are normally prevalent in acute inflammatory 
responses like bacterium or virus-induced acute lung injury (Abraham, 2003); 
whereas mononuclear cells (e.g. macrophages and lymphocytes) represent the main 
infiltrating cells in subacute and chronic phase of the majority of inflammatory 
reactions such as late phase of influenza virus infection and chronic obstructive 
pulmonary disease (COPD) (Bruder et al., 2006; O'Donnell et al., 2006). Eosinophils, 
mast cells and CD4+ T cells are predominant when inflammation is initiated by an 
allergic reaction like asthma, while neutrophils markedly increase as asthma develops 
into a more severe type (Tillie-Leblond et al., 2005). In addition to inflammatory cells, 
abundant evidence has shown that airway resident cells are not passive, but rather, 
they actively participate in airway inflammation through several mechanisms 
(Laberge and El Bassam, 2004). The potential contribution of two major airway 
resident cells, bronchial epithelial cells and lung fibroblasts, to the inflammatory 
events will be reviewed and discussed. 
 
1.2.1. Bronchial Epithelial Cells 
Upon pro-inflammatory cytokine such as TNF-a and IFN-g stimulation, airway 
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epithelial cells recruit inflammatory cells by up-regulating cellular adhesion 
molecules such as vascular cell adhesion molecule-1 (VCAM-1), intracellular 
adhesion molecule-1 (ICAM-1), E-selectin (Paludan, 2000) and homing-associated 
cell adhesion molecule (H-CAM/CD44) (Leir et al., 2003), and releasing various 
chemo-attractants such as monocyte chemoattractant protein (MCP)-1, IL-8 (Cerri et 
al., 2006; Liu et al., 2007), eotaxins (Komiya et al., 2003), RANTES (regulated upon 
activation, normal T cell expressed and secreted) (Chan et al., 2005). Thymus and 
activation-regulated chemokine (TARC/CCL17) and macrophage-derived chemokine 
(MDC/CCL22), two recently described ligands for chemokine receptor CCR4 on T 
cells, have been found markedly up-regulated following allergen provocation 
(D’Ambrosio et al., 2001). T-helper 1 (Th1) cytokine TNF-a and IFN-g, in 
combination with Th2 cytokine IL-4 and IL-13, up-regulate both TARC and MDC 
production in airway epithelial cell lines (Sekiya et al., 2000; Lezcano-Meza et al., 
2003). Another molecule which is a mammalian homologue of an enzyme associated 
with parasitic infection in lower organisms, named acidic mammalian chitinase 
(AMCase) has been interestingly identified to be up-regulated in Th2-mediated 
pulmonary inflammation like asthma. Airway epithelial cells are one of the major 
sources of AMCase expression. AMCase is induced via IL-13-mediated pathway in 
epithelial cells. AMCase neutralization ameliorates Th2 inflammation, partially by 
inhibiting IL-13-induced chemokine induction. (Zhu et al., 2004). These studies show 
that chemokine production by airway epithelial cells is intricately regulated by the 
balance of Th1/Th2 cytokines and other mediators. 
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A recently identified epithelial cell-derived cytokine, human thymic stromal 
lymphopoietin (TSLP), can induce the production of Th2-attracting chemokines 
TARC and MDC from CD11c+ dendritic cells (DCs) (Soumelis et al., 2002). These 
chemokines further activate the differentiation of naïve CD4+ and CD8+ T cells into 
effector cells with pro-allergic phenotype, releasing cytokine IL-4, IL-5, IL-13 and 
TNF-a while concurrently diminishing production of IL-10 and IFN-g (Soumelis et 
al., 2002). Th1 cytokine IL-1b and TNF-a are also capable of inducing rapid TSLP 
production in primary human bronchial epithelial cells (Lee and Ziegler, 2007). 
Further analysis has shown that TSLP-induced Th2 differentiation is dependent on 
STAT6, and that TSLP leads to immediate and direct IL-4 gene transcription, 
suggesting TSLP is directly involved in Th2-mediated responses via the induction of 
IL-4 production (Omori and Ziegler, 2007).  
 
In summary, epithelial cells are capable of producing a variety of chemokines and 
cytokines upon stimulation, forming a complex network regulating immune and 
inflammatory responses. They also express adhesion molecules that can interact 
directly with inflammatory cells, favoring their transmigration into the airway lumen. 
 
1.2.2. Lung Fibroblasts 
Similar to bronchial epithelial cells, upon stimulation with pro-inflammatory 
cytokines such as TNF-a and IFN-g, lung fibroblasts up-regulate adhesion molecule 
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VCAM-1 and ICAM-1 expression (Sabatini et al., 2002), and release various 
chemokines like RANTES, eotaxin, MCPs, IL-8 and so on (Letuve et al., 2006; 
O’Kane et al., 2007), favoring the infiltratoin of inflammatory cells into the airways. 
Moreover, airway fibroblasts also produce inflammatory cytokines such as TNF-a, 
IL-1b, GM-CSF and IL-6, and inflammatory mediators like cysteinyl-leukotrienes 
and its receptors, which amplify inflammatory responses (Molet et al., 2001; James et 
al., 2006). The inflammatory activities of fibroblasts are widely regulated by various 
cytokines and growth factors. Th2 cytokine IL-13 and pro-fibrotic growth factor 
transforming growth factor (TGF)-b synergistically increase eotaxin-1 production in 
human airway fibroblasts (Wenzel et al., 2002). Another Th2 cytokine IL-4 also 
synergize with TNF-a to increase the production of eotaxin by lung fibroblasts, 
mediated by the mRNA-stabilizing protein HuR (Atasoy et al., 2003). IL-17E is a new 
Th2 cytokine that promotes airway eosinophilia in mice. Human primary lung 
fibroblasts constitutively express IL-17B receptor, a receptor for IL-17E, whose 
mRNA levels are increased in cells stimulated with TNF-a (Letuve et al., 2006). 
Human primary bronchial fibroblasts also express proteinase-activated receptors 
(PARs), which belong to a novel family of G-protein-coupled receptors. PAR2-driven 
up-regulation of VCAM-1 cell surface expression and the release of IL-8 and 
granulocyte colony-stimulating factor (G-CSF) from bronchial fibroblasts may be 
important in promoting neutrophilic airways inflammation (Ramachandran et al., 
2006). In addition to cytokine and growth factor, cigarette smoke water extract also 
significantly stimulates CXC chemokine IL-8 production by primary human lung 
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fibroblasts (Li et al., 2007). Taken together, these findings provide compelling 
evidence that fibroblasts can be actively involved in immune responses and play 
important roles in inflammatory reactions upon activation by kinds of stimulus. 
Therefore, tissue fibroblasts could be an important target for future anti-inflammatory 
therapy (Buckley et al., 2001). 
 
1.3. Lung Structrual Cells in Airway Tissue Repair 
In pulmonary diseases with chronic inflammation such as asthma, COPD, CF and 
interstitial lung diseases, in addition to the recruitment and activation of inflammatory 
cells, extensive changes to the airways with shedding of the epithelial cells and 
thickening of the lamina reticularis with increased number of mesenchymal cells such 
as fibroblasts and myofibroblasts, have been identified. A lot of evidence indicates 
that airway epithelial cells and fibroblasts are the two major cell types that appear to 
be involved in the processes leading to tissue repair after injury. 
 
Airway epithelial cells and fibroblasts are major sources of ECM components in the 
lung. Upon stimulation by various growth factors and cytokines, increased ECM 
molecules such as collagen I, III and V (Chakir et al., 2003), laminin, fibronectin, 
glycoproteins such as tenascin and vitronectin (Nakamura et al., 2004; Takayama et 
al., 2006) and glycosoaminoglycan like hyaluronan (Wilkinson et al., 2004) are 
released by activated airway epithelial cells and fibroblasts, which paves a way for 
wound healing to occur. 
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Matrix metalloproteinases (MMPs) were first recognized for their ability to degrade 
many ECM proteins, including collagens, fibronectin, laminin, proteoglycans and 
glycoproteins. Their inhibitors, named tissue-specific inhibitors of metalloproteinases 
(TIMPs) are another family of proteins which modulate MMPs activity in a 1:1 
stoichiometric binding fashion. Altered expression profiles of both families of MMPs 
and TIMPs have been reported in asthma (Cataldo et al., 2004; Matsumoto et al., 2005; 
Lee et al., 2006). Airway epithelial and mesenchymal cells regulate the levels of 
MMPs, TIMPs and their ratios in response to various external stimuli (Warner et al., 
2004; Ishida et al., 2006; Boucherat et al., 2007). Interestingly, collagen could also 
modulate MMPs activity as well (Henderson et al., 2007). These findings suggest a 
complex and mutual regulatory system between ECM components, MMPs and TIMPs, 
which may be responsible for the degradation or deposition of ECM components, 
leading to tissue repair. 
 
In addition to directly secreting ECM proteins, airway epithelial cells and fibroblasts also 
produce a variety of fibrogenic growth factors, such as TGF-b, epidermal growth factor 
(EGF), and platelet-derived growth factor (PDGF), among which TGF-b is a central 
mediator to initiate and control tissue repair. TGF-b is mainly released from activated 
epithelial cells and promotes fibroblast proliferation by interacting with its receptors on 
these cells (Perng et al., 2006; Sugiura et al., 2007). It has been demonstrated that TGF-b 
induces epithelial-mesenchymal transition (EMT) in airway epithelial cells in vitro and in 
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vivo, serving as a source of fibroblasts during lung fibrosis (Willis and Borok, 2007). 
TGF-b also induces the transformation of fibroblasts into myofibroblasts which are 
characterized by a marked expression of a-smooth muscle actin (a-SMA) (Hu et al., 
2006). Myofibroblast is generally viewed as a transient cell type, activated upon 
connective tissue injury, and play a major role in fibrotic diseases by secreting ECM 
molecules, and expressing MMPs and TIMPs (Postma and Timens, 2006; Makinde et al., 
2007). On the other hand, Th1 cytokine TNF-a has also been shown in airway 
remodeling by promoting the production of collagen, fibronectin and hyaluronan (Hetzel 
et al., 2005; Wilkinson et al., 2004), and expressing MMP-1, MMP-3 and MMP-9, and 
tenascin by airway structural cells (Fang et al., 2004; Nakamura et al., 2004). In 
comparison, the other Th1 cytokine IFN-g has been implicated in preventing the 
generation of myofibroblasts and can also moderately inhibit the production of a-SMA in 
TGF-b-induced myofibroblasts (Tanaka et al., 2003). 
 
It is recently proposed that airway remodeling process is a reactivation of the 
epithelial-mesenchymal trophic unit (EMTU), which is so named because of its 
pivotal function in fetal lung development where the release of complex soluble 
mediators such as TGF-b, EGF, PDGFs, MMPs and TIMPs by epithelial cells and 
fibroblasts is crucial at different times of airway growth and branching (Knight et al., 
2004; Araya et al., 2006) (Figure 1). However, it is not clear yet whether airway 
remodeling is a normal response to external danger signals, or alternatively, it is due 

















Figure 1. Model of epithelial-mesenchymal trophic unit in airway. Susceptibility 
to environmental oxidants causes epithelial damage which triggers a normal 
injury–repair response involving release of mediators that promote inflammation and 
tissue repair (which involves transient remodelling responses). However, the release 
of endogenous oxidants by inflammatory cells causes further injury to the susceptible 
epithelium, resulting in a chronic state of tissue damage which maintains the 
appropriate environment for persistent inflammation and tissue remodeling (Davies 
and Holgate, 2002).  
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1.4. Tumor Necrosis Factor (TNF)-a 
TNF belongs to the TNF ligand family, which consists of 18 genes that encodes 20 
type II transmembrane proteins characterized by a trimeric domain, which is sequence 
specific for individual members and responsible for their receptor binding (Bodmer et 
al., 2002). TNF exists in two forms: TNF-a and TNF-b. Human TNF-b is a relatively 
larger molecule of 22 kDa with 205 amino acid as compared with human TNF-a (17 
kDa, 157 amino acid). In general, TNF-a and TNF-b share considerable homology in 
biologic activities, but TNF-b is not as abundant as TNF-a, less potent, and produced 
predominantly by T cells (Aggarwal, 1992). 
 
TNF-a is produced from a precursor protein by TNF-a-converting enzyme (TACE) 
or TNF-a-converting activity. TACE is also known as a disintegrin and 
metalloprotease (ADAM) 17, which is responsible for cleaving the 26 kDa 
transmembrane TNF-a to the 17 kDa soluble bioactive cytokine. After detaching 
from cell membrane, soluble TNF-a molecules aggregate into trimolecular complexes 
that subsequently bind to TNF receptors (Cerretti, 1999). TACE also cleaves the 
extracellular domain of its cognate receptor, forming soluble TNF-a receptors 
(sTNFRs) (Canault et al., 2006). The shed sTNFRs are released into the extracellular 
space, where they are free to bind to active TNF-a molecules, preventing TNF-a 




1.4.1. Cellular sources of TNF-a 
The principal source of TNF-a are activated macrophages, although other cells 
including mast cells, CD4+ T cells, eosinophils, neutrophils, smooth muscle cells, 
fibroblasts, epithelial cells and endothelial cells have also been shown to secrete 
TNF-a. Among the most potent stimuli for the production of TNF-a are 
lipopolysaccharide (LPS); however, all potentially noxious stimuli, ranging from 
physical, chemical, to immunologic, can rapidly induce TNF-a production and release 
(Mukhopadhyay et al., 2006). 
 
1.4.2. TNF-a receptors 
TNF-a works by binding to two related receptors designated as TNF receptor 1 
(TNFR1, p55, CD120a, or TNFR superfamily member 1A) and TNFR2 (p75, 
CD120b, TNFR superfamily member 1B). The TNFR1 is expressed on cells that are 
susceptible to the cytotoxic action of TNF, whereas TNFR2 is expressed restrictively 
on stimulated B cells and T cells (Thomas, 2001). The cytoplasmic domain of TNFRs 
contains a so-called death domain (DD), which is present on a number of related 
molecules that are primarily involved in signaling for cell death (Cottin et al., 2002). 
 
1.4.3. TNF-a cellular signaling 
Most of the biological functions induced by TNF-a are mediated via TNFR1 (Chen 
and Goeddel, 2002). The binding of TNF-a to TNFR1 results in the activation of 
intracellular signaling pathways that lead to a wide range of cellular responses, 
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including differentiation, activation, release of pro-inflammatory mediators, and 
apoptosis (Hehlgans and Pfeffer, 2005). TNFR1 possesses sequences that are capable 
of binding intracellular adaptor proteins which link TNF receptor stimulation to the 
activation of intracellular signaling cascades. Upon stimulation, TNFR1 binds to an 
adaptor protein named TNF receptor-associated death domain (TRADD) via its DD 
sequence, which further recruits its downstream adaptor molecules Fas-associated 
death domain (FADD), TNF receptor-associated factor 2 (TRAF2) and receptor 
interacting protein (RIP). FADD contains a death effector domain (DED), which 
interacts with the DED sequence in a few cell death regulating molecules such as 
caspase-8 and caspase-3, initiating a protease cascade that leads to apoptosis (Sheikh 
and Huang, 2003).  
 
NF-kB is a critical transcription factor to control the induction of pro-inflammatory 
mediator genes. TNF-a is well documented as a potent stimulus for NF-kB activation. 
In the resting cells, NF-kB are retained in a complex, associated with its inhibitor IkB 
within the cytoplasm. The activation of TNF receptor results in recruitment of TRAF2, 
which activates NF-kB-inducing kinase (NIK). NIK phosphorylates IkB kinase (IKK), 
which further phosphorylates IkB. The phosphorylated IkB undergoes structural 
transformation and frees the bound NF-kB, which is then translocated from cytoplasm 




Regulation of protein phosphorylation by kinase and dephosphorylation by 
phosphatase is very important for signaling transduction. TNF-a is able to activate 
mitogen-activated protein kinase kinase kinase (MAPKKK), such as extracellular 
signal-regulated kinase kinase kinase 1 (MEKK1) or apoptosis-stimulated kinase 1 
(ASK1). These two kinases phosphorylate MKK-7, which further activates MAPK 
family member p38 MAPK and c-Jun N-terminal kinase (JNK), leading to the 
activation of transcription factor activator protein (AP)-1 (Wadgaonkar et al., 2004; 
Zhao et al., 2007). The activation of MAPK family can be achieved by TNF receptor 
interaction with factor associated with neutral sphingomylinase (SMase) activation 
(FAN) adaptor protein (Malagarie-Cazenave et al., 2004). FAN is responsible for 
neutral SMase-mediated generation of ceramide-containing sphingolipids, which are 
capable of activating ceramide-activated protein kinase (CAPK), an upstream 
















Figure 2. Major signaling pathways by TNF-a. Upon contact with its ligand, TNF 
receptor enables the adaptor protein TRADD to bind to the death domain, serving as a 
platform for subsequent protein binding. Following TRADD binding, three pathways 
can be initiated: (A) Induction of death signaling: TRADD binds FADD, which then 
recruits the cysteine protease caspase-8. A high concentration of caspase-8 induces its 
autoproteolytic activation and subsequent cleaving of effector caspases like caspase-3, 
leading to cell apoptosis. (B) Activation of NF-kB: TRADD recruits TRAF2 and RIP, 
which activate NIK. NIK phosphorylates IKK, which further phosphorylates IkB. The 
phosphorylated IkB undergoes structural transformation and frees the bound NF-kB. 
NF-kB is a heterodimeric transcription factor that translocates to the nucleus and 
mediates the transcription of a vast array of proteins involved in cell survival and 
proliferation, inflammatory response, and anti-apoptotic factors. (C) Activation of the 
MAPK pathways: Of the three major MAPK cascades, TNF-a induces a strong 
activation of the stress-related JNK group and a moderate response of the p38-MAPK. 
TRAF2 activates the JNK-inducing upstream kinases of MEKK1 and ASK1, and 
these two kinases phosphorylate MKK7, which then activates JNK. JNK translocates 
to the nucleus and activates transcription factors such as AP-1. The JNK pathway is 
involved in cell differentiation, proliferation, and is generally pro-apoptotic (Wajant et 
al., 2003).  
NIK 
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In addition, TNF-a could also induce signaling enzymes such as cytosolic 
phospholipase A2 (cPLA2), which is responsible for intracellular arachidonic acid 
metabolism, further generating eicosanoids and reactive oxygen species (ROS) 
(Kitatani et al., 2004). Other phospholipases stimulated by TNF-a include PLC and 
PLD, which are responsible for protein kinase C (PKC) isoform activation and 
phosphatidic acid generation, subsequently activating the downstream signaling 
molecules such as ras, raf, MEK, MAPK and NF-kB (MacEwan, 2002).  
 
1.4.4. Role of TNF-a in pulmonary pathophysiology 
It is well-established that TNF-a and its soluble receptors play critical roles in the 
pathogenic mechanisms of almost all inflammatory responses, particularly in 
pulmonary diseases including asthma, chronic bronchitis, COPD, acute lung injury 
and acute respiratory distress syndrome (ARDS) (Bhatia and Moochhala, 2004; 
Howarth et al., 2005; Parsons et al., 2005; Mukhopadhyay et al., 2006; Qiu et al., 
2007). TNF-a stimulates the production of various mediators (eotaxin, RANTES, 
MCP, MIP, IL-8, IL-6, ROS, leukotrienes, etc.) and increases the expression of 
adhesion molecules (E-selectin, VCAM, ICAM, H-CAM, integrins, etc.) by airway 
resident cells, which are involved in the recruitment of inflammatory cells to the 
airways (Sabatini et al., 2002; Letuve et al., 2006; O’Kane et al., 2007). In addition, 
there is evidence that TNF-a has a role in tissue remodeling by promoting 
myofibroblast proliferation and increasing MMPs expression and ECM components 
synthesis (Wilkinson et al., 2004; Hetzel et al., 2005; Fang et al., 2006). 
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1.4.5. TNF-a as a therapeutic target for pulmonary diseases 
Various molecules are available for blocking the effects of TNF-a. The monoclonal 
antibody targeting at TNF-a (infliximab) and the soluble TNF receptor (etanercept) 
are already in clinical use. Other TNF-a-targeting immunobiologic drugs including 
polyethylene glycol-bound p55 TNF receptor (PEG-TNFRI), PEGylated TNF-a 
antibody fragments (CDP-870), fully human anti-TNF-a antibodies D2E7 
(adalizumab), and TACE inhibitors (Lorenz and Kalden, 2002) are in development. 
 
Infliximab has been tested in a bronchial model of post-transplant obliterative 
bronchiolitis (Alho et al., 2003), moderate to severe COPD (van der Vaart et al., 2005; 
Rennard et al., 2007) and asthmatic patients (Erin et al., 2006; Edwards and Polosa, 
2007; Kim and Remick, 2007), with airway inflammation, rate of epithelial loss, 
fibrosis, sputum neutrophils and change in morning peak expiratory flow as endpoints. 
However, it did not show significant benefit in most of the cases. On the other hand, 
the effect of treatment with soluble TNF receptor etanercept has also been evaluated 
in subjects with severe asthma, and it is found that etanercept treatment is associated 
with improvement in asthma symptoms, lung function, and bronchial 
hyperresponsiveness (Howarth et al., 2005; Oliveri and Polosa, 2006). However, it 
has also been shown that anti-TNF-a could cause cases of cancer and high incidence 
of respiratory infections such as pneumonia and tuberculosis (Keane et al., 2001; 
Oliveri and Polosa, 2006; Rennard et al., 2007). Thus it is suggested to be used with 
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much care, and studies on the therapeutic value in asthma should be focused on 
patients with severe debilitating disease only (Krouwels, 2007). 
 
1.5. Interferon-g (IFN-g) 
The IFNs was originally identified as agents that inhibited viral replication. They are 
classified into type I and type II according to receptor specificity and sequence 
homology. The type I IFNs include IFN-a, IFN-b, IFN-w and IFN-t, all of which are 
structurally related and bind to a common hetorodimeric receptor (IFNAR). IFN-g is 
the sole type II IFN. It is structurally unrelated to type I IFNs, and binds to a different 
receptor (Schroder et al., 2004). 
 
1.5.1. Cellular sources of IFN-g 
The only known sources of IFN-g are CD4+, CD8+ T cells and natural killer (NK) 
cells (Schroder et al., 2004). IFN-g production is controlled by cytokines secreted by 
antigen-presenting cells (APCs), most notably IL-12 and IL-18. These cytokines serve 
as a bridge to link infection with IFN-g production in the innate immune response 
(Munder et al., 2001). It is recently reported that IL-15 and IL-7 lower the threshold 
concentrations of IL-12 and IL-18 required for induction of IFN-g by 100-fold in 
human CD8+ T cells, increasing cell sensitivity to pro-inflammatory cytokine 
stimulation (Smeltz, 2007). Negative regulators of IFN-g production include IL-4, 
IL-10, TGF-b, and glucocorticoids (Sen, 2001; Schindler et al., 2001). 
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1.5.2. IFN-g receptor 
IFN-g receptor (IFNR) is a single transmembrane protein, a member of the cytokine 
receptor type II superfamily, which includes two subunits, IFNR1 and IFNR2 
(Schroder et al., 2004). IFNR is widely expressed on nearly all the cell types 
(Schreiber and Farrar, 1993). IFNR lacks intrinsic kinase/phosphatase activity and 
must associate with signaling machinery for signal transduction. The IFNR 
intracellular domain contains binding motifs for Janus tyrosine kinase (JAK) 1 and the 
latent cytosolic factor, STAT1, which are essential for IFN-g intracellular signaling 
transduction (Kotenko and Pestka, 2000). 
 
1.5.3. IFN-g cellular signaling 
JAK-STAT is the primary pathway for IFN-g signal transduction, which involves 
sequential receptor recruitment and activation of members of the JAKs and STATs to 
control transcription of target genes via specific response elements (Kotenko and 
Pestka, 2000). IFN-g binding induces JAK2 autophosphorylation and activation, 
which allows JAK1 transphosphorylation by JAK2. The activated JAK1 
phosphorylates IFNR to form docking sites for STAT1 binding. A pair of STAT1 are 
recruited and phosphorylated by JAK2, inducing dissociation of a STAT1 homodimer, 
which enters the nucleus and binds to DNA at IFN-g-activation site (GAS) element or 
IFN-stimulated response element (ISRE) (Schroder et al., 2004). The early phase of 
IFN-g-induced transcription occurs within minutes, and many of the induced genes 
are in fact transcription factors such as IRF-1, which are activated by IFN-g and are 
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able to mediate secondary IFN-g responses including the up-regulation of major 
histocompatibility complex (MHC)-I and II, expression of the chemokine IP-10, and 
antiviral mechanisms (Bach, 1997). In addition to the classical STAT1-dependent 
signaling pathway, recent microarray studies on STAT1-null cells have shown that 
IFN-g-receptor activates additional signaling pathways and can regulate gene 
expression such as MCP-1, IL-1b, fibronectin, etc. by STAT1-independent pathways 
(Ramana et al., 2002). 
 
A wide range of inflammatory genes including VCAM-1, ICAM-1, IL-6, IL-8, IP-10, 
RANTES, iNOS, etc. are synergistically stimulated by pro-inflammatory agents 
TNF-a/LPS and IFN-g (Paludan, 2000). In recent years, the intracellular mechanism 
leading to these synergistic actions has been proposed and discovered. As described in 
Figure 3, IFN-g induces activation of STAT1, which in turn triggers the production of 
another transcription factor IRF-1. These two proteins are responsible for the 
activation of most IFN-g-induced gene either independently or cooperatively. Because 
IRF-1 is also induced by TNF-a and LPS in some cell types, the cooperation between 
IRF-1 and STAT1 could possibly contribute to some synergistic gene induction. The 
major synergistic effects, however, appears to be the cooperative action between 
STAT1/IRF-1 and NF-kB. The presence of NF-kB binding sites have been identified 
along the functional GAS or ISRE sites among the majority of promoters induced 





















Figure 3. Molecular mechanisms for synergistic gene induction by IFN-g and 
LPS or TNF-a. First of all, NF-kB activated by TNF-a or LPS acts synergistically 
with STAT1 activated by IFN-g. In addition, IFN-g-induced IRF-1 also acts 
cooperatively with NF-kB. Furthermore, LPS and TNF-a synergize with IFN-g in 
IRF-1 induction in some cell types. Lastly, LPS induces phosphorylation of STAT1, 
thus enhancing its trans-activating potential (Adapted from Paludan, 2000).  
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1.5.4. Role of IFN-g in pulmonary pathophysiology 
IFN-g is well-known as a critical antiviral mediator which is central to the elimination 
of viruses. Several IFN-g regulated antiviral mechanisms have been defined and 
described. In mice the most prominent mechanisms include Mx, ribonucleic acid 
nuclease (RNase) L, 2’, 5’-oligoadenylate synthetase (2’-5’ OAS), double-stranded 
(ds) RNA protein kinase (PKR), and NOS (Chesler and Reiss, 2002). For example, 
MxA protein inhibits influenza A and other members of the orthomyxovirus family by 
blocking primary transcription (Pavlovic et al., 1992). The contribution of 
IFN-g-mediated antiviral responses is pathogen-specific due the wide range of DNA 
and RNA virus-host cell replication patterns as well as viral evasion proteins 
involved.  
 
In addition, IFN-g modulates immune responses by affecting cell proliferation, 
differentiation, and apoptosis (Schroder et al., 2004). IFNs were the first human 
proteins to be effective in cancer therapy. IFNs may mediate anti-tumor effects either 
indirectly by immunomodulatory and anti-angiogenic responses or by directly 
affecting proliferation or differentiation of tumor cells (Chawla-Sarkar et al., 2003). 
Airway epithelial cells are normally resistant to pro-apoptotic stimuli like TNF-a and 
Fas ligand, however, they become more fragile in some airway inflammatory diseases 
like asthma (Trautmann et al., 2002). It has been shown that activated T cells and 
eosinophils from healthy and atopic individuals induce airway epithelial cells 
apoptosis, and the cell death is blocked when the activated T cells and eosinophils are 
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preincubated with antibodies to IFN-g and TNF-a. Moreover, the activated 
eosinophils induce airway epithelial cells apoptosis only when the epithelial cells are 
pretreated with IFN-g. And again, normal bronchial epithelial cells only show 
significant cell death in response to FasL when pretreated with IFN-g for 24 h 
(Trautmann et al., 2002; Trautmann et al., 2005; Meiler et al., 2006). These studies 
suggest that IFN-g sensitize airway epithelial cells to TNF-a or FasL-induced cell 
death. However, the mechanisms of this sensitization process are not known.  
 
Interestingly, IFN-g contains both anti-inflammatory and pro-inflammatory effects, 
probably depending on the microenvironment it exists. IFN-g is produced by Th1 cells 
and exerts an inhibitory effect on Th2-cell-induced inflammatory responses. For 
example, IFN-g inhibits late allergic airway responses and eosinophilia in the rats 
(Isogai et al., 2007). More frequently, IFN-g shows potent pro-inflammatory activity. 
It often cooperates with TNF-a in the pathophysiology of a variety of pulmonary 
diseases. They are not only actively involved in virus-infected respiratory diseases 
(Neff-LaFord et al., 2007), severe acute respiratory syndrome (Cameron et al., 2007), 
but also implicated in the pathogenesis of chronic asthma, COPD and 
hypoxia-induced lung injury (Kumar et al., 2004 and 2006; Fujii et al., 2005; Siegle et 
al., 2006; Yamada et al., 2004). The synergistic pro-inflammatory activities of TNF-a 
and IFN-g have been well documented (Paludan, 2000). Upon TNF-a and IFN-g 
stimulation, airway resident cells recruit inflammatory cells by up-regulating cellular 
adhesion molecules like VCAM-1, ICAM-1 and E-selectin, and releasing several 
 26 




The human genome has been successfully sequenced (officially completed on April 
14, 2003). As we are entering the “post-genomic era”, we have been trying to 
characterize all the functional proteins based on the genomic sequences. However, 
functional protein expression is always hard to be directly correlated with genomic 
sequence. Thus the term “proteome” is coined to represent the composition of all 
proteins expressed by the genome of a biological system. The large-scale 
characterization of the entire protein complement is then defined as “proteomics” 
(Wasinger et al., 1995).  
 
As mentioned above, one of the most important tasks of proteomics is to functionally 
annotate the total number of genes in a given genome because it is still difficult to 
predict genes accurately from genomic data due to the exon-intron structure of most 
genes (Eisenberg et al., 2000). The conventional idea of “one gene, one protein” is 
over-simplified because one gene often has more than one protein forms (Gygi et al., 
1999). In addition, bodily fluids such as serum or urine have no mRNA source and 
therefore they cannot be studied by mRNA analysis. Another impotant aspect of 
proteomics which cannot be achieved by genomic study is the simultaneous analysis 
of post-translational modifications such as phosphorylation, oxidation and 
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nitrosylation (Spickett et al., 2006). 
 
The definition of proteomics has changed greatly over time. It was originally 
restricted to describe the large-scale identification of proteins resolved by 
two-dimensional polyacrylamide gel electrophoresis (2-DE). Currently, proteomics 
denotes nearly any type of technology focusing upon protein analysis, ranging from a 
single protein to thousands in one experiment. Proteomics thus has replaced the 
phrase “protein science” (Baak et al., 2005). 
 
A typical proteomics workflow contains the following three steps: (i) separation and 
isolation of proteins from a cell line, tissue, or organism; (ii) acquisition of protein 
structural information for the purposes of protein idenfitication and characterization; 
and (iii) database utilization (Graves and Haystead, 2002). 
 
1.6.1. Separation of proteins 
The protein samples for proteomics analysis are often complex protein mixtures. 
Therefore, it is essential to separate and resolve the protein mixtures into individual 
proteins, which can be analyzed, identified, and further characterized. In spite of 
complementary technologies and promising alternatives that have emerged recently, 
2-DE is still the predominant and most cost-effective technology for protein 
separation until now. 
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1.6.1.1. Two-dimensional gel electrophoresis 
Since 2-DE was first introduced thirty years ago (O'Farrell, 1975), it has become a 
powerful and widely used method for the analysis of complex protein mixtures 
extracted from cells, tissues, or organisms. This technique separates proteins 
according to two independent properties in two discrete steps. The first-dimension 
step, isoelectric focusing (IEF), separates proteins based on their isoelectric points 
(pI); the second-dimension step, sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE), separates proteins based on their molecular weights 
(Mr, relative molecular mass). Depending on the gel size and pH gradient used, 2-DE 
can resolve more than 10,000 proteins simultaneously, and can detect proteins less 
than 1 ng (Wittmann-Liebold et al., 2006). One of the greatest strengths of 2-DE is its 
capability to study proteins that have undergone some forms of post-translational 
modification such as phosphorylation, glycosylation or limited proteolysis, which 
might be located readily in 2-DE gel maps as they may appear as distinct spots in the 
horizontal and/or vertical axis of the 2-DE gel (Kwon et al., 2006). 
 
A number of improvements have been made in 2-DE over the years. One of the 
biggest improvements was the introduction of immobilized pH gradients and 
Immobiline™ reagents (Gorg et al., 1988), which brought superior resolution and 
reproducibility to first-dimension IEF (Gorg et al., 2000; Cargile et al., 2005). Based 
on this concept, carrier-ampholyte-generated pH gradients have been replaced by 
immobilized pH gradients (IPG), and tube gels replaced with gels supported by a 
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plastic backing. Later on, narrow range IPG strips were also introduced with pH 1-3 
unit wide with overlapping pH range (e.g. pH 4.5-5.5, 5-6, 6.2-8.2). A narrow pH 
gradient strip has a relatively higher loading capcity and increased spatial resolution 
(Hoving et al., 2002).  
 
However, there are other drawbacks of the classical 2-DE technique which are related 
to the complexicity of samples, inaccessibility of large or hydrophobic proteins into 
gels, and poor resolution of extremely acidic or basic proteins (Bae et al., 2003; 
Wittmann-Liebold et al., 2006). Pre-fractionation appears to be the logic way to make 
a step in the right direction. In fact, pre-fractionation could be a potent tool for 
“mining below the tip of the iceberg to find low abundance and membrane proteins” 
(Pederson et al., 2003). Electrophoretic pre-fractionation protocols include all those 
electrokinetic methodologies which are performed in free solution, essentially all 
relying on isoelectric focusing steps. The devices include the multi-compartment 
electrolyzer with Immobiline membranes: the Off-Gel electrophoresis in a multicup 
device (Michel et al., 2003 and 2006); the Rotofor, an instrument also based on a 
multi-chamber system but exploiting the conventional technique of 
carrier-ampholyte-focusing (Zhu and Lubman, 2003; Xiao et al., 2004); the Octopus, 
a continuous-flow device for isoelectric focusing (FF-IEF) in an upward flowing 
liquid curtain (Hoffman et al., 2001; Weber et al., 2004); and the Gradiflow, where 
different pI cuts are obtained by a multistep passage through two compartments 
buffered at different pH values (Wasinger et al., 2005). It is felt that this panoply of 
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methods could offer a strong step forward in “mining below the tip of the iceberg” for 
detecting the “unseen proteome” (Righetti et al., 2003 and 2005). 
 
The use of fluorescent dyes has improved the sensitivity of protein detection (Patton, 
2000). An exciting advance in 2-DE, called differential gel electrophoresis (DIGE) 
was developed, which utilizes two different dyes (e.g. Cy3 and Cy5) to label two 
different sets of protein samples (Unlu et al., 1997). The tagged proteins are run on 
the same 2-D gel, and two fluorescent images are created by using fluorescence 
imaging system. The pattern of the two images generated from the same gel is highly 
consistent, which avoids comparing several 2-D gels. This technology offers a method 
for controling system variations, allowing biological changes in protein expression to 
be identified with statistical confidence (Marouga et al., 2005). 
 
In addition, automation of steps after 2-DE, such as gel image analysis, spot picking, 
spot digestion, and target preparation for mass spectrometry, have facilitated the 
protein analysis process and allowed a significant increase in the throughput of 
protein identification and characterization (Righetti et al., 2004).  
 
1.6.1.2. Alternatives to electrophoresis 
The limitations of 2-DE have inspired a number of approaches to bypass the 
conventional protein gel electrophoresis. One approach is to convert an entire protein 
mixture to peptides which is normally digested by trypsin and then purify the peptides 
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using multi-dimensional liquid chromatography and/or capillary electrophoresis 
before subjecting them to analysis by mass spectrometry (MS) (Huang et al., 2006; 
Huck et al., 2006). Combining two or more orthogonal (multimodal) separation 
procedures dramatically improves the overall resolution and results in a large number 
of peptides being identified from complex proteome digests (Issaq et al., 2004). One 
more new concept named molecular scanner has been raised and developed recently. 
This highly flexible and data-rich approach has combined the power of 
electrophoretic protein separation, the simultaneous digestion and transfer of proteins 
through an enzymatic membrane, the immediate use of the matrix assisted laser 
desorption/ionization (MALDI) mass spectrometer to scan a collecting membrane, 
and the development of dedicated bioinformatics tools to perform protein 
identification and molecular imaging of the proteome. Clinical applications of the 
molecular scanner have also started to be developed for disease diagnosis in 
biological material (Binz et al., 2004).  
 
The technique of isotope-coded affinity tags (ICAT) is introduced for relative 
quantitation of protein abundance without the use of electrophoresis (Han et al., 2001). 
In this method, the two samples to be compared are labeled either covalently or 
metabolically with different isotopes (e.g. heavy atom deuterium and light atom 
hydrogen), proteolysed, mixed in equal quantities and analyzed by MS (Patton et al., 
2002; Elrick et al., 2006). Another mass spectrometry-based technique has been 
developed to detect differences in protein abundance between two samples from cell 
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culture, named Stable Isotope Labelling with Amino acids in Cell culture (SILAC) 
(Ong et al., 2002). Two populations of cells are cultivated in cell culture. One of the 
cell populations is fed with growth medium containing normal amino acids (e.g. the 
normal 12C6 form of arginine); whereas the other cell population is cultured in the 
growth medium containing amino acids labeled with stable heavy isotopes (e.g. 13C6 
form of arginine), leading to a difference of six mass units. In this way, two forms of 
each arginine-containing peptides are measured in subsequent MS. The ratio of peak 
intensities in the mass spectrum for such peptide pairs accurately reflects the 
abundance ratio for the two proteins (Ong et al., 2003). SILAC has emerged as a very 
powerful method to study cell signaling and protein-protein interaction (Blagoev et al., 
2003; Olsen et al., 2006).  
  
In recent years, microarrays have rapidly attracted the interest of users, due to their 
high throughput (Lee and Saeed, 2007). In spite of the problems related to 
manufacturing and use of microarray technology for proteins, a variety of interesting 
applications of this technique have been reported, such as analysis of the various 
interactions among proteins, oligonucleotides and oligosaccharides, identification of 
potential substrates for enzyme, and discovery of disease biomarkers (Templin et al., 
2003; Venkatasubbarao, 2004; Merkel et al., 2005; Becker et al., 2006). In protein 
array analysis, a large set of purified proteins or peptides or even an entire proteome is 
spotted and immobilized for screening of a range of biochemical interactions, or 
determining protein abundances in a complex matrix such as serum (Cretich et al., 
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2006). Protein microarray technology is not as straightforward as DNA technology 
due to the complex nature of proteins that can be hydrophobic or hydrophilic, acidic 
or basic. Post-translational modifications further enhance protein molecular variability. 
Moreover, the wide dynamic range of protein concentration in real samples presents 
great challenges for detection strategies. The technical concerns on the design of the 
optimal microarray surface together with improved and straightforward detection 
methods are the key to be the success of microarray experiments and must be 
addressed to maximize the usefulness of protein microarrays in the large-scale study 
of protein interactions (Cretich et al., 2006). 
 
1.6.2. Mass spectrometry 
Edman sequencing, which was used to obtain N-terminal amino acid sequences 
achieved considerable success for routine protein identification in the eighties, but the 
method is relatively slow and insensitive (Sutton et al., 1995). The introduction of the 
soft ionization techniques, MALDI and electrospray ionization (ESI) in the late 
eighties enabled MS to replace Edman sequencing to rapidly become the routine 
method for protein identification (Domon and Aebersold, 2006).  
 
1.6.2.1. Principles of Mass spectrometry 
MS is an analytical technique that measures the molecular weight of molecules based 
upon the motion of a charged particle in an electric or magnetic field. The sample 
molecules are converted into ions in the gas phase and separated according to their 
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mass: charge ratio (m/z). Positively and negatively charged ions can be formed. The 
technique is performed by a mass spectrometer (Figure 4). Basically, protein 
identification by MS can be divided into three stages: (i) in-gel digestion; (ii) sample 
ionization; and (iii) mass analysis.  
 
(i) In-gel digestion. Extraction of a whole protein from gels is inefficient; however, 
if a protein is “in-gel” digested with proteases like trypsin, endoproteinase, 
chymotrypsin, elastase and so on, many of the peptides can be extracted. Because of 
its highly reproducible cleavage on the COOH-terminal side of arginine and lysine 
residues to generate peptides of an appropriate size for efficient MS analysis, trypsin 
is the proteolytic enzyme used most often. In most cases, the peptides recovered 
following in-gel digestion need to be concentrated and purified to remove gel 
contaminants before subjecting to MS (Cramer et al., 2004).  
 
(ii) Sample ionization. For biological samples to be analyzed by MS, the molecules 
must be charged and dry, which is accomplished by converting them to desolvated 
ions. The two most common methods for this are ESI and MALDI, which are called 
“soft” ionization methods because they allow the formation of ions without significant 
loss of sample integrity (Domon and Aebersold, 2006). This is important because it 






















Figure 4. Mass spectrometry technology for proteomics. Two ionization 
techniques are currently used for biomolecules. (A) Electrospray ionization (ESI) is 
used to volatilize and to ionize peptides and proteins from liquid samples. (B) For 
matrix-assisted laser-desorption ionization (MALDI), the analyte is first 
co-crystallized in a surplus of matrix molecules, and then evaporated by a pulsed 
ultraviolet laser. (C) Scheme of a MALDI-time of flight (TOF) instrument. (D) 
Scheme of a MALDI-TOF/TOF instrument (Mocellin et al., 2004). 
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Electrical spray, which comprises charged microdrops, is formed when a high voltage 
is applied to a liquid flowing through a narrow capillary. This process is repeated 
several times until ionizable analytes present in the solution escape from microdrops, 
which are further desolvated in the interphase with the mass spectrometer (Wilm et al., 
1996). A significant improvement in ESI technology occurred with the development 
of nanospray ionization (Chelius et al., 2003). In ESI, peptides often require some 
form of purification after in-gel digestion, and alternatively, electrospray sources can 
be connected in line with liquid chromatography (LC) systems that automatically 
purify and deliver the sample into the mass spectrometer such as reverse-phase LC 
(RPLC) (Gygi et al., 2000). 
 
MALDI remains a valuable alternative ionization technique for peptides and proteins 
and is often used to complement results obtained by ESI-MS. In MALDI, the sample 
is incorporated into matrix molecules and then subjected to irradiation by a laser 
which promotes the formation of ionized analyte, followed by spotting on a metal 
plate. The plate is then placed in the mass spectrometer, and the laser is automatically 
targeted to specific places on the plate. Since sample application can be performed by 
a robot, the entire process including data collection and analysis can be automated. 
This is the single biggest advantage of MALDI. Another advantage of MALDI over 
ESI is that MALDI is more tolerant to the presence of contaminants such as salts or 
small amount of detergents, so samples can often be used directly without any 
purification after in-gel digestion (Graves and Haystead, 2002). 
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(iii) Ion separation. After the gas phase ions have been produced, they are 
accelerated from the ion source and guided into the region of ion separation or called 
analyzer. This is achieved by resolving the molecular ions in the mass analyzers based 
on their mass and charge in a vacuum. Many types of analyzer exist and the type of 
proteomic application usually determines the type of analyzer used. 
 
A time-of-flight (TOF) analyzer is one of the simplest mass analyzers. It measures the 
m/z ratio of an ion by determining the time required for it to traverse the length of a 
flight tube. Recently a newly developed dual-polarity TOF which comprises two 
identical TOF mass analyzers located symmetrically can simultaneously measure both 
positive and negative ions from one MALDI ion source (Tsai et al., 2006). 
 
Ion trap (IT) mass analyzers function to trap molecular ions in a 3-D electric field. 
The main advantage of an IT mass analyzer is the ability to allow ions to be “stored” 
and then selectively ejected from the ion trap, increasing sensitivity. The IT 
technology is characterized by MS/MS capabilities with high sensitivity and fast data 
acquisition. Recently, the development of linear ion trap (LIT) analyzers with higher 
ion-trapping capacities has expanded the dynamic range and the overall sensitivity of 
this technique (Douglas et al., 2005).  
 
Hybrid quadrupole TOF (Q-Q-TOF) analyzers exhibit high resolution and mass 
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accuracy in both MS and MS/MS mode. MALDI-Q-Q-TOF instrument has recently 
been reported in post-translational modification and structural characterization of 
glycosylation (Bykova et al., 2006). 
 
A TOF/TOF analyzer has recently been coupled with a MALDI ion source generating 
peptide mass fingerprint data and peptide sequence derived by high energy 
collision-induced dissociation (CID). Basically, two TOF analyzers are separated by a 
collision cell, with the first TOF analyzer used for precursor ion selection and the 
second TOF analyzer for the ion resolving (Khatun et al., 2007). The configuration 
allows for high sensitivity and high resolution in both MS and MS/MS modes, and is 
capable of reducing protein identification to a one tier process. 
 
Similar to ion trap, a fourier transform ion cyclotron (FT-ICR) is also capable of 
trapping and storing ions. An FT-ICR is the top performing mass spectrometer in 
terms of resolution and mass accuracy. Very recently, a new type of mass analyzer 
called orbitrap has emerged. It is the first analyzer based on a new physics principle, 
which separates ions in an oscillating electric field (Scigelova and Makarov, 2006; 
Williams et al., 2007). 
 
1.6.2.2. Types of mass spectrometers 
Most mass spectrometers consist of four basic elements: (i) an ionization source; (ii) 
one or more mass analyzers; (iii) an ion mirror; (iv) a detector. The names of the 
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various instruments are derived from the name of ionization source and the type of 
mass analyzer. 
 
There are two modes of operation of a mass spectrometer. Firstly, the MS mode 
where mass are measured and composition inferred; and secondly where the analyte 
ion of interest is specifically selected and fragmented by CID in the mass 
spectrometer, generating structural information. This second technique is termed 
tandem mass spectrometry or MS/MS. Generally, MS/MS analysis is performed 
successively on two types of instrument such as the hybrid quadrupole-TOF where 
analyzers are in series (tandem in space) (Ens and Standing, 2005) or the FT-ICR 
analyzer where ion trapping mechanisms are employed (tandem in time) (Bogdanov 
and Smith, 2005). 
 
MALDI-TOF is frequently used as a first-pass instrument for protein identification 
because it can be completely automated for peptide mass fingerprinting (PMF). If 
proteins cannot be identified by PMF, they can then be analyzed by electrospray and 
MS/MS (Ekstrom et al., 2000). MALDI ion source is also coupled with a Q-Q-TOF 
mass analyzer, which permit both PMF and amino acid sequencing (Bykova et al., 
2006). Triple-quadrupole mass spectrometers are most commonly used to obtain 
amino acid sequences. The first quadrupole may be set to “filter” for an ion of a 
known mass, which is fragmented in the second quatrupole, followed by scanning the 
entire m/z ratio in the third quadrupole, giving information on the sizes of the 
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fragments made (Chernushevich et al., 2001). Thus, the amino acid sequences of the 
original ion can be deduced. In recent years, several “hybrid” mass spectrometers 
have emerged from the combination of different ionization sources with mass 
analyzers. For example, LITs have been combined with TOF and FT-ICR MS 
(Hopfgartner et al., 2004).  
 
A number of recent developments are opening new opportunities for the 
characterization of biomolecules. Alternate fragmentation techniques to CID that are 
based on electron transfer of the ions present in the collision cell have been developed 
to improve peptide sequencing. In particular, electron capture dissociation (ECD) 
(Horn et al., 2000) and electron transfer dissociation (ETD) (Syka et al., 2004) have 
been implemented on FT-ICR and LIT instruments respectively, yielding full amino 
acid coverage and precise identification and localization of modifications (Kelleher, 
2004). 
 
1.6.3. Protein database and protein identification 
MS has become the preferred method of choice for protein identification. The 
development of several software programs and continuous updating of sequence 
databases are crucial to the success of MS in this field. Generally, MS data can be 
used in three approaches for protein identification: (i) PMF - MS mode; (ii) PMF and 
partial sequence information; (iii) amino acid sequence data from one or more peptide 
- MS/MS mode. 
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PMF was originally described in 1993 which comprises protein digestion, 
MALDI-TOF analysis and sequence database search algorithms (Pappin et al., 1993). 
In this method, the masses of peptides obtained from the proteolytic digestion of an 
unknown protein are compared to the predicted masses of peptides from the 
theoretical digestion of proteins in a database. If enough peptides from the real mass 
spectrum and the theoretical one overlap, protein identification can be made. The 
principal advantage of PMF is speed. The analysis and database search can be fully 
automated (Cottrell, 1994). The single biggest disadvantage of PMF is ambiguity in 
protein identification because of peptide mass redundancy. In the database, there are 
many peptides which might have the same theoretical mass (Green et al., 1999). 
Another factor affecting the success of PMF is mass accuracy. The improved mass 
accuracy constrains the database search, reducing the potential for ambiguous protein 
identification (Clauser et al., 1999). Finally, PMF does not work well with protein 
mixtures. Several programs are available to perform this type of search, including 
MASCOT at www.matrix-science.com, ProFound at www.prowl.com, and MS-Fit at 
www.prospector.ucsf.edu.  
 
Supplementing PMF data with some partial sequence is an attractive approach. If the 
two pieces of data can be acquired on the same instrument and the resultant 
information combined in the same search, sample throughput and identification rates 
can be enhanced significantly (Shadforth et al., 2005). The data required for this type 
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of database search can be readily obtained with a MALDI-TOF instrument. PMF and 
sequence information can be used in the same search using the sequence query 
function with the MASCOT search engine.  
 
The most specific type of database searching for protein identification uses peptide 
amino acid sequence which could be obtained by MS/MS. One of the biggest 
advantages of utilizing MS/MS to obtain peptide amino acid sequence is its 
compatibility with protein mixtures, as compared with PMF (Peng and Gygi, 2001). 
The major disadvantage of performing MS/MS is that the process is not easily 
automated. Again a number of search engines can be used to perform this analysis 
including SEQUEST at fields.scripps.edu/sequest/index.html, SONAR at 
www.proteometrics.com, MASCOT and MS-TAG at prospector.ucsf.edu. 
 
Despite the automated searches having overtaken the manual methods as the choice 
for searching product ion MS/MS data, manual peptide sequencing still has to be 
performed, particularly for de novo sequencing (Dancik et al., 1999). However, 
manual peptide sequencing is time-consuming and requires considerable familiarity 
with the interpretation of MS/MS product ion spectra, it is not the first choice for 
peptide identification. If other search methods fail, de novo sequence information can 
be obtained and used to identify the protein. 
 
1.6.4. Application of proteomics 
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The greatest demand for proteomics comes from pharmaceutical research for faster 
new drug protein target identification in transformed cell lines or diseased tissues. The 
validation of the detected targets, in vitro and in vivo toxicology studies, and tests for 
side effects could also be performed with this approach. Clinical researchers want to 
compare normal versus disease samples and disease versus treated samples, to find 
molecular markers from body fluids for diagnosis, and to monitor diseases and their 
treatments. Biologists use proteomics to study basic cell functions, molecular 
organizations and signal transduction. In addition, proteomics is also applied for 
chemistry, plant biology and microbiology research for many different purposes 
(Graves and Haystead, 2002). 
 
1.6.4.1. Expression proteomics 
The quantitative study of protein expression between samples is known as expression 
proteomics. In this approach, protein expression levels of the entire proteome or of the 
sub-proteomes between different samples are compared. Novel protein molecules in 
signal transduction or disease-specific proteins can be potentially idenfitied by this 
approach (Grant et al., 2007). 
 
1.6.4.2. Structural proteomics 
Structural proteomics is to determine and predict the atomic resolution 3-D structures 
of proteins on a genome-wide scale for better understanding of their 
structure–function relationships. It usually involves research in biochemistry, 
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bioinformatics, molecular biology, instrumental methods such as X-ray 
crystallography and nuclear magnetic resonance (NMR) spectroscopy, and 
computational approaches. The large number of protein structures will yield valuable 
information to the rules for predicting protein folding/unfolding mechanisms and 
understanding their biological functions (Liu and Hsu, 2005). 
 
1.6.4.3. Functional proteomics 
“Functional proteomics” is a broad term for various applicatons by using proteomics 
approaches. A good example is the study of protein-protein interactions. In this case, 
specific sub-proteomes are isolated by affinity chromatography, including the 
isolation of protein complexes or the use of protein ligands to isolate specific types of 
proteins. This approach allows a selected group of proteins to be studied and 
characterized and can provide important information about protein signaling, disease 
mechanisms or protein-protein interactions (Figeys et al., 2001). Another case in this 
regard is the use of phosphoproteome to study signal transduction in recent years 
(Cantin et al., 2006; Morandell et al., 2006; Schmelzle and White, 2006).  
 
1.7. Rationale and Purpose of Study 
Bronchial epithelial cells and lung fibroblasts play pivotal roles in pulmonary 
immunity, inflammation and remodeling, by producing a wide range of cell protective 
proteins, inflammatory mediators and ECM components, either constitutively or upon 
cytokine and growth factor stimulation. Functional proteomics studies of TGF-b, the 
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well-known growth factor for airway remodeling, on lung epithelial cells (Kanamoto 
et al., 2002) and lung fibroblasts have been investigated (Malmstrom et al., 2001). On 
the other hand, major effects have been made on the proteomics of epithelial-origin 
diseases for the identification of novel prognostic, diagnostic, and therapeutic markers 
(Zhao et al., 2006), particularly in lung cancer (Liu et al., 2004, Li et al., 2006, Lou et 
al., 2007), cystic fibrosis (Pollard et al., 2005 and 2006), and inhalational 
particle-induced or virus-infected respiratory tract (Andrew et al., 2003, Brasier et al., 
2004, Cha et al., 2007). In contrast, the roles of airway epithelial cells and fibroblasts 
in response to pro-inflammatory cytokines are less well-characterized, and the global 
protein profilings of human bronchial epithelial cells and lung fibroblasts in response 
to any pro-inflammatory cytokine have not been reported. Initially and dominantly 
released by airway macrophages which are the first type of cells to respond to external 
danger signals, and subsequently by various other infiltrated immune cells and even 
airway resident cells, TNF-a is considered the most abundant and potent 
pro-inflammatory cytokine in the acute phase of lung injury (Mukhopadhyay et al., 
2006). IFN-g, on the other hand, mainly generated by infiltrated immune cells 
especially CD4+ T cells, reflects the start of adaptive immunity. In addition to its 
potent inflammatory activity, IFN-g is also one of the most potent stimuli for 
macrophages, further amplifying airway inflammation (Dabrowska et al., 2006). 
 
In spite of promising alternative or complementary technologies that have emerged 
recently, 2-DE is currently the only technique that can be routinely applied for parallel 
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quantitative expression profiling of large sets of complex protein mixtures such as 
total cell lysates (Gorg et al., 2004). The purpose of the present study was to employ 
2-DE based proteomics technology to investigate differential global protein 
expression in human bronchial epithelial cells and lung fibroblasts stimulated with 
pro-inflammatory cytokines TNF-a and/or IFN-g, and to examine potential functional 
role of at least one of these identified proteins in TNF-a and/or IFN-g-induced 
biological responses. Human bronchial epithelial and lung fibroblast total lysates and 
culture supernatants were resolved by 2-DE, and protein spots with statistically 
significant change in optical density were identified by MALDI-TOF MS and/or 
MS/MS. By providing direct profiles of TNF-a and/or IFN-g-regulated protein 
expression of human bronchial epithelial cells and lung fibroblasts, these studies 
could give us a better understanding of TNF-a and/or IFN-g-regulated biological 
actions, and it is also possible to identify new TNF-a and/or IFN-g-regulated proteins, 
which could potentially be novel anti-inflammatory therapeutic targets for the 












2. METHODS AND MATERIALS 
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2.1. Cell culture 
Normal human lung fibroblasts (NHLF) (Lonza, Basel, Switzerland) were grown in 
the optimized fibroblast growth medium (FGM)-2 BulletKit including both fibroblast 
basal medium (FBM) and FGM-2 SingleQuots supplements containing 2% fetal 
bovine serum (FBS), 1 ng/ml human fibroblast growth factor B (hFGF-B), 5 μg/ml 
insulin, 50 μg/ml gentamicin and 50 ng/ml amphotericin-B (Lonza) in 5% CO2  and 
at 37oC, subcultured at 90-95% confluency. Normal human bronchial epithelia 
(NHBE) (Lonza) were grown in the optimized bronchial epithelial cell growth 
medium (BEGM) BulletKit including bronchial epithelial cell basal medium (BEBM) 
500 ml and the following supplements: bovine pituitary extract (BPE), 2 ml; 
hydrocortisone, 0.5 ml; human epidermal growth factor (hEGF), 0.5 ml; epinephrine, 
0.5 ml; transferrin, 0.5 ml; insulin, 0.5 ml; retinoic acid, 0.5 ml; triiodothyronine, 0.5 
ml; 50 μg/ml gentamicin and 50 ng/ml amphotericin-B (all from Lonza) in 5% CO2  
and at 37oC, subcultured at 80-85% confluency. Human airway smooth muscle cells 
(HASM) (Lonza) were grown in the optimized smooth muscle cell gowth medium 
(SmGM)-2 BulletKit including both smooth muscle cell basal medium (SmBM) and 
SmGM-2 SingleQuots supplements containing 5% FBS, 0.5 ml hEGF, 2 ng/ml human 
hFGF-B, 5 μg/ml insulin, 50 μg/ml gentamicin and 50 ng/ml amphotericin-B (Lonza) 
in 5% CO2 and at 37oC, subcultured at 90-95% confluency. Cells were washed once in 
HEPES Buffered Saline Solution, trypsinized using special Trypsin/EDTA, stopped 
by Trypsin Neutralizing Solution as recommended (all from Lonza), centrifugated at 
1000 rpm for 5min and then re-suspended in respective medium. Experiments were 
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performed on cells between passages 4 and 7. The two major stimuli used in this 
project, recombinant human TNF-a (Biosource, Camarillo, CA) and IFN-g (R&D 
Systems, Minneapolis, MN) are dissolved with H2O and further diluted in 1 ´ PBS 
containing 0.1 % bovine serum albumin (BSA) as a carrier. NHLF were stimulated 
with 10 ng/ml TNF-a for 24 h, and NHBE were stimulated with 10 ng/ml 
recombinant human TNF-a and/or IFN-g for 24 h and 48 h for proteomics studies. 
NHLF, NHBE and HASM were also treated with 10 ng/ml human IL-1b (R&D 
Systems), 10 ng/ml human IL-13 (R&D Systems), 10 ng/ml human TGF-b (R&D 
Systems) and 1000 U/ml human IFN-b (PBL InterferonSource, Piscataway, NJ) for 6 
h, 12 h, and 24 h. Until confluency, the adherent cells were washed and then scraped 
in 1 ´ phosphate buffered saline (PBS). Pellets were collected after centrifugation at 
1000 rpm for 5 min. Cell culture supernatants were precipitated using trichloroacetic 
acid (TCA, 10% final concentration). After centrifugation, the pellet was 
re-suspended in ice-cold acetone and spun again, followed with air-dry.  
 
2.2. Proteomics analysis 
The general workflow of proteomic analysis involves sample preparation, 
first-dimensional separation, second-dimensional separation, staining, imaging, image 


























Figure 5. Scheme of proteomics workflow and intruments. (A) Reswelling tray for 
rehydration (Amersham Biosciences, San Francisco, CA). (B) IPGphor for 
first-dimensional electrophoresis (Amersham Biosciences). (C) EttanTM DALTtwelve 
vertical system for second-dimensional electrophoresis (Amersham Biosciences). (D) 
GS-800 imaging densitometer (Bio-Rad, Hercules, CA). (E) PDQUEST (Version 
7.2.0.) software (Bio-Rad). (F) Proteomics Analyzer with TOF-TOFTM optics work 
station (Applied Biosystems). 








2.2.1. Sample preparation 
The cell pellets and the air-dried supernatant pellets were solubilized in lysis buffer 
containing 8 M urea (Bio-Rad), 2 M thiourea (Sigma, St. Louis, MO), 4% 
3-(3-cholamidopropyl)-dimethylammonio-1-propanesulfonate (CHAPS, Bio-Rad), 65 
mM dithiothreitol (DTT, Bio-Rad), 0.8 M Pharmalyte 3-10 (Amersham Biosciences), 
20 μg/ml DNAase, 5 μg/ml RNAase and 20 μg/ml protease inhibitor cocktail (Roche 
Diagnostic Corporation, Mannheim, Germany) for 30 min at 4oC. Protein lysates were 
spun at 14,000 rpm for 15 min and the supernatants were stored at -80oC until 
proteomics study. Protein concentration was measured using a modified Bradford 
assay (Bio-Rad).  
 
2.2.2. Two-dimensional gel electrophoresis 
The first dimension gel electrophoresis used Immobiline DryStrip (18 cm, pH 4-7 and 
pH 6-11, Amersham Biosciences). The pH 4-7 strips were rehydrated in 350 μl of the 
solution containing 8 M urea, 2 % CHAPS, 0.5% IPG buffer (pH 4-7, Amersham 
Biosciences), 0.0005% bromophenol blue, and together with the samples (100 μg for 
analytical purpose and 600 μg ~ 1 mg for preparative purpose) for 12 h. For pH 6-11, 
the strips were rehydrated in solution containing 7 M urea, 2 M thiourea, 4% CHAPS, 
10% isopropanol, 5% glycerol, 0.5% IPG buffer (pH 6-11, Amersham Biosciences) 
and 2.5% DTT (Hoving et al., 2002). The protein sample was cup-loaded to the 
anodic side just before electrophoresis. The isoelectrofocusing (IEF) was performed 
in an IPGphor (Amersham Biosciences) at 20oC using the programs listed in Table 1. 
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The isoelectrofocused strips were stored at -80oC.  
 
Table 1. Running programs for IEF 
Running Voltage & Duration  








































Step & Hold 
 
Acrylamide gels with a single percentage of 12% were prepared in EttanTM DALT Gel 
Caster (Amersham Biosciences). About 50 ml of gel solution containing 0.375 M 
Tris-Cl (pH 8.8), 0.1% SDS, 12% acrylamide, 0.05% ammonium persulfate (APS), 
0.0005% tetramethylethylenediamine (TEMED) was used for one gel. For second 
dimensional separation, the strips were equilibrated for 15 min in 50 mM Tris-HCl, 
pH 8.8, 6 M urea, 30% glycerol, 2% sodium dodecyl sulphate (SDS) and 1% DTT, 
followed by another 15 min equilibration in the same solution except for DTT, which 
was replaced with 2.5% iodoacetamide (Sigma). The strips were soaked in the 1 x 
electrophoresis running buffer (25 mM Tris-base, 0.2 M glycine and 0.1% SDS) and 
then transferred onto the top of acrylamide gels and sealed with 0.5% agarose. 
Electrophoresis was run in an EttanTM DALTsix or DALTtwelve electrophoresis unit 
(Amersham Biosciences) at 15oC, under the condition of 2.5 W/gel for 30 min 
followed by 10 W/gel for approximately 5 h. The gels were fixed in solution 
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containing 40% (v/v) ethanol, and 10% (v/v) acetic acid overnight. 
 
2.2.3. Silver staining and imaging 
Silver staining was performed according to the manufacturer’s instruction (Amersham 
Biosciences). The gel containers were placed on an orbit shaker Unimax 2010 
(Heidolph Instrument, Kelheim, Germany) at 30-40 rpm throughout the staining. 
After fixation, the gels were sensitized in 30% (v/v) ethanol, 5% (w/v) sodium 
thiosulfate, and 6.8% (w/v) sodium acetate for 30 min. After washing with distilled 
water 3 times at 5 min/wash, the gels were incubated in 0.25% (w/v) silver nitrate for 
20 min. Then the gels were rinsed shortly with distilled water 2 times at 1 min/wash 
and developed in 2.5% (w/v) sodium carbonate and 0.015% (w/v) formaldehyde until 
the desired intensity of spots was achieved. Then the development was terminated 
with 1.46% (w/v) EDTA-Na2 ´ 2H2O. The gels were scanned using GS-800 
Densitometer (Bio-Rad Laboratories) following washing with distilled water 3 times 
at 5 min/wash.  
 
2.2.4. Image analysis 
Image analysis was performed using the PDQuest (Version 7.2.0., Bio-Rad). Protein 
spots that were automatically detected and matched by the software were carefully 
reviewed. Some missing spots were added to the analysis, some redundant spots were 
removed, and some improperly matched spots were rectified. Every spot was given a 
quantity of optical density (OD) fitted by Gaussian model. Because of potential 
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variation in protein loading, rehydration and staining, the gel images were normalized 
based on the total quantity of all valid spots. In this normalization method, the raw 
quantity of each spot in a member gel is divided by the total quantity of all the spots 
in that gel that have been included in the master gel. This normalization method 
assumes that few protein spots change within the experiment, and that the changes 
average out across the whole gel. In comparison with other common normalization 
methods such as total quantity in analysis set, total density in gel image and 
housekeeping protein, we found this method was the most stable and consistent for 
our case. The normalized quantity of each spot was expressed as parts per million 
(PPM). A quantitative analysis set was created by the PDQuest and the protein spots 
with significant PPM changes between control and treatment group were selected for 
protein identification. 
 
2.2.5. In-gel digestion and MALDI-TOF MS or MS/MS analysis 
Protein spots with significant OD changes were excised from the stained gels and 
digested with modified trypsin (Promega, Madison, WI) according to the method 
described before (Shevchenko et al., 1996). Brifely, in-gel digestion was preformed in 
an orderly sequence starting from destaining, dehydration, drying, digestion, to 
extraction. Samples were analyzed using a Voyager DE-STR Biospectrometry work 
station or 4700 Proteomics Analyzer with TOF-TOFTM optics work station (Applied 
Biosystems, Foster City, MA). The peptide mass fingerprints (PMF) obtained using 
the Voyager DE-STR Biospectrometry, together with the observed pI and Mr were 
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searched against the National Center for Biotechnology Information (NCBInr) 
database (21 April 2005) using MASCOT 2.0 search algorithm 
(http://www.matrixscience.com, Matrix Science, London, UK) or the MS-Fit program 
(Version 3.1.1, http://prospector.ucsf.edu). The MS PMF obtained using the ABI 4700 
Proteomics Analyzer were acquired with 800-4000 m/z mass range and 1,000 laser 
shots per spectrum. Nitrogen was used for collision induced dissociation (CID) with a 
collision energy of 1 kV. The MS/MS data were acquired with stop conditions so that 
3,000-6,000 laser shots were accumulated for each spectrum. The MS and MS/MS 
spectra were searched against the National Center for Biotechnology Information 
(NCBInr) database 060912 (3952414 sequences; 1361850369 residues) using data 
processing software Data Explorer 4.6 (Applied Biosystems) and MASCOT 2.0. 
Searches were performed without restriction of protein pI or Mr, but with mandatory 
carbamidomethylation of cysteines and variable oxidation of methionine residues. 
One trypsin miscleavage was allowed. Peptide mass tolerance and fragment mass 
tolerance were set to ±100 ppm and ±0.2 Da, respectively.  Probability based 
MOWSE scores were estimated by comparison of search results against estimated 
random match population and were reported as -10 ´ log(p) where p is the absolute 
probability. The result of a MS-Fit database search was significant if the protein was 
ranked as best hit with a MOWSE score of at least 1e+003. For MASCOT MS/MS 
ion search, the identified proteins had to be in the top hit with at least two peptide 




Total RNA was extracted from cells and mouse lung tissues using TRIzol reagent 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. First strand 
cDNA was synthesized from 1 μg RNA using oligo (dT) 15 primers and 10 U AMV 
reverse transcriptase (Promega). PCR was performed in a GeneAmp PCR system 
2700 thermal cycler (Applied Biosystems). The primers (Research Biolabs, Singapore) 
used and the product sizes are listed in Table 2. The PCR products were run in 1.5% 
(w/v) agarose gel electrophoresis with ethidium bromide staining using Chemi-Smart 
3000 gel documentation system (Vilber Lourmat, Marne La Vallee, France) for gel 
band analysis.  
 
Table 2. PCR primer sets 
Target gene PCR primer (5’-3’) Product Size 
h/mb-Actin 
5’-TCA TGA AGT GTG ACG TTG ACA TCC GT-3’ 
5’-CTT AGA AGC ATT TGC GGT GCA CGA TG-3’ 285 bp 
hDCIP 5’-TCC ATC CCG ACT ACA AGA C-3’ 5’-ACA TAG TAA CCA CCT CCC AG-3’ 355 bp 
hIRF-1 5’-GAC CCT GGC TAG AGA TGC AG-3’ 5’-GAG CTG CTG AGT CCA TCA G-3’ 439 bp 
hVCAM-1 5’-ATT GGG AAA AAC AGA AAA GAG -3’ 5’-GGC AAC ATT GAC ATA AAG TG -3’ 642 bp 
hICAM-1 5’-TAT GGC AAC GAC TCC TTC T-3’ 5’-CAT TCA GCG TCA CCT TGG-3’ 238 bp 
hIL-6 5’-CAG GAG AAG ATT CCA AAG AT-3’ 5’-ACT GGT TCT GTG CCT GCA GC-3’ 459 bp 
hIL-8 5’-ATG ACT TCC AAG CTG GCC GTG GCT-3’ 5’-TCT CAG CCC TCT TCA AAA ACT TCT C-3’ 292 bp 
hIP-10 5’-TCT AAG TGG CAT TCA AGG AGT ACC-3’ 5’-CAT CTC TTC TCA CCC TTC TTT TTC-3’ 171 bp 
hMnSOD 5’-GGT AGC ACC AGC ACT AGC AG-3’ 5’-CTG CAG TAC TCT ATA CCA CTA CA-3’ 780 bp 
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hTSLP 5’-CCT TAG AGC CCA CTG ACT GC-3’ 5’-CCC CAC TTC TGT CAT GGT TT-3’ 394 bp 
hApoL1 5’-AAG AAA CAG CGG CTC CAC TA-3’ 5’-AAC GAC CAT CAT CAG GAA GC-3’ 159 bp 
hApoL2 5’-CAG AGG AGG TTG AGC AGG TC-3’ 5’-GTG CCC GCA ATT TGT TTA CT-3’ 225 bp 
hApoL3 5’-AGC CTG GAA GAG ATT CGT GA-3’ 5’-AGC CTC TGT GGA CCT CTT CA-3’ 239 bp 
hApoL4 5’-TGA CGA AGC CAC AAA AAT GA-3’ 5’-GGT TCC GGG CTA CTT TTC TC-3’ 167 bp 
hApoL5 5’-ATG AGG CTG GTA TGC TGT CC-3’ 5’-GTT CCT CTG CTG TCT CCG TC-3’ 761 bp 
hApoL6 5’-AGC AAC AGG AGG AGG AAG C-3’ 5’-TGG TCG TAG GTG GGC AGT A-3’ 153 bp 
htropomyosin
3, isoform 2 
5’-AGA GAC CCG TGC TGA GTT TG-3’ 
5’-GAC TGG GGC GTT CTA CAT CT-3’ 163 bp 
hg-actin 
5’-TCT GTG GCT TGG TGA GTC TG-3’ 
5’-AAC TGG GTC CTA CGG CTT G-3’ 163 bp 
hSerpinB1 5’-TTC CTG AGT TCT TGG TTT CG-3’ 5’-ATT CGT CGT GGC TTC TTT C-3’ 245 bp 
hNDRG1 5’-AGA AAG GGG AGA CCA TCA CC-3’ 5’-AAG AGG GGG TTG TAG CAG GT-3’ 178 bp 
hWars 5’-GCT TTT CCC CTG ACT GTG TC-3’ 5’-TTC CCT GAG ATT TGG CTT TG-3’ 242 bp 
mTNF-a 
5’-ACG GCA TGG ATC TCA AAG AC-3’ 
5’-CGG ACT CCG CAA AGT CTA AG-3’ 324 bp 
mMG11 5’-AAA ACA CCG ACC TCC GAA CC-3’ 5’-AAA ACA TAG TAG CCG CCC CC-3’ 358 bp 
mIRF-1 5’-CCC ACA GAA GAG CAT AGC AC-3’ 5’-GGA GCA GGT AGT GAG GCA GA-3’ 210 bp 
mVCAM-1 5’-CAA GGG TGA CCA GCT CAT GAA-3’ 5’-TGT GCA GCC ACC TGA GAT CC-3’ 518 bp 
mICAM-1 5’-AGG GCT GGC ATT GTT CTC TA-3’ 5’-CTG CTG TTT GTG CTC TCC TG-3’ 216 bp 
mIL-6 5’-TTC CAT CCA GTT GCC TTC TT-3’ 5’-TTT CCA CGA TTT CCC AGA GA-3’ 169 bp 
mMnSOD 5’-GAA GGT AAT GGT GCC TCT GG-3’ 5’-TTG CCG CTA CTG AGA AAG GT-3’ 245 bp 
mApoL2 5’-TGA TTT AGG GAT GGG GAG TG-3’ 5’-GCA GAG AGG TGG TCT TGT CC-3’ 167 bp 
mApoL3 5’-CTC CTG GTC TCA ATC CTC CA-3’ 5’-GCA TTC TCT GTC TGG GGT GT-3’ 181 bp 
mApoL6 5’-GAG GCT GAT GCT GAG TTG CT-3’ 5’-GGC TTT CGT CAA TGT GGT CT-3’ 154 bp 
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mSerpinB1a 5’-GAC AGA GGA CAC AAC GGA TG-3’ 5’-TTT AGG CAG CAG AAT GAC CA-3’ 177 bp 
mWars 5’-CCA GTG CTT CTG CTT TGA CA-3’ 5’-TAC GGC TTC TGC TTT TCC AA-3’ 188 bp 
mNDRG-1 5’-TCT GGA CAC TGA AAC CCA CA-3’ 5’-TCT CCC TCT GCC TCA AAG AA-3’ 244 bp 
mTapasin 5’-GAG CCT GTC GTC ATC ACC AT-3’ 5’-AGC ACC TTG AGG AGT CCG AG-3’ 848 bp 
mGAPDH 5’-CAT GTT CCA GTA TGA CTC CAC TC-3’ 5’-GGC CTC ACC CCA TTT GAT GT-3’ 136 bp 
 
2.4. Real-time PCR 
Cellular RNA was extracted using RNAqueous-4PCR kit (Ambion, Austin, TX) 
according to the manufacturer’s instructions. The 20 μl real time PCR mixture 
contained 10 μl of 2 ´ QuantiFast SYBR Green PCR Master Mix (Applied 
Biosystems), 2 μl of 10 ´ QuantiTect Primer Assay (Qiagen), 1 μl template cDNA, 
and RNase-free water. Each sample was run in triplicate. Amplification and detection 
was performed using the ABI 7500 Real-Time PCR System (Applied Biosystems) 
using the following settings: 2 min at 95°C, 40 cycles of 10 sec at 95°C, and 30 sec at 
60°C. 18s was used as an endogenous control to normalize each target sample. All 
data were analyzed using the Sequence Detection System SDS software package, 
version 1.4.0.25 (Applied Biosystems). A Relative Quantification plate document was 
created for analysis. 
 
2.5. Antibodies and immunoblots 
Rabbit polyclonal antibody to human dendritic cell-derived IFN-g-induced protein 
(DCIP) was raised against synthetic peptide corresponding to amino acid residues 
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(609RLREASKSRVQLFKDDPM626) (Invitrogen). Cells were lysed in lysis buffer (50 
mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 5 mM 
phenylmethanesulphonylfluoride (PMSF), 10 μg/ml aprotinin and leupeptin). Proteins 
(20 μg per lane) were separated by 10% SDS-PAGE and then transferred to a 
polyvinylidene difluoride (PVDF) membrane (Bio-Rad) using a semi-dry transblotter 
(ATTO Corp., Tokyo, Japan). The membrane was probed with anti-DCIP polyclonal 
antibody (1:1000) or rabbit anti-interferon regulatory factor (IRF)-1 polyclonal 
antibody (1:1000; Cell Signaling Technology, Deverly, MA), followed by horseradish 
peroxidase (HRP)-conjugated secondary antibody (1:5000; Dako, Denmark), and 
visualized using the ECL reagent (Amersham Biosciences). The membrane was then 
washed and stripped using restore Western blot stripping buffer (Pierce, Rockford, IL), 
and re-probed with anti-b-actin monoclonal antibody (1:10,000; Sigma), followed by 
alkaline phosphatase (AP) or HRP-conjugated secondary antibodies (1:5000; 
DakoCytomation, Glostrup, Denmark), and visualized colorimetrically by adding 
substrate 5-bromo-4-chloro-3-indoyl-phosphate (BCIP) and nitroblue tetrazolium 
(NBT) in AP buffer (100 mM Tris-HCl pH 9.5, 100 mM NaCl, 50 mM MgCl2) 
(Bio-Rad). Protein band intensity was quantitated using Gel-Pro imaging software 
(Media Cybernetics, Silver Spring, MD).  
 
2.6. MTT assay 
3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT), a tetrazole 
was used as an indicator of cell viability as determined by its 
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mitochondrial-dependent reduction to formazone. Briefly, cells were seeded in 
96-well plates for 24 h, followed by different treatment for indicated time points. 
MTT (0.5 mg/ml diluted with medium) was added to the wells for 4 h. Then, the 
supernatant was removed, and the formazone crystals were dissolved using dimethyl 
sulfoxide (DMSO). The absorbance was read at 595 nm with a microplate reader 
(Model 680, Bio-Rad). 
 
2.7. Transfection with antisense oligodeoxynucleotides 
Two DCIP antisense oligodeoxynucleotides (ASOs) were designed to target at 
different sites of the coding region of human DCIP mRNA using published mRNA 
sequence (GenBank accession number NM_015474). The ASO and the corresponding 
scrambled oligodeoxynucleotide (ODN) design strategy was based on a combined 
consideration of free energy for duplex ASO/mRNA formation, G-C contents, 
specific sequence motifs, and secondary mRNA structures as described previously by 
our laboratory (Chan et al., 2006 and 2007). ODNs and ASOs were synthesized with 
full backbone modification with phosphorothioate to resist endonuclease degradation 
and promote RNase H-mediated mRNA degradation. Inhibitory efficiency of the two 
designed DCIP ASOs was compared and the ASO with higher inhibitory efficiency 
was used for the following study. Human lung fibroblasts were maintained in 
fibroblast basal medium and were transfected with 200 nM IRF-1 ASO or control 
ODN (Wagner et al., 2002) (Proligo, Singapore), or DCIP ASO or control ODN 
(Research Biolabs, Singapore) (Table 3) in the presence of lipofectin (Invitrogen) for 
6 h at 37oC. Thereafter, the optimized FGM-2 BulletKit medium (without antibiotics) 
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containing 30% fetal bovine serum was added to the transfected lung fibroblasts for 4 
h for cell recovery. After that, the media were replaced by fresh optimized FGM-2 
BulletKit medium containing 10 ng/ml TNF-a and the stimulated cells were harvested 
at indicated times. 
 
Table 3. Sequences of antisense ODNs 
Gene Target Sequence 
Mismatch 5’-CsgsAsgsTsgsgsTsAsgsAsCsgsTsAsTsTsgsgsC-3’ hIRF-1 
Antisense 5’-CsgsAsgsTsgsAsTsgsgsgsCsAsTsgsTsTsgsgsC-3’ 
Scramble 5’-AsAsCsTsTsAsCsAsTsgsTsgsCsgsTsAsCsgsAsC-3’ hDCIP 
Antisense 5’-CsAsgsCsAsTsgsCsgsTsgsTsAsCsAsTsTsCsAsA-3’ 
 
2.8. Transfection with siRNA 
Allstars Negative Control siRNA (designated as siRNA A) and target siRNA duplexes 
(designated as siRNA 1, 2, 3 and 4) consisted of two complementary 21-nucleotide 
RNA strand with 3' dTdT overhangs were chemically synthesized (Qiagen) (Table 4). 
Human bronchial epithelial cells were seeded at 50 to 60% confluency in 
antibiotics-free media one day before transfection. Cells were maintained in 
GIBCOTM opti-MEM I Reduced Serum Medium (Invitrogen) and were transfected 
with 100 nM siRNAs or Allstars Negative Control siRNA in the presence of 
lipofectamine2000 (Invitrogen) for 5 h at 37oC. Transfection was stopped by 
replacing the siRNA-containing opti-MEM with optimized BEGM BulletKit medium 
(without antibiotics) overnight for cell recovery. After which, the media were replaced 
by fresh optimized BEGM BulletKit medium containing 10 ng/ml TNF-a or IFN-g 
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and the stimulated cells were harvested or analyzed at indicated times. 
 
Table 4. Sequences of siRNAs 
Gene Target Sequence 
Sense r(GGA CAA CCU UGC AAG ACA A)dTdT hApoL1 
Antisense r(UUG UCU UGC AAG GUU GUC C)dAdG 
Sense r(GCG GCA CCA AUG UAG CAA A)dTdT hApoL2 
Antisense r(UUU GCU ACA UUG GUG CCG C)dTdT 
Sense r(CAG UCU CAU UAC UCA UAU A)dTdT hApoL3 
Antisense r(UAU AUG AGU AAU GAG ACU G)dTdT 
hApoL4 Sense r(GCA AUU GUU CAG GGA AUA A)dTdT 
 Antisense r(UUA UUC CCU GAA CAA UUG C)dTdG 
 
2.9. Lipopolysaccharide-induced acute lung injury in mice 
Animal experiment was performed according to the Institutional Guidelines for 
Animal Care and Use Committee of the National University of Singapore. 
Lipopolysaccharide (LPS, Escherichia coli serotype 0111: B4, 40 μg, Sigma) in a 
volume of 40 μl was instilled into the lungs of male BALB/c mice 8-10 wk of age 
(Interfauna, East Yorkshire, UK) via intratracheal route. Briefly, mice were 
anesthetized by an intraperitoneal injection of 100 μl of anesthetic mixture 
(Medetomidine and Ketamine, Apex Laboratories, Somersby, New South Wales, 
Australia), and upon the cessation of activity were suspended on a board in supine 
position at a 45° angle. A string anchored above their head in the inclined board was 
looped around their front teeth, and their body weight was supported by taping the 
base of their tail to the inclined board. Upon opening the jaw of the mouse, the tongue 
was gently drawn outward, opening the trachea. LPS or saline was pipetted directly 
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into the throat, momentarily blocking the mouse’s airway. Respiration by the mouse 
carried the LPS and vehicle into the lungs. Animals were sacrificed 24 h later. 
 
2.10. Influenza A virus stock and inoculation of mice 
Mouse-adapted influenza A/PR/8/34 was propagated in the allantoic fluid of 10-day 
old embryonated chicken eggs at 37°C, as described previously (Williams and 
Mackenzie, 1977). In brief, 0.1 ml of influenza virus or sterile saline was injected into 
the allantoic cavity of individual 10-day old eggs. After an incubation period of 48 h 
at 37°C, the shell at the air-sac end of the egg was carefully removed and the allantoic 
fluid collected, clarified via centrifugation (10,000 × g for 5 minutes), stored in 100 μl 
aliquots at -80°C. Virus infectivity was assessed using a plaque assay in Madin-Darby 
Canine Kidney (MDCK) cells, with 10-fold serial dilutions starting from 1:10 in PBS 
(Brown, 1990). Virus titre was determined to be 150,000 pfu/ml. Mice were 
anesthetized by an intraperitoneal injection of 100 μl of anesthetic mixture, and upon 
the cessation of activity were inoculated intranasally with 100 pfu of influenza A 
virus or a 1 in 30 dilution of allantoic fluid from virus-free chicken eggs in sterile 
saline. The total amount inoculated was always 20 μl. The virus dose chosen was 
based on preliminary studies which demonstrated that inoculation with 100 pfu of 
influenza A results in a robust pulmonary inflammation in response to virus infection. 
Following inoculation, mice were administered atipamezole (0.5 mg/kg, Novartis 
Animal Health, Auckland, New Zealand) to reverse the effects of the anesthetic. 
Animals were sacrificed 4 d later. 
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2.11. Acute asthma model 
Male BALB/c mice 8-10 wk of age were sensitized by intraperitoneal injections of 20 
μg ovalbumin (OVA) (Grade V, Sigma, St. Louis, MO) together with 4 mg Al(OH)3 
in 0.1 ml saline on days 0 and 14. On days 18, 19, and 20, animals were challenged 
with 1% OVA aerosol for 20 min using DeVibiss ultrasonic nebulizer (Sunrise 
Medical Respiratory Products, Somerset, PA). Aerosol particle size is in 0.5 to 5 µm 
range. Control mice were sensitized and challenged with saline. Animals were 
sacrificed 24 h later after the last challenge. 
 
2.12. Bronchoalveolar lavage fluid cell counts 
Bronchoalveolar lavage (BAL) fluid collection was performed when the animals were 
sacrificed. Briefly, mice were anesthetized by an intraperitoneal injection of 100 μl of 
anesthetic mixture. Tracheotomy was performed and a cannula was inserted into the 
trachea. Ice-cold PBS (0.5 ml × 3) was infused into the lungs, and BAL fluid was 
collected. Total cell counts were performed using a hemocytometer. For cytological 
examination, cytospin preparations were prepared using Cytospin (Thermo Shandon, 
Pittsburgh, PA), fixed, and stained in a modified Wright stain. Differential cell counts 
were performed on at least 500 cells on each cytospin slide. 
 
2.13. Enzyme-linked immunosorbent assay (ELISA) 
Mouse TNF (Mono/Mono) and IFN-g ELISA Set (BD Biosciences, San Diego, CA) 
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were used to measure the TNF-a and IFN-g level in mouse BAL fluid, respectively. 
Briefly, 96-well BD Falcon ELISA plates were coated overnight at 4°C with 100 μl of 
the anti-mouse TNF and IFN-g monoclonal capture antibody, respectively. Aftere 
washing for 5 times, wells were blocked with 1 ´ PBS with 10% heat-inactivated FBS, 
pH 7.0 for 2 h at room temperature. 100 μl of BAL fluid samples or standards were 
added to the wells and incubated at room temperature for 2 h, followed by washing 
for 5 times. The biotinylated anti-mouse TNF or IFN-g monoclonal detection antibody, 
mixed with enzyme reagent streptavidin-HRP conjugate was added in and incubated 
for 1 h at room temperature. The plates were washed for 10 times and developed with 
the tetramethylbenzidine (TMB) peroxidase EIA substrate kit (Bio-Rad). The reaction 
was stopped with stopping solution (1.8 N H2SO4), and the OD was read at 450 nm 
with l correction 570 nm on a microplate reader (Bio-Rad). 
 
2.14. Statistical methods 
Data are presented as mean ± SEM. Student’s t-test was used to determine significant 
difference in optical densities for proteomics study. One-way ANOVA followed by a 
Dunnett’s T3 multiple-comparisons test was used to determine differences between 
treatment groups in subsequent functional studies. The critical level for significance 











3. DENDRITIC CELL-DERIVED IFN-g-INDUCED 
PROTEIN (DCIP) MEDIATES TNF-a  
STIMULATION OF NHLF 
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3.1. Results 
3.1.1. Proteomics analysis of DCIP induction by TNF-a 
Normal human lung fibroblasts (NHLF) were harvested 24 h after TNF-a stimulation. 
2-DE proteomics approach was employed to identify differentially expressed proteins 
in TNF-a-treated human lung fibroblasts (n = 9 gels from 9 separate experiments) as 
compared with control fibroblasts (n = 9 gels from 9 separate experiments). Both cell 
lysates and cell culture supernatants were resolved in both pH 4-7 and pH 6-11 gels. 
Following image analysis, about 1000 protein spots were consistently detected in pH 
4-7 gel for cell lysates, 500 protein spots in pH 6-11 gel for cell lysates, and 400 
protein spots in both pH 4-7 and pH 6-11 gels for culture supernatants. A total of 18 
differentially expressed protein spots were detected in TNF-a-treated lung fibroblasts 
based on statistically significant changes in optical density, corresponding to 13 
up-regulated and 5 down-regulated protein spots. Ten proteins (spot nos. 1-10) were 
identified in pH 4-7 gel for cell lysates, 5 proteins (spot nos. 11-15) in pH 6-11 gel for 
cell lysates, and 3 proteins (spot nos. 16-18) in pH 6-11 gel for cell culture 
supernatants. The location of the identified protein spots is shown in representative 
gels (Figure 6A). Direct comparison of the optical densities of protein spots between 
untreated and TNF-a-treated lung fibroblasts was illustrated in Figure 6B. Protein 
spots were subjected to peptide mass fingerprinting by MALDI-TOF analysis, and the 
identity of 11 spots were confirmed by the MS (Table 5). To our knowledge, many of 
these proteins were identified for the first time to be altered by TNF-a in lung 
fibroblasts, which include anti-viral proteins myxovirus resistance protein A (MxA, 
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spot no. 3) (Holzinger et al., 2007) and interferon-stimulated gene 15 (ISG15, spot no. 
15) (Ritchie et al., 2004), serine protease inhibitor plasminogen activator inhibitor 
type-2 (PAI-2, spot no. 5) (Medcalf et al., 2005), extracellular matrix-related proteins 
lysyl hydroxylase 2 (isoform a) (LH2a, spot no. 1) (Wu et al., 2006), prolyl 
4-hydroxylase (a subunit) (P4Ha, spot no. 4) (Myllyharju, 2003) and laminin 
receptor-1 (spot no. 6) (Givant-Horwitz et al., 2005), immunomodulatory mediator 
annexin 1 (spot no. 8) (Lim and Pervaiz, 2007) and ubiquitination system processor 
ubiquitin-conjugating enzyme E2 variant 1 (spot no. 14) (Zhang and Matunis, 2005). 
Unexpectedly, human DCIP was found for the first time ever to be up-regulated by 
TNF-a in any cell type (spot no. 11), and its biological function is at present unknown. 
We further investigated the expression regulation and functional role of DCIP in 
TNF-a-stimulated human lung fibroblasts. Details of the identified peptides of DCIP 
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Figure 6. Differential protein profiling of TNF-a stimulation of normal human 
lung fibroblasts. (A) Representative raw 2-D gels of lung fibroblast lysate pH 4-7 
(left panel), lung fibroblast lysate pH 6-11 (middle panel) and fibroblast supernatant 
pH 6-11 (right panel), showing the locations of all 18 protein spots that have been 
shown to be significantly altered by TNF-a, together with the landmark housekeeping 
protein Galectin. Numbers correspond to the spot identification numbers listed in 
Table 5. (B) Direct comparison of TNF-a-induced differentially expressed proteins 
with control protein spots in randomly selected raw 2-D gels, together with the 
landmark protein Galectin on top showing gel running consistency (right panel). The 
left panel shows the corresponding bar charts of spot relative intensities (PPM) 
expressed as mean ± SEM. Protein spot relative intensities of control and 
TNF-a-treated lung fibroblasts were analysed using Student’s t-test. *, Significant 
difference from control, p < 0.05 (n = 9 gels from 9 separate sets of experiment). 
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1 Lysyl hydroxylase 2, isoform a (LH2a) gi|33636742 6.3/100 6.24/87 5 10 78 +6.0 
2 Unknown N/A 5.6/76 N/A N/A N/A N/A +5.3 
3 Myxovirus resistance protein A (MxA) gi|106803 5.7/76 5.60/76 14 29 111 +34.3 
4 Prolyl 4-hydroxylase, α subunit (P4Ha) gi|190788 5.8/63 5.70/61 8 18 82 +2.2 
5 Plasminogen activator inhibitor, type II (PAI-2) gi|4505595 5.6/43 5.46/47 11 26 2.3e+007b) +5.6 
6 Laminin receptor-1 gi|1125065 4.8/33 4.79/33 4 22 65 -2.7 
7 Unknown N/A 5.0/34 N/A N/A N/A N/A -5.5 
8 Annexin I gi|442631 5.2/28 7.77/35 6 22 69 -2.9 
9 Unknown N/A 5.7/20 N/A N/A N/A N/A -2.3 
10 Unknown N/A 6.2/12 N/A N/A N/A N/A +2.7 
11 Dendritic cell-derived IFN-g-induced protein (DCIP) gi|38016914 7.3/75 7.0/73 18 39 179 +5.0 
12 Unknown N/A 8.0/35 N/A N/A N/A N/A +3.6 
13 Manganese superoxide dismutase (MnSOD) gi|16877367 7.4/23 6.80/22 6 39 2.5e+007b) +5.0 
14 Ubiquitin-conjugating enzyme E2 variant1 gi|11323320 7.2/17 7.71/17 6 44 68 -2.7 
15 Interferon stimulated protein 15 (ISG-15) gi|4826774 7.4/15 6.84/18 5 32 128 +8.9 
16 Unknown N/A 6.8/62 N/A N/A N/A N/A +42.5 
17 Unknown N/A 7.0/63 N/A N/A N/A N/A +34.2 
18 Matrix metalloproteinase 1 (MMP-1) gi|4505215 7.0/60 6.47/54 20 39 332 +12.6 
 
a) Score is -10 ´ log(p), where p is the probability that the observed match is a random event. Protein scores greater than 63 are considered 
significant (p<0.05). 









Mascot Search Results 
Search title      : SampleSetID: 581, AnalysisID: 1005, MaldiWellID: 30476, SpectrumID: 93922, 
Path=\Michelle 2008\080123_173\173 
Database        : NCBInr 070714 (5370027 sequences; 1856289661 residues) 
Timestamp       : 23 Jan 2008 at 18:07:29 GMT 
Top Score       : 179 for gi|38016914, SAM domain- and HD domain-containing protein 1; SAM 
domain and HD domain, 1; dendritic cell-derived [Homo sapiens] 
 
 
Probability Based Mowse Score 
Score is -10*Log(P), where P is the probability that the observed match is a random event. 












Protein Summary Report 
 
Index 
  Accession        Mass     Score         Description 
1. gi|38016914        72896     179   SAM domain- and HD domain-containing protein 1; SAM 
domain and HD domain, 1; dendritic cell-derived [Homo sapiens] 
2. gi|22209036        72996     179   SAM domain and HD domain 1 [Homo sapiens] 





 1. gi|38016914       Mass: 72896    Score: 179    Expect: 6.8e-012  Queries matched: 21 
















 876.41  875.41  875.49  -0.08 545 551 0  K.FAEQLIR.V 
 892.44  891.43  891.52  -0.08 100 106 0  K.LLSYIQR.L 
 1117.52  1116.51  1116.59  -0.08 135 143 0  R.IIDTPQFQR.L 
 1117.52  1116.51  1116.59  -0.08 135 143 0  R.IIDTPQFQR.L 
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 1307.57  1306.56  1306.65  -0.09 86 97 0  R.FENLGVSSLGER.K 
 1307.57  1306.56  1306.65  -0.09 86 97 0  R.FENLGVSSLGER.K 
 1355.61  1354.61  1354.72  -0.12 295 305 1  K.SFLYEIVSNKR.N 
 1372.51  1371.50  1371.60  -0.10 567 576 0  R.QYFVQWCADR.N 
 1379.58  1378.57  1378.63  -0.07 513 523 0  K.NPIDHVSFYCK.T 
 1479.63  1478.62  1478.70  -0.08 44 55 0  K.TWGPEQVCSFLR.R 
 1533.61  1532.60  1532.69  -0.09 597 609 0  K.EWNDSTSVQNPTR.L 
 1598.64  1597.64  1597.75  -0.11 306 318 1  R.NGIDVDKWDYFAR.D 
 1650.74  1649.74  1649.87  -0.13 378 392 0  K.VGNIIDTMITDAFLK.A 
 1722.72  1721.72  1721.83  -0.11 149 164 0  K.QLGGGYYVFPGASHNR.F 
 1724.71  1723.71  1723.80  -0.09 353 366 1  R.DKEVGNLYDMFHTR.N 
 1816.75  1815.74  1815.87  -0.13 70 85 0  R.ENEITGALLPCLDESR.F 
 1881.84  1880.84  1880.98  -0.14 422 437 0  K.LTDNIFLEILYSTDPK.L 
 2072.04  2071.04  2071.17  -0.13 117 134 0  K.VINDPIHGHIELHPLLVR.I 
 2072.04  2071.04  2071.17  -0.13 117 134 0  K.VINDPIHGHIELHPLLVR.I 
 2512.02  2511.01  2511.16  -0.14 21 43 0  R.TPSNTPSAEADWSPGLELHPDYK.T 
 
 
Figure 7. The MS spectrum and Mascot search results of the identified peptides 
of DCIP produced by MALDI-TOF MS. 
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3.1.2. Verification of proteomics data by RT-PCR 
To validate the observation from our proteomics system, and to reduce potential false 
positive results, further studies were applied to confirm our proteomics findings. 
Because of the limited commercial supplies and cost of antibodies for the proteins we 
identified, we chose a few protein spots for RT-PCR analysis. The RT-PCR results are 
shown in Figure 8. The alteration of all tested transcripts is consistent with the 




















Figure 8. RT-PCR analysis of mRNA from control and TNF-a-treated human 
lung fibroblasts. Cells was treated with TNF-a for 12 h. Total cellular RNA was 
extracted by Trizol reagent, and PCR was performed using PCR master mix with 2 mg 
of total cDNA. PCR products were run in a 2% agarose gel and visualized under UV 
light. Two gene targets from pH 4-7 and two from pH 6-11 were representatively 
selected to confirm our proteomics findings. β-actin was used to demonstrate the 
equal amount of mRNA was converted to cDNA. 




Control TNF-a  
 b-Actin 
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3.1.3. TNF-a-induced DCIP expression is dependent on IRF-1 activity 
Based on computer analysis using TRANFAC database (Wingender et al., 2001) from 
the University of Pennsylvania, two consensus sequences for binding IRF-1 
transcription factor (–-641AAGTG-636– and –-553GCCACTTTCC-542–) are clustered in 
the promoter region of the human DCIP gene. We hypothesized that the induction of 
DCIP gene by TNF-a depends on IRF-1 expression. To validate this hypothesis, we 
first observed that the mRNA and protein levels of IRF-1 and DCIP were up-regulated 
by TNF-a in human lung fibroblasts using RT-PCR and immunoblotting, respectively 
(Figure 9). Next, IRF-1-selective ASO was able to knock down TNF-a-induced IRF-1 
transcript and protein to their basal levels (Figure 9A). Finally, we demonstrated that 
IRF-1 ASO was also able to significantly suppress TNF-a-induced DCIP transcript 
and protein levels in lung fibroblasts by about 85% and 78%, respectively (Figure 9B). 










































Figure 9. TNF-a-induced DCIP expression in human lung fibroblasts is mediated by 
IRF-1. Normal human lung fibroblasts were transfected with 200 nM IRF-selective ASO 
for 6 h. Corresponding scrambled ODN was used as control. (A) Expression of IRF-1 
mRNA and protein in normal human lung fibroblasts was significantly inhibited by 
IRF-selective ASO at 6 h and 9 h, respectively, after TNF-a stimulation. (B) Expression 
of DCIP mRNA and protein in normal human lung fibroblasts was markedly suppressed 
by IRF-selective ASO at 12 h and 18 h, respectively, after TNF-a stimulation. Whole cell 
extracts were prepared, proteins (20 mg per lane) separated by SDS-PAGE, probed with 
either anti-IRF-1 antibody or anti-DCIP antibody and developed using ECL reagent. Both 
agarose gel and immunoblot bands were analyzed using Gel-Pro imaging software 
(Media Cybernetics). Values are expressed as mean ± SEM of 3 separate experiments. *, 
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3.1.4. TNF-a-induced DCIP expression is blocked by DCIP-selective ASO 
Kinetics study reveals that induction of DCIP protein expression in lung fibroblasts 
occurred at as early as 6 h after TNF-a stimulation. The expression level reached 
plateau in about 24 h and maintained at that level until 48 h (Figure 10A). In order to 
study the role of DCIP in TNF-a action, we first designed and synthesized a 
DCIP-selective ASO. Pre-treatment of the human lung fibroblasts with this DCIP 
ASO resulted in a dramatic repression of TNF-a-induced DCIP mRNA and protein 
levels at 12 to 24 h; whereas the scramble ODN showed no inhibitory effects (Figure 





























Figure 10. Development of DCIP-selective ASO that blocks TNF-a-induced DCIP 
mRNA and protein expression in normal human lung fibroblasts. (A) Induction of 
DCIP protein expression in human lung fibroblasts occurred at as early as 6 h after 
TNF-a stimulation. The expression level reached plateau in about 24 h and 
maintained at that level until 48 h. DCIP-selective ASO markedly repressed 
TNF-a-induced DCIP mRNA (B) and protein (C) expression in human lung 
fibroblasts. In contrast, scramble ODN showed no inhibitory effects. Values are 
expressed as mean ± SEM of 4 separate experiments. *, significant difference from 





































































































































3.1.5. DCIP regulates TNF-a-responsive gene targets 
DCIP contains a sterile alpha motif (SAM) and a HD domain which is so named due 
to the conserved doublet of predicted catalytic residue histidine (H) and aspartate (D) 
in its N-terminus. SAM domain is a putative protein-protein interaction module 
present in a wide variety of proteins involved in biological processes (Qiao and 
Bowie, 2005), and HD domain is a catalytic domain involved in the metabolism of 
certain signaling molecules (Aravind and Koonin, 1998). We hypothesized that DCIP 
mediates some biological actions of TNF-a in lung fibroblasts that ultimately 
contribute to airway inflammation and remodeling. We found that TNF-a markedly 
increased mRNA expression of adhesion molecules VCAM-1 and ICAM-1, 
pro-inflammatory cytokines IL-6, IL-8 and TSLP, transcription factor 
interferon-g-inducible protein-10 (IP-10), and anti-oxidant MnSOD in human lung 
fibroblasts. DCIP ASO significantly abated TNF-a-induced mRNA levels of all of 
these TNF-a-responsive gene targets. Scramble ODNs did not show any significant 
effects on these gene targets (Figure 11A and 11B). However, DCIP ASO failed to 
block TNF-a-induced MCP-1, MMP-1, eotaxin and RANTES mRNA expression 
(Figure 11C). Our findings clearly confirm a role of DCIP in TNF-a-mediated 
























Figure 11. DCIP mediates TNF-a-induced gene target expression in normal 
human lung fibroblasts. TNF-a markedly increased mRNA expression of VCAM-1, 
ICAM-1, MCP-1, IL-6, IL-8, eotaxin, RANTES, IP-10, MMP-1 and MnSOD in 
human lung fibroblasts. DCIP-selective ASO significantly abated TNF-a-induced 
mRNA levels of VCAM-1, ICAM-1, IL-6, IL-8, IP-10, TSLP and MnSOD, but not 
MCP-1, eotaxin, RANTES and MMP-1. Scrambled ODNs did not show any 
significant effects on these gene targets. Values are expressed as mean ± SEM of at 
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3.1.6. Up-regulation of DCIP in airway resident cells by Th1 cytokine 
In order to have a better understanding of the expression and regulation of DCIP in 
airway resident cells, we stimulated NHLF, human airway smooth muscle cells 
(HASM), and human bronchial epithelial cells (NHBE) with 10 ng/ml TNF-a, 10 
ng/ml IFN-g, 10 ng/ml IL-1b, 10 ng/ml IL-13, 10 ng/ml TGF-b, and 1000 U/ml IFN-b, 
for 6 h, 12 h and 24 h, respectively, and investigated DCIP protein expression. The 
immunoblotting results are shown in Figure 12. TNF-a strongly stimulated DCIP 
protein expression in NHLF and HASM in a time-dependent manner. In comparison, 
IFN-g and IL-1b only slightly induced DCIP protein, while neither IL-13 or TGF-b or 
IFN-b had any effect on the change of expression of DCIP. On the other hand, IFN-g 
was the major stimulus of DCIP expression in NHBE, while TNF-a and IL-1b 
showed some minor up-regulation of DCIP. Again, IL-13, TGF-b or IFN-b did not 
alter the DCIP expression in NHBE. These data comfirm that DCIP is mainly 

























Firgure 12. Regulation of DCIP protein expression in airway resident cells by 
various cytokines and growth factor. NHLF, HASM, and NHBE were treated with 
10 ng/ml TNF-a, 10 ng/ml IFN-g, 10 ng/ml IL-1b, 10 ng/ml IL-13, 10 ng/ml TGF-b, 
and 1000 U/ml IFN-b, for 6 h, 12 h and 24 h, respectively. DCIP protein was 
markedly induced in NHLF and HASM, and mildly induced in NHBE by Th1 
cytokine TNF-a. The other Th1 cytokine IFN-g strongly stimulated DCIP in NHBE, 
and slightly stimulated DCIP in NHLF. IL-1b, Th2 cytokine IL-13, type I interferon 
IFN-b, and growth factor TGF-b did not show obvious effects on DCIP protein level 
in all the three types of airway resident cells tested.  
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3.1.7. MG11 (an orthologue of human DCIP) is up-regulated in a mouse acute 
lung injury model 
To determine whether DCIP can also be up-regulated in vivo, we studied a 
TNF-a-dependent LPS-induced acute lung injury model in mice (Ulich et al., 1991; 
Mukhopadhyay et al., 2006). Intratracheal administration of LPS for 24 h induced a 
4-fold increase in total cell count in BAL fluid. The majority of the infiltrated cells 
were neutrophils (Figure 13A). In addition, BAL fluid protein level of TNF-a was 
markedly elevated (Figure 13B). More importantly, we detected a dramatic 
up-regulation of mouse MG11 (an orthologue of human DCIP) mRNA in acutely 
inflamed lung tissues, together with marked induction of IRF-1, VCAM-1, ICAM-1, 
IL-6 and MnSOD gene targets (Figure 13C). In a major contrast, no observable 
increase in MG11 and TNF-a transcript levels in lung tissues was detected from an 






































Figure 13. MG11 (an orthologue of human DCIP) is up-regulated in a mouse 
acute lung injury model. Acute lung injury model was developed by giving 40 mg of 
LPS intratracheally into the lungs of mice. BAL fluids were collected at 24 h, and 
total and differential cell counts were performed. (A) LPS induced a 4-fold increase in 
total cell count in BAL fluid, majority of which were neutrophils. (B) BAL fluid 
protein level of TNF-a was dramatically elevated in acute lung injury. (C) As 
expected, we observed a drastic up-regulation of mouse MG11 mRNA in acutely 
inflamed lung tissues, together with marked inductions of TNF-a, IRF-1, VCAM-1, 
ICAM-1, IL-6 and MnSOD gene targets. (D) In contrast, we did not detect any 
increase in MG11 and TNF-a transcript levels in lung tissues from an acute mouse 
asthma model. Values are expressed as mean ± SEM of 4 separate experiments. *, 






































































3.1.8. MG11 is also up-regulated in an influenza A virus-infected lung injury 
murine model 
Because IFN-g is also a potent stimulus for DCIP in bronchial epithelial cells, we 
studied the early phase of an influenza A virus-infected lung injury model in mice, 
where IFN-g is markedly stimulated (Matsuo et al., 2000). Intranasal administration of 
influenza A virus induced a 15-fold increase in total cell count in BAL fluid. The 
majority of the infiltrated cells were neutrophils (Figure 14A). In addition, BAL fluid 
protein levels of TNF-a and IFN-g were elevated markedly (Figure 14B). More 
importantly, we detected a dramatic up-regulation of MG11 mRNA in influenza A 
virus infected lung tissues, together with marked induction of IFN-g, TNF-a, IRF-1, 






















































































































Figure 14. MG11 is up-regulated in the early phase of an influenza A 
virus-infected lung injury murine model. 100 pfu of influenza A virus or a 1 in 30 
dilution of allantoic fluid from virus-free chicken eggs in sterile saline was given 
intranasally in a volume of 20 µl. BAL fluids were collected at day 4, and total and 
differential cell counts were performed. (A) Influenza A virus induced a more than 
15-fold increase in total cell count in BAL fluid, majority of which were neutrophils. 
(B) BAL fluid protein levels of both TNF-a and IFN-g were dramatically elevated 
during the early days of infection. (C) As expected, we observed a drastic 
up-regulation of mouse MG11 mRNA in the lungs of influenza A virus-inoculated as 
compared with sham mice, together with marked inductions of IFN-g, TNF-a, IRF-1, 
VCAM-1, ICAM-1, IL-6 and MnSOD gene transcripts. Values are expressed as mean 




It is generally accepted that lung fibroblasts play important roles in airway 
remodeling due to their key function in modulating tissue repair (Postma and Timens, 
2006). There are a few clinical proteomics studies focusing on roles of lung 
fibroblasts in airway remodeling obtained from patients who suffer from pulmonary 
diseases, especially chronic asthma. In early studies, comparison of global protein 
expression was made in lung fibroblasts obtained from human bronchial biopsies 
from patients with asthma and interstitial lung diseases, in which cytoskeleton, 
adhesion, scavenger and metabolic proteins were identified (Malmström et al., 2002; 
Waldburg et al., 2004). More recently, haptoglobin, an acute-phase glycoprotein 
considered to be involved in tissue repair, has been found elevated expression in 
circulating fibrocytes obtained from BALF of patients with mild asthma when 
compared to nonasthmatic control subjects (Larsen et al., 2006). These studies 
suggest critical roles of lung fibroblasts in airway remodeling under the real 
pathological conditions. 
 
In contrast, the role of lung fibroblasts in inflammatory responses is less 
well-characterized, and so far there is no clinical proteomics study ever performed to 
achieve this goal. Our results provide the first differential protein profiling of 
pro-inflammatory cytokine TNF-a stimulation of normal human lung fibroblasts for 
24 h. There is a prior proteomics study on TNF-a stimulation of human lung 
fibroblasts, but it focused only on phosphoproteome signaling changes induced by 
TNF-a for no more than 10 min, a period far too short to allow differential protein 
expression to take place (Guy et al., 1994). In the present study, the identity of 11 
differentially expressed proteins induced by TNF-a was confirmed by 
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MALDI-TOF-MS, and many of them with potential role in airway inflammation and 
remodeling were identified for the first time in lung fibroblasts. The identified 
proteins of interest will be discussed mainly in three groups: (1) Cell protective 
proteins (MxA, ISG15, PAI-2 and MnSOD), (2) Remodeling related protein (P4H a 
subunit and LH2a), and (3) Function unknown protein DCIP. 
 
3.2.1. Cell protective proteins 
The Mx proteins are key components of the anti-viral state induced by type I IFN-a/b 
in many species (Holzinger et al., 2007). In human, two distinct Mx proteins are 
encoded on chromosome 21, called MxA and MxB, but only MxA has detectable 
antiviral activity (Horisberger, 1992). Human MxA has a comparatively wide 
anti-viral spectrum against different types of viruses including members of the 
vesicular stomatitis virus, influenza virus, hepatitis B virus, and so on (Pavlovic et al., 
1990 and 1992; Gordien et al., 2001). Mx proteins appear to detect viral infection by 
sensing nucleocapsid-like structures, and as a consequence, these viral components 
are trapped and sorted to locations where they become unavailable for the generation 
of new virus particles (Lee and Vidal, 2002). Similar to MxA, ISG15 is another 
IFN-induced anti-viral protein which has been reported to be induced by both type I 
and type II IFNs (Ritchie et al., 2004). There is evidence showing that ISG15 may be 
involved in the inhibition of HIV replication by IFN-ω (Kunzi and Pitha, 1996). 
Interestingly, ISG15 can be secreted and works as a cytokine. It has been shown that 
constitutively secreted ISG15 from melanoma cells induces E-cadherin expression on 
tumor-infiltrating DCs and possibly negatively regulates the migratory behavior of 
DCs to escape tumor immune surveillance (Padovan et al., 2002). The major function 
of ISG15 comes from its ubiquitin-like activity, which changes other proteins’ 
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function and fate by the process of what is called ISGylation (Zou et al., 2007). It has 
been shown that influenza B virus can prevent the activation of host defense system 
as a counteraction to anti-viral response by blocking protein ISGylation, suggesting 
the anti-viral activity of protein ISGylation (Samuel, 2001). We have reported here 
that TNF-a promotes the expression of anti-viral protein MxA and ISG15 in normal 
human lung fibroblasts. Our RT-PCR analysis also showed an increase of IFN-b 
mRNA expression in lung fibroblasts stimulated with TNF-a (data not shown), which 
may be responsible for the up-regulation of MxA and ISG15 proteins in our fibroblast 
culture.  
 
Serine protease inhibitor PAI-2 is conventionally characterized as an inhibitor of the 
extracellular serine protease (urokinase-type plasminogen activator) uPA, which 
cleaves the plasminogen into plasmin, catalyzing the breakdown of many ECM 
components (Kruithof et al., 1995). However, unlike PAI-1, most newly synthesized 
PAI-2 remains intracellular, with only a fraction of PAI-2 secreted as a glycosylated 
product (Kruithof et al., 1995). A dramatic up-regulation of PAI-2 by TNF-a has been 
detected in lung fibroblasts, which is believed to act intracellularly to regulate cell 
proliferation, differentiation, and apoptosis (Medcalf and Stasinopoulos, 2005). It has 
been shown that cytoplasmic expression of PAI-2 protects cells from 
TNF-a-mediated cytolysis and apoptosis (Kumar et al., 1991; Dickinson et al., 1995). 
Moreover, PAI-2 has been postulated as a virus response gene. PAI-2 mediates 
induction of constitutive low-level type I IFN production and IFN-stimulated gene 
factor 3 (ISGF3) activation in macrophages, which prime the cells for rapid induction 
of anti-viral genes (Antalis et al., 1998). A recent study has shown that in 
TNF-a-stimulated HeLa cells, PAI-2 could be co-immunoprecipitated with IRF-3, 
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suggesting a possible mechanism for the constitutive low-level type I IFN production 
by PAI-2 (Zhang et al., 2003). 
 
Lung cells experience enhanced oxidant stress by environmental irritants and 
pollutants, which contribute to a significant part of the pathogenesis of obstructive 
lung diseases such as asthma and scleroderma (Larsen et al., 2006). Lung tissue is 
protected against these oxidants by a variety of anti-oxidant mechanisms among 
which the superoxide dismutases (SODs) are the only ones converting superoxide 
radicals to hydrogen peroxide. There are three SODs: cytosolic copper-zinc, 
mitochondrial manganese, and extracellular SODs. MnSOD is essential for survival as 
dramatically illustrated by the neonatal lethality of mice that are deficient in MnSOD 
(Li et al., 1995). It has been shown that TNF-a stimulates MnSOD expression via 
increased reactive oxygen species (ROS) (Rogers et al., 2001). In addition to its 
anti-oxidant activity, MnSOD expression has also been related with anti-apoptotic 
(Ranjan and Boss, 2006) and anti-viral (Raineri et al., 1996) actions. 
 
In summary, TNF-a is able to induce expression of functionally related protein 
including MxA, ISG15, PAI-2, MnSOD and the type I IFN-b in normal lung 
fibroblasts to set up a network with strong anti-viral, anti-apoptotic and anti-oxidant 
activities to give the airway a second defense besides the airway epithelium.  
 
3.2.2. Airway remodeling-related proteins 
Collagen deposition in subepithelial layer is a classical feature of airway remodeling. 
The biosynthesis of collagen molecules involves several intracellular 
post-translational modifications followed by excretion and extracellular aggregation 
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of the collagen molecules into fibrils, which are subsequently stabilized by 
intermolecular cross-links. Prolyl 4-hydroxylase (P4H) and lysyl hydroxylase (LH) 
are the two major enzymes for the intracellular events. The up-regulation of P4H a 
subunit and LH2a by TNF-a has implication in fibroblast-mediated airway 
remodeling. 
 
P4H occupies a key position in the intracellular sequence of events in collagen 
biosynthesis, which converts accessible proline residues in the Y position of 
-Gly-X-Y- triplets to peptidyl 4-hydroxyproline within the collagen pro a-chains 
(Kegan, 2000). Vertebrate P4H enzymes are a2b2 tetramers containing two different 
subunits. The a subunit is responsible for its catalytic function, with iron as an 
essential cofactor (Myllyharju, 2003). It has been shown that ROS-dependent NF-κB 
activation induces the P4H a subunit gene expression (Dai et al., 2002). TNF-a is 
well documented for its ability to generate ROS and the downstream NF-κB 
activation, which is probably the mechanism for its stimulation of PH a subunit gene.  
 
The enzymes responsible for modification of lysyl residues belong to the lysyl 
hydroxylase family comprising three members LH1, LH2 and LH3, which 
hydroxylate selected lysine residues to 5-hydroxylysine (Kegan, 2000). For LH2, 
alternative splicing has been documented resulting in splice variants LH2a and LH2b 
(Walker et al., 2005). It has been shown that an overexpression of LH2 in a mouse 
osteoblastic cell line directs collagen cross-linking pathway towards 
5-hydroxylysine-derived collagen cross-links (Pornprasertsuk et al., 2004). It is the 
first time ever reported that TNF-a up-regulates LH2 variant in lung fibroblasts, 




3.2.3. Function unknown protein DCIP 
Unexpectedly, DCIP was strongly induced by TNF-a in lung fibroblasts in our 2-DE 
images. Moreover, DCIP was also found to be markedly up-regulated in bronchial 
smooth muscle cells by TNF-a and in bronchial epithelial cells by IFN-g. The 
biological function of this protein is at present unknown. The gene locus for DCIP 
locates on chromosome 20pter-q12 (Deloukas et al., 2001), and the cDNA encoding 
DCIP (1881 bp ORF) was originally identified in peripheral blood monocyte-derived 
dendritic cells (Nan et al., 2000). The deduced amino acid sequence (626 aa), which 
is 72% identical to a mouse SAM and HD domain-containing protein 1 (SAMHD1) 
protein MG11 (Nan et al., 2000), contains several phosphorylation and 
N-myristoylation sites, an N-glycosylation site, and an amidation site. It has no signal 
peptide or transmembrane region, suggesting that DCIP is an intracellular protein. A 
BLAST search based on the protein sequence of DCIP shows that this protein 
contains an N-terminal SAM domain followed by a highly conserved HD domain 
containing metal-dependent phosphohydrolase activity. The SMART database 
identifies over 2000 proteins containing SAM domains in all genomes. The SAM 
domain exhibits diverse protein-protein interaction modes, and even binds to RNA 
hairpins and lipids (Barrera et al., 2003; Qiao and Bowie, 2005; Aviv et al., 2006). 
The NMR structure of the N-terminal SAM domain of DCIP has been determined and 
shown to contain the typical a-helical fold of SAM domain (PDB ID: 2E8O) (Figure 
15). The HD domain contains a unique pattern of histidine and aspartic acid residues 
for metal coordination (Aravind and Koonin, 1998), but the structure of this HD 
domain-containing phosphohydrolase is still unknown. Nevertheless, secondary 
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structure prediction shows that it is mainly a-helical with a C-terminal region rich in 
b-strands. HD domain-containing proteins constitute a superfamily of 
phosphodydrolases predicted to function in nucleic acid metabolism and signal 
transduction (Aravind and Koonin, 1998; Yakunin et al., 2004). Northern blot analysis 
of DCIP revealed expression of a 5.2 kb transcript in most normal tissues including 
heart, skeletal muscle, spleen, liver, lung and peripheral blood leukocytes, but not 
brain and thymus (Nan et al., 2000).  
 
We conducted a series of experiments to explore potential role of DCIP in TNF-a 
effects in lung fibroblasts. First, we investigated the regulatory mechanism of DCIP 
expression in lung fibroblasts. Computer-based analysis of the promoter region of 
human DCIP cDNA revealed several consensus sequence motives for binding 
transcription factors including IRF-1, SP-1 and NF-1. IRF-1 activity is primarily 
regulated at the transcriptional level and its expression has been shown to be strongly 
induced by TNF-a (Kroger et al., 2002). We speculated that the induction of DCIP by 
TNF-a may be dependent on IRF-1 level. Indeed, TNF-a was able to increase the 
IRF-1 mRNA and protein expression in lung fibroblasts. By using a IRF-1-selective 
ASO (Wagner et al., 2002), TNF-a-induced DCIP expression in human lung 
fibroblasts was markedly reduced to basal level, indicating that the induction of DCIP 






























Figure 15. NMR structure of the N-terminal SAM domain of human DCIP. The 
SAM domain of human DCIP contains the typical a-helical fold (shown in red color), 
but the structure of HD domain is still unknown (Adapted from Molecular Modeling 
Database ID 53006) (Chen et al., 2003). 
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Our kinetics study showed that DCIP protein could be up-regulated by TNF-a in as 
early as 6 h post-stimulation and lasting for 48 h. We speculated that DCIP may 
mediate the biological actions of TNF-a. To test this hypothesis, we designed a 
DCIP-selective ASO, had the ASO synthesized with full backbone 
phosphorothioate-modified, and confirmed the ASO knockdown effects in both DCIP 
mRNA and protein levels in lung fibroblasts. As expected, DCIP ASO pretreatment 
was able to markedly suppressed mRNA levels of a wide range of TNF-a-stimulated 
gene targets including VCAM-1, ICAM-1, IL-6, IL-8, TSLP and MnSOD (Bonizzi 
and Karin, 2004; Hoffmann and Baltimore, 2006; Lee and Ziegler, 2007), indicating 
an important role of DCIP in TNF-a-induced inflammatory responses. However, the 
exact mechanism of how DCIP can regulate TNF-a biological actions remains to be 
determined. A few recent studies support a possible role of DCIP in signal 
transduction. First of all, DCIP has been localized in cytoplasm and nucleus by GFP 
fusion analysis (Simpson et al., 2000). Moreover, its phosphorylated protein has also 
been detected in both cytoplasm and nucleus after EGF stimulation (Olsen et al., 
2006). Thirdly, in a proteomics study for protein-protein interaction, DCIP has been 
identified to interacte with the bait pleckstrin homology-like domain, family A, 
member 3 (PHLDA3), a protein predicted for cell communication and signal 
transduction (Ewing et al., 2007). As DCIP contains SAM and HD domains in its 
protein structure, it is highly possible that DCIP may bind to certain signaling 
molecules in the TNF-a signaling cascade via its SAM domain and modulate their 
functions via its intrinsic phosphohydrolase activity within the HD domain. 
 
To verify our novel findings in normal human lung fibroblasts, we investigated DCIP 
expression in a TNF-a-dependent LPS-induced (Ulich et al., 1991), and an influenza 
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A virus-infected IFN-g-predominant mouse lung injury model (Matsuo et al., 2000). 
Consistent with the in vitro observation, we detected for the first time a drastic 
increase in mouse lung tissue MG11 mRNA level, together with marked inductions of 
IRF-1, VCAM-1, ICAM-1, IL-6 and MnSOD transcripts in both the LPS-induced and 
influenza A virus-infected mouse lung injury model. As expected, we also detected a 
substantial elevation of TNF-a and IFN-g levels in bronchoalveolar lavage fluid from 
the LPS-induced and influenza A virus-infected mouse lung injury model, 
respectively. These data further support a role of DCIP in TNF-a and/or 
IFN-g-dependent airway inflammation. In a major contrast, mouse lung MG11 
mRNA level was either unchanged or slightly lowered in an acute mouse allergic 
airway inflammation, a model primarily mediated by Th2 immunity. Therefore, it 
seems that DCIP is up-regulated by and may contribute to Th1-mediated immune 










4. PROTEOMICS STUDIES OF TNF-a AND/OR 




4.1.1. Proteomics analysis of apoL2 induction by IFN-g 
Human bronchial epithelial cells were harvested 24 h and 48 h after stimulation with 
TNF-a and/or IFN-g. 2-DE proteomics approach was employed to identify 
differentially expressed proteins in TNF-a and/or IFN-g-treated human bronchial 
epithelial cells (n ³ 4 gels from at least 4 separate experiments) as compared with 
controls (n ³ 4 gels from at least 4 separate experiments). Cell lysates were resolved 
in both pH 4-7 and pH 6-11 gels. Following image analysis, about 1000 protein spots 
were consistently detected in pH 4-7 gel, and 500 protein spots in pH 6-11 gel. A total 
of 13 differentially expressed protein spots were detected and identified in TNF-a 
and/or IFN-g-stimulated bronchial epithelial cells based on statistically significant 
changes in optical density, corresponding to 12 by IFN-g and 2 by TNF-a, with 1 
shared by both. All the detected protein spots with significant changes were found to 
be up-regulated by the treatments, with IFN-g showing a much more substantial effect 
on the proteome alteration of human bronchial epithelial cells as compared to TNF-a. 
Most of the up-regulation could be elicited by IFN-g alone, whereas adding TNF-a 
did not further enhance the elevation of these proteins. The fold change of the 
detected protein spots by TNF-a and/or IFN-g is shown in Table 6. Ten proteins (spot 
nos. 1-10) were identified in pH 4-7 gel, 3 proteins (spot nos. 11-13) in pH 6-11 gel. 
The location of the identified protein spots is shown in representative gels (Figure 16). 
Protein spots were subjected to MALDI-TOF/TOF mass spectrometer analysis, and 
the identities were confirmed by MS/MS (Table 7). Direct comparison of the optical 
densities of protein spots between control and TNF-a and/or IFN-g-treated bronchial 
epithelial cells is illustrated in Figure 17. To the best of our knowledge, many of these 
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proteins were identified for the first time to be altered by IFN-g in normal human 
bronchial epithelial cells at the protein expression level, which include metastasis 
suppressor N-myc downstream-regulated gene-1 (NDRG-1, spot no. 4) (Kovacevic 
and Richardson, 2006), serine protease inhibitor, clade B, member 1 (SERPINB1, 
spot no. 7) (Yasumatsu et al., 2006), cytoskeleton protein keratin10 (spot no. 5) 
(Siegel and Howard, 2005), tropomyosin 3 isoform 2 (spot no. 2) (McMichael et al., 
2006), g-actin (spot no. 3) (Sonnemann et al., 2006) and apolipoprotein 2 (apoL2, spot 
no. 10) (Sana et al., 2005).  
 
ApoLs have been reported to be strongly induced at the mRNA level by the 
pro-inflammatory cytokine TNF-a (Horrevoets et al., 1999; Monajemi et al., 2002) or 
IFN-g (Sana et al., 2005) in endothelial cells, but we could only observe major change 
in apoL2 protein level induced by IFN-g, but not by TNF-a in the human bronchial 
epithelial cells. The function of apoLs is largely unknown at the present. They have 
been proposed to be involved in cytokine-induced apoptosis, based on their similarity 
to a well-established apoptotic family of proteins named Bcl-2 family (Vanhollebeke 
and Pays, 2006). We further investigated the potential function of apoLs in TNF-a 
and IFN-g-induced cytotoxicity to human bronchial epithelial cells. 
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Table 6. The fold change of detected protein spots in normal human bronchial 
epithelial cells stimulated with TNF-a and/or IFN-g 
 
24 hours 48 hours Spot 
ID TNF-α IFN-γ TNF-α and IFN-γ TNF-α IFN-γ TNF-α and IFN-γ 
1 1.71 -1.10 2.08 2.50* -1.14 2.46* 
2 1.00 13.91* 14.65* -1.25 16.56* 15.74* 
3 -1.07 4.57* 4.55* 1.01 6.44* 6.16* 
4 -1.5 6.63* 6.07* -1.07 9.78* 8.94* 
5 -1.36 11.82* 11.40* -2.11 16.55* 17.94* 
6 -1.15 11.28* 12.37* 1.02 14.01* 14.82* 
7 -1.04 6.44* 6.07* -1.21 9.31* 8.94* 
8 1.03 22.36* 23.21* -1.00 31.45* 34.07* 
9 1.02 8.82* 8.36* 1.08 19.54* 19.17* 
10 -1.01 3.62* 3.89* 1.00 5.31* 5.60* 
11 1.09 3.02* 3.18* -1.14 6.72* 6.13* 
12 1.15 4.11* 3.70* 1.06 7.13* 6.86* 
13 4.54* 16.69* 18.28* 6.37* 18.05* 24.41* 
 





































Figure 16. Representative raw 2-D gels of normal human bronchial epithelial cell 
lysates. The location of all 13 protein spots that have been found to be significantly 
altered by TNF-a and/or IFN-g is shown in the representative raw 2-D pH 4-7 (left 
panel) and pH 6-11 (right panel) gels. Numbers correspond to the spot identification 
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1 MMP-9 gi|13543893 80.0/5.69 80/6.0 80 28 N/A N/A 
2 tropomyosin 3, isoform 2 gi|24119203 29.0/4.75 29/4.8 393 66 6 149 
3 g-actin gi|178045 26.1/5.65 26/5.5 154 42 5 113 
4 NDRG-1 gi|37655183 43.3/5.49 44/5.5 229 39 7 164 
5 keratin10 gi|40354192 59.0/5.09 35/5.8 109 9 2 91 
6 IFP-35 gi|19861692 31.2/5.75 35/5.8 129 34 2 59 
7 Serpin B1 gi|13489087 42.8/5.90 42/6.0 538 52 9 360 
8 tryptophanyl-tRNA 
synthetase, isoform a 
gi|47419916 53.5/5.83 55/6.0 350 48 7 156 
9 tryptophanyl-tRNA 
synthetase, isoform b 
gi|47419918 49.2/6.03 49/6.1 316 39 7 193 
10 apolipoprotein L2 gi|13325156 37.1/6.28 37/6.3 246 24 7 185 
11 tapasin isoform 3 precursor gi|27436897 44.1/6.35 50/6.8 96 21 3 48 
12 tapasin isoform 1 precursor gi|27436893  47.9/6.50 50/7.0 225 22 5 183 
13 Mn-superoxide dismutase gi|16877367 22.0/6.79 22/6.8 268 34 6 186 
 
a) Protein scores are derived from ions scores as a non-probabilistic basis for ranking protein hits. Protein score of greater than 75 is considered 
significant (p < 0.05). 
b) Sequence coverage of matched peptide. 
c) Number of matched MS/MS peptides. 
d) Ion score is -10 ´ log(p), where p is the probability that the observed match is a random event. Total ion scores are calculated from weighted 
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Figure 17. Differential protein profiling of TNF-a and/or IFN-g stimulation of normal human bronchial epithelial cells. Direct 
comparison of TNF-a and/or IFN-g-induced differentially expressed proteins with control protein spots individually in randomly selected 2-D 
gels. The corresponding bar charts show the individual spot intensities (PPM) expressed as mean ± SEM. Protein spot intensities of control and 
TNF-a and/or IFN-g-treated bronchial epithelial cells were analysed using One-way ANOVA followed by a Dunnett’s T3 multiple-comparisons. 
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4.1.2. Up-regulation of the whole apoL family members by IFN-g 
To validate the observation from our proteomics study, we chose a few protein spots 
for RT-PCR analysis. The RT-PCR results are shown in Figure 18A. Except for 
trypomyosin 3, isoform 2 and g-actin, alteration of all the other transcripts correlated 
well with the differential protein expression observed in proteomics analysis. 
Interestingly, by using RT-PCR we found that the transcripts of all apoL family 
members except apoL5, were dramatically up-regulated by IFN-g (Figure 18B). 
Besides the reported trypanolytic activity of apoL1 in human serum (Vanhamme et al., 
2003), and pro-apoptotic action of apoL6 (Liu et al., 2006), the biological functions of 
the rest of the members of this family are mostly unknown so far. We further 
investigated the expression and functional roles of apoL1, 2, 3 and 4 in 






































Figure 18. RT-PCR analysis of mRNA from control and TNF-a and/or 
IFN-g-treated human bronchial epithelial cells. Cells was treated with TNF-a 
and/or IFN-g for 12, 24, 36 h. Total cellular RNA was extracted by Trizol reagent, and 
PCR was performed using PCR master mix with 1 mg of total cDNA. PCR products 
were run in a 2% agarose gel and visualized under UV light. (A) Representative gene 
SERPINB1, NDRG-1, WARS (tryptophanyl-tRNA synthetase) and apoL2 transcript 
was found markedly induced by IFN-g, while tropomyosin3, isoform2 and g-actin 
gene were not. (B) Interestingly, the transcripts of apoL family member 1 ~ 6 except 5, 
were dramatically up-regulated by IFN-g. β-actin was used to demonstrate the equal 
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4.1.3. Selective induction of apoL2 by IFN-g 
We detected a consistent up-regulation of apoL2 in both mRNA and protein levels. In 
order to have a better understanding of the regulation of apoL2, we stimulated human 
bronchial epithelial cells with 10 ng/ml TNF-a, 10 ng/ml IFN-a, 10 ng/ml IL-1b, 10 
ng/ml IL-13, 10 ng/ml TGF-b, and 1000 U/ml IFN-b, for 24 h and 48 h, respectively, 
and investigated its mRNA expression. The real-time PCR result is shown in Figure 
19. IFN-g specifically stimulated apoL2 mRNA expression in bronchial epithelial 
















Firgure 19. Regulation of apoL2 mRNA expression in bronchial epithelial cells 
by various cytokines and growth factor. Human bronchial epithelial cells were 
treated with 10 ng/ml TNF-a, 10 ng/ml IFN-g, 10 ng/ml IL-1b, 10 ng/ml IL-13, 10 
ng/ml TGF-b, and 1000 U/ml IFN-b, for 24 h and 48 h, respectively. ApoL2 mRNA 
expression was markedly induced by IFN-g only, while none of the other stimuli 
tested showed obvious effects on apoL2 mRNA level. Values are expressed as mean ± 



























4.1.4. ApoLs siRNA characterization 
In order to study the role of apoLs in IFN-g-related biological activity, we used 
pre-designed apoL1, 2, 3 and 4-selective siRNAs (designated as siRNA 1, 2, 3 and 4) 
to knock down its respective gene expression. Pre-treatment of the human bronchial 
epithelial cells with siRNA 1, 2 and 3 resulted in a dramatic repression of 
IFN-g-induced apoL1, 2 and 3 mRNA levels at 24 and 48 h, respectively; whereas the 
all-star siRNA negative control (designated as siRNA A) and siRNA 4 did not show 


















































Figure 20. ApoLs siRNA characterization. Pre-treatment of the human bronchial 
epithelial cells with apoL1, 2 and 3 siRNA designated as 1, 2 and 3 resulted in a 
substantial inhibition of IFN-g-induced apoL1, 2 and 3 mRNA levels at 24 and 48 h, 
respectively; whereas the all-star negative control siRNA A and apoL4 siRNA did not 
show any significant effects. Values are expressed as mean ± SEM of at least 3 
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4.1.5. ApoL2 siRNA facilitates TNF-a or IFN-g-induced cytotoxicity 
ApoL family has been proposed to be involved in cytokine-induced apoptosis, based 
on their possession of a motif called Bcl-2 homology signature motif (BH1 to BH4) 
(Figure 21). Bcl-2 homology signature motif is present in a family of proteins named 
Bcl-2 family which is composed of both pro- (e.g. Bid, Bax, Bcl-Xs) and anti- (e.g. 
Bcl-2, Bcl-xL, Bcl-w) apoptotic proteins (Vanhollebeke and Pays, 2006). Indeed, 
apoL6 has been confirmed to be a novel BH3-only protein which promotes apoptosis 
(Liu et al., 2005). However, a number of recent reports have shown increased 
expression of apoLs in several cancer tissues, such as apoL2 in cervical cancer (Ahn 
et al., 2004) and apoL3 in breast cancer cell line (Jung et al., 2005). In the present 
study, normal human bronchial epithelial cells have shown potent resistence to TNF-a 
or IFN-g-induced cytotoxicity up to 72 h, with only 15% and 18% cell decrease, 
respectively (Figure 22A). We hypothesized that apoL family members might protect 
the bronchial epithelial cells from TNF-a or IFN-g-induced pro-apoptotic effects. In 
this regard, we observed a significant cytotoxic effect of IFN-g, with 54% cell loss 
when the epithelial cells were pretreated with apoL2 siRNA. All-star negative control, 
apoL1, 3, and 4 siRNA did not produce any significant effect on epithelial cell 
number (Figure 22B). Similar results were observed in epithelial cells treated with 














Figure 21. Schematic representation and alignment of the domains of apoLs. (A) Schematic comparison of apoLs and multidomain Bcl-2 
family members (drawn to scale). Black and white boxes, respectively, depict a helices and the hydrophobic a helices forming the core of the 
pore-forming domain. TM, transmembrane domain (hydrophobic tail anchoring the protein in membranes). The numbering of the a-helices of 
apoLs is based on that of helices of the colicin A pore-forming domain. (B) Alignment of the three domains of apoLs. Black and grey shadings, 















































Figure 22. ApoL2 siRNA facilitated TNF-a or IFN-g-induced cytotoxicity. MTT 
assay was used to measure the live cell number. Brochial epithelial cells were 
incubated in 0.5 mg/ml MTT reagent for 4 h to form the purple color formazone 
crystals, followed by dissolving of the crystals using DMSO. The absorbance was 
read at 595 nm. (A) Normal human bronchial epithelial cells showed potent resistence 
to TNF-a or IFN-g-induced cytotoxicity up to 72 h. (B) A significant drop in epithelial 
cell number was observed in response to IFN-g for 72 h only when the cells were 
pretreated with apoL2 siRNA. All-star negative control, apoL1, 3, and 4 siRNAs did 
not produce any significant effect on epithelial cell number. (C) Similar results were 
observed in epithelial cells treated with TNF-a for 72 h. Values are expressed as mean 
± SEM of at least 4 separate experiments. *, significant difference from all-star siRNA 
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4.1.6. ApoLs are up-regulated in an influenza A virus-infected lung injury 
mouse model 
To determine whether apoLs can also be up-regulated in vivo, we studied the early 
phase of an IFN-g-dependent influenza A virus-infected lung injury model in mice. 
Intranasal administration of influenza A virus for 4 days induced a more than 15-fold 
increase in total cell count in BAL fluid. The majority of the infiltrated cells were 
neutrophils (Figure 23A). In addition, BAL fluid protein levels of TNF-a and IFN-g 
were elevated markedly (Figure 23B). As expected, we detected dramatic 
up-regulation of mouse apoL2, apoL 3 and apoL6 mRNA, which are the only 3 mouse 
orthologues of apoLs, and mouse SERPINB1a (mouse orthologue of human 
SERPINB1) , NDRG-1, WARS, and tapasin transcript in influenza A virus-infected 
lung tissues. In contrast, the tested targets did not show any obvious mRNA level 





























































































































Figure 23. ApoLs are up-regulated in an influenza A virus-infected lung injury 
mouse model. 100 pfu of influenza A virus or a 1 in 30 dilution of allantoic fluid from 
virus-free chicken eggs in sterile saline was given intranasally in a volume of 20 µl. 
BAL fluids were collected at day 4, and total and differential cell counts were 
performed. (A) Influenza A virus induced a more than 15-fold increase in total cell 
count in BAL fluid, majority of which were neutrophils. (B) BAL fluid protein levels 
of IFN-g and TNF-a were dramatically elevated in virus-infected lung. (C) 
Interestingly, we observed a drastic up-regulation of mouse apoL orthologue, apoL2, 
apoL3, and apoL6 mRNA, and also mouse SERPINB1a, NDRG-1, WARS, and 
tapasin in the lungs of influenza A virus-inoculated mice. In a major contrast, none of 
the tested targets showed obvious change of mRNA expression in inflamed lung 
tissues obtained from LPS-induced acute lung injury model. Values are expressed as 




Airway epithelial cells play an important role in both physiological and 
pathophysiological considitions. Clinical proteomics studies, which have been used to 
study airway epithelia-associated diseases, are mostly focused on epithelia-origin 
cancer, to identify novel prognostic, diagnostic and therapeutic biomarkers (Liu et al., 
2004, Li et al., 2006, Lou et al., 2007). An interesting study was performed to 
compare protein profiles between human lung nonsmall cancer cell lines (e.g. large 
cell carcinoma H1299, alveolar cell carcinoma SW 1573, adenocarcinoma H23, 
squamous cell carcinoma H266), immortalized normal human bronchial epithelial cell 
line (HBE4-E6/E7), and primary human bronchial epithelial cells (NHBE). The 
results demonstrated that expression of the cytokeratin 8 and proto-oncogene 
translation elongation factor 1d (TEF1d) were increased; whereas expression of tumor 
suppressor gene 14-3-3d was decreased in cancer cell lines as compared with normal 
cell line and primary cells (Liu et al., 2003). Recently, laser capture microdissection 
technology has been widely employed to isolate specific cell types from clinical 
human tissues, followed by proteomics analysis (Domazet et al., 2008, Mustafa et al., 
2008, Sanders et al., 2008). In this way, annexin A3 has been identified as a novel 
biomarker for lymph node metastasis and prognosis in lung adenocarcinoma (Liu et 
al., 2008). 
 
Though impressive, these studies are mostly restricted to cancer research, and there is 
still a significant gap in the investigation of epithelial proteomics of acute and chronic 
lung inflammation and remodeling. Our results provide the first differential protein 
profiling of pro-inflammatory cytokine TNF-a and/or IFN-g stimulation of normal 
human bronchial epithelial cells. It is surprising that IFN-g showed much more 
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substantial effects on the proteome alteration of human bronchial epithelial cells than 
TNF-a. There is a prior microarray study on IFN-g stimulation of human bronchial 
epithelial cells, but it only reported the mRNA profile (Pawliczak et al., 2005). By 
using 2-DE followed by MALDI-TOF-MS/MS, the present study confirmed some of 
the microarray data like SERPINB1, NDRG-1, IFP-35, WARS and MnSOD being 
up-regulated by IFN-g at a protein level. In addition, it identified a few other 
IFN-g-regulated proteins which were not picked up by the microarray study such as 
cytoskeleton protein tropomyosin 3, g-actin and keratin10, whose protein 
up-regulation might be due to translational regulation instead of gene induction. 
Interestingly, the microarray study found an increased mRNA level of apoL1 while 
we identified an up-regulated protein level of apoL2 in response to IFN-g. Many of 
the identified proteins with potential role in airway inflammation, cytoskeleton 
reconstitution, cell proliferation and apoptosis were found for the first time to be 
up-regulated by IFN-g in human bronchial epithelial cells at a protein level. 
 
4.2.1. Apolipoproteins 
ApoL1 was identified as a member of the subclass of high-density lipoprotein in 
human blood (Duchateau et al., 1997), which is conventionally considered as related 
to lipid transport and metabolism. This protein is encoded by a gene belonging to a 
multigene family that consists of six members, apoL1 ~ 6, organized as a cluster on 
the 22q13.1 locus (Duchateau et al., 2001; Page et al., 2001). Studies aiming at 
understanding the mechanism of resistance of T. b. rhodesiense, a African 
trypanosome to human serum lytic activity leads to the identification of apoL1 as 
trypanolytic factor (Vanhamme et al., 2003). ApoL1 is found capable of generating 
anionic pores in asolectin membranes, and it is as efficient as the pore-forming protein 
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colicin A at depolarizing the membrane of Escherichia coli (Perez-Morga et al., 2005). 
Based on the effect of apoL1 on trypanosomes and the demonstrated anionic 
pore-forming activity of this protein in asolectin and T. brucei lysosomal membranes, 
the original function of apoLs has been speculated as ionic channels of intracellular 
membranes (Vanhollebeke and Pays, 2006). 
 
ApoL1 is distinguished from the other members of apoL family due to the presence of 
an additional N-terminal signal peptide for its secretion into the serum. The other 
members do not possess such a signal peptide sequence and are proposed to be 
intracellular (Vanhollebeke and Pays, 2006). Though ApoL transcripts are present in a 
wide variety of organs, the intracellular localization of apoLs is totally unknown 
(Duchateau et al., 2001; Page et al., 2001; Monajemi et al., 2002). ApoLs are strongly 
stimulated by pro-inflammatory cytokines TNF-a and IFN-g in endothelial cells 
(Horrevoets et al., 1999; Monajemi et al., 2002; Sana et al., 2005). In addition, type I 
interferon IFN-a and IFN-b can also regulate apoL transcripts, and apoLs are 
up-regulated in some virus infected cells (Hayashi et al., 2005, Stojdl et al., 2003).  
 
Given the optimal activity of apoL1 at acidic pH and the localization of this protein in 
the lysosomal membrane of trypanosomes (Perez-Morga et al., 2005), lysosome has 
been proposed to be a candidate target site and apoLs might be involved in 
cytokine-induced and lysosome-mediated apoptosis under some pathlogical 
conditions (Vanhollebeke and Pays, 2006). Several pieces of evidence suggest this 
hypothesis, based on their possession of a motif called Bcl-2 homology signature 
motif (BH1 to BH4). Bcl-2 homology signature motif is present in a family of 
proteins named Bcl-2 family which is composed of both pro- (such as Bid, Bax, 
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Bcl-Xs, Bak, Bad, Bim, Puma) and anti- (such as Bcl-2, Bcl-xL, Bcl-w) apoptotic 
proteins (Vanhollebeke and Pays, 2006). Various proteins containing only the BH3 
motif (termed BH3-only proteins) can sense different stress conditions and initiate 
apoptosis (Bouillet and Strasser, 2002). In fact, the presence of a BH3 domain in helix 
6 of the pore-forming domain (Perez-Morga et al., 2005) could characterize the entire 
apoL family (Figure 24). Moreover, in a screen for novel BH3-only proteins, apoL6 
has been selected and found to promote apoptosis (Liu et al., 2005). Overexpression 
of apoL6 in cells devoid of p53 leads to typical signs of apoptosis, and the 
pro-apoptotic effect of apoL6 is significantly lost upon deletion of the putative BH3 
motif (Liu et al., 2005). On the other hand, however, a growing number of recent 
reports point to significant increase of the expression level of apoLs in several cancers, 
particularly cervical cancer, ovarian cancer and breast cancer (Ahn et al., 2005; Jung 
et al., 2005; Hayashi et al., 2005), indicating a proliferation-promoting or 




















Figure 24. Alignment of the BH3 signature motif of the apoLs with other human 




The available data indicate that the family of apoLs might contain both pro- and anti- 
apoptotic proteins, similar to Bcl-2 family. Because of the reported pro-apoptotic 
effect of apoL6, we are interested in identifying the pro- or anti- apoptotic effect of 
other apoL members (except for apoL5), which are induced by a well-known 
anti-tumor cytokine, IFN-g (Chawla-Sarkar et al., 2003). Due to the observed 
cytotoxic resistence of human bronchial epithelial cells to IFN-g, we hypothesized the 
up-regulation of apoL family members by IFN-g might be involved in the 
anti-apoptotic effect induced by IFN-g. By using apoLs-selective siRNAs, we 
dramatically knocked down IFN-g-induced apoL1, 2 and 3 mRNA levels. More 
importantly, we detected a significant cell number decrease in response to IFN-g for 
72 h only when the cells were pre-treated with apoL2 siRNA but not apoL1, 3 or 4 
siRNA. Interestingly, a similar profile of the effects of apoL siRNAs was observed on 
these cells after stimulation with another notorious pro-apoptotic cytokine, TNF-a. 
Since TNF-a could not up-regulate apoLs expression, the basal level of apoL2 might 
function to prevent cell loss. This reflects a more general function of apoL2, which 
might be an anti-apoptotic protein, protecting the airway epithelium layer from 
cytokine-induced apoptosis during inflammation. Moreover, apoL3 siRNA slightly 
decreased cell number in response to TNF-a or IFN-g, though the data were not 
significant. These data are consistent with two recent findings that apoL2 and apoL3 
are markedly up-regulated in some cancers (Ahn et al., 2004; Jung et al., 2005), which 
might be the cause for the potent anti-apoptotic ability of these cancer cells. However, 
more direct evidence is needed to address this. Furthermore, the underlying 
mechanisms for the anti-apoptotic ability of apoL2 and apoL3 remain to be 
investigated. ApoL3 has recently been shown to activate NF-kB pathway (Matsuda et 




To verify our in vitro findings in normal human bronchial epithelial cells, we 
investigated apoLs expression in an influenza A virus-infected IFN-g-predominant 
mouse lung injury model (Matsuo et al., 2000). Consistent with the in vitro 
observation, we detected for the first time a drastic increase of mouse lung tissue 
apoL2, apoL3 and apoL6 mRNA level in the influenza A virus-infected lung injury, 
together with a substantial elevation of IFN-g level in bronchoalveolar lavage fluid. 
These data further support a role of apoLs in IFN-g-dependent airway inflammation. 
In contrast, mouse lung tissue apoL2 and apoL3 mRNA level was either unchanged or 
slightly lowered, whereas apoL6 transcript was increased in a LPS-induced 
TNF-a-dependent acute lung injury model. However, the exact stimulus to apoL6 
gene induction in the LPS-induced lung injury model is unknown. Therefore, it seems 
that apoLs are up-regulated by and may contribute to IFN-g-mediated inflammatory 
responses such as viral infection. 
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4.2.2. NDRG-1 
Human NDRG-1 has been identified as a metastasis suppressor in prostate, colon and 
breast cancers (Guan et al., 2000, Bandyopadhyay et al., 2003 and 2004, Shah et al., 
2005). Although the tissue expression of NDRG-1 mRNA is ubiquitous, NDRG-1 
protein is mainly found in epithelial cells, suggesting that NDRG-1 has a specific 
function in epithelial cells (Lachat et al., 2002). 
 
NDRG-1 has been shown to be involved in differentiation. Studies examining 
NDRG-1 overexpression in metastatic colon cancer cells have reported morphological 
changes resembling differentiation (Guan et al., 2000). Further evidence shows that 
NDRG-1 is involved in cell cycle regulation and required to maintain spindle 
structure during cell division in human mammary epithelial cells. In fact, NDRG-1 is 
a microtubule associated protein that localizes to centrosomes and participates in the 
spindle checkpoint in a p53-dependent manner (Kim et al., 2004).  
 
The up-regulated NDRG-1 has also been proposed to be one of the genes necessary 
for p53-dependent apoptosis following p53 induction in the colon cancer cell line 
DLD-1 (Stein et al., 2004). Selective knockdown of p53 using siRNA results in 
reduced NDRG-1 expression in DLD-1 cells. Furthermore, a luciferase reporter assay 
shows that NDRG-1 is a direct target gene of p53 (Stein et al., 2004). Together, these 
data suggest that the frequent loss of p53 expression in cancers might be responsible 
for reduced NDRG-1 expression. Paradoxically, a recent study has found that 
NDRG-1 inhibits p53 expression in human placental trophoblasts, acting to alleviate 
apoptosis and promote cell survival in response to hypoxic injury (Chen et al., 2006). 
This might suggest the different roles of NDRG-1 between normal trophoblasts and 
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cancer cells, which requires further investigation.  
 
IFN-g is well-known to possess cell growth inhibitory ability (Schroder et al., 2004). 
It is the first time that NDRG-1 protein expression has been found to be up-regulated 
by IFN-g in normal bronchial epithelial cells, which suggests a possible way that 
IFN-g inhibits epithelial cell proliferation. However, we did not detect a significant 
cell loss up to 72 h in response to IFN-g, indicating a minor role that NDRG-1 plays, 
if any. On the other hand, the potential anti-proliferative effect of NDRG-1 might be 
overwhelmed by the cyto-protective effect of apoL family members. Therefore, the 
significance of up-regulation of NDRG-1 by IFN-g remains to be answered.  
 
4.2.3. SERPINB1 
SERPINB1 was firstly described as a monocyte-derived protein that was a fast-acting 
inhibitor of neutrophil and pancreatic elastase. It is unique, as it is the only human 
clade B serpin that effectively neutralizes all of the major proteinases of the 
azurophilic granule (Remold-O’Donnell, 1985). SERPINB1 is detected at low levels 
in the airways of healthy individuals, however, in the airways of patients with CF, a 
neutrophil-mediated lung disease, SERPINB1 is markedly increased (Cooley et al., 
2001). In addition, recombinant SERPINB1 reduces inflammatory damage and 
enhances bacterial clearance from the lung in a rat model of chronic pseudomonas 
aeruginosa infection (Woods et al., 2005). The protective role of recombinant 
SERPINB1 might be related to its protection for surfactant protein (SP) A and D, 
members of the collectin family from degradation by neutrophil proteases (Hirche et 
al., 2004; Rubio et al., 2004). Interestingly, SERPINB1 expression has been shown in 
the conducting airway and glandular epithelial cells, increased with advancing 
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gestational age and in the bronchopulmonary dysplasia (BPD) model. The 
up-regulation of SERPINB1 in BPD may be protective by contributing to the 
regulation of neutrophil proteases neutrophil elastase or cathepsin G (Yasumatsu et al., 
2006). SERPINB1 knockout mice have considerably increased mortality relative to 
wild type mice in association with late-onset failed bacterial clearance. It has been 
found that SERPINB1-deficient neutrophils recruited to the lungs have an intrinsic 
defect in survival accompanied by release of neutrophil protease activity, sustained 
inflammatory cytokine production, and proteolysis of the collectin SP-D during the 
host response to bacterial infection (Benarafa et al., 2007).  
 
It is the first time that SERPINB1 has been identified to be up-regulated by IFN-g in 
human bronchial epithelial cells. This is important because during airway 
inflammation, a lot neutrophils come into the airways, SERPINB1 expression might 
protect the airway epithelium layer from the destruction of neutrophil proteinases, 
which are actually intended to clear the pathogens. This hypothesis has been 
confirmed, at least partially, by our influenza A virus-infected mouse model. It is also 
the first time that SERPINB1 has been found with increased transcript level in vivo 
under viral infection, where neutrophils dominantly transmigrate into the airway 
during the early phase of infection. This well correlates with our in vitro data, further 
suggesting a protective role of SERPINB1 during viral infection. However, it is 
puzzling that in the LPS-induced acute lung injury model, SERPINB1 has been 
detected with decreased mRNA level, while the mouse airway is dramatically 
infiltrated with neutrophils. It is possible that airway epithelium is more fragile during 
bacterial than viral infection due to less expression of SERPINB1. Alternatively, 
infected mouse might stimulate some other neutrophil proteinase inhibitors under 
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such circumstance. These questions need further experiments to answer.  
 
4.2.4. Tapasin 
Assembly of the MHC class I heavy chain with b2-microglobulin (b2M) and a 
cytosolically generated peptide occurs in the endoplasmic reticulum and is assisted by 
several chaperones to ensure proper protein folding, efficient peptide loading and, 
ultimately, recognition by CD8+ T cells (Cresswell et al., 2005). Tapasin is a 
necessary MHC class I–specific chaperone for the formation of multisubunit 
peptide-loading complex (Cresswell et al., 2005). However, the exact roles that 
tapasin plays in helping the binding of peptide to MHC class I molecules in the 
peptide-loading complex have not been fully understood. 
 
Several mechanisms have been proposed to explain the requirement for tapasin in 
promoting the optimal folding and assembly of peptide–MHC class I complexes 
(Momburg and Tan, 2002). Tapasin has been suggested to directly bind TAP, which 
stabilizes the transporter, enhancing its expression and increasing the peptide supply 
to the lumen of the endoplasmic reticulum (Garbi et al., 1999). Tapasin also promotes 
the retention of MHC class I molecules in the endoplasmic reticulum (Barnden et al., 
2000, Grandea et al., 2000), which may improve the efficiency of peptide loading. It 
has also been suggested that tapasin catalyzes binding of peptide to MHC class I 
molecules and ‘edits’ the repertoire of bound peptides to maximize the affinity of the 
interaction (Williams et al., 2002, Howarth et al., 2004, Elliott and Williams, 2005).  
 
Both tapasin mRNA and protein are strongly induced in a time- and dose- dependent 
manner in embryonic fibroblasts treated with the cytokine IFN-g, mediated by 
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secondary transcription factor IRF-1, while weakly induced after treatment with 
TNF-a (Abarca-Heidemann et al., 2002). In addition, tapasin mRNA is strongly 
induced in vivo after infection with pathogenic bacterium Listeria monocytogenes in 
an IFN-g-dependent fashion (Boehm et al., 1998). Our study identified dramatic 
up-regulation of two isoforms of tapasin protein in bronchial epithelial cells 
stimulated by IFN-g, suggesting an active role of airway epithelium in the assembly of 
peptide–MHC class I complexes for antiviral defense. The consistent up-regulation of 
tapasin transcript in our influenza A virus-infected mouse model further confirmed 
this in vivo.  
 
4.2.5. Tryptophanyl-tRNA synthetase 
Tryptophanyl-tRNA synthetase (TrpRS) catalyzes the aminoacylation of tRNA(trp) 
with tryptophan. Two forms of TrpRS exist, a cytoplasmic form, named WARS, and a 
mitochondrial form, named WARS2. WARS gene produces two TrpRS isoforms, 
full-length isoform a and a shorter isoform b. The isoform b uses a downstream start 
codon but has the same C-terminus compared to isoform a. Human tyrosyl-tRNA 
synthetase (TyrRS) and TrpRS were discovered to regulate angiogenesis (Otani et al., 
2002, Wakasugi et al., 2002). In mammalian cells, TrpRS is activated for 
anti-angiogenic signaling by proteolysis and a few naturally spliced isoforms are 
generated called T1-TrpRS, T2-TrpRS and mini-TrpRS (similar to isoform b) (Otani 
et al., 2002) (Figure 25). TrpRS expression in human umbilical vein endothelial cells 
is specifically and robustly stimulated by IFN-g, and neither IL-4 nor TGF-b has any 
effect on TrpRS or IFN-g-stimulated TrpRS expression (Liu et al., 2004). These few 
isoforms are different in catalytic activity, anti-proliferative and anti-angiogenic 
activity (Otani et al., 2002). Mini-TrpRS and T2-TrpRS inhibit development of new 
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vessels without affecting pre-established vasculature. The anti-angiogenic activity of 
T2-TrpRS and mini-TrpRS has been demonstrated in cell-based assays in vitro and 
also in vivo in the mouse matrigel assays. Moreover, in vitro studies on endothelial 
cells have shown that the inhibitory activity of mini-TrpRS and T2-TrpRS abrogates 
cellular responses involved in angiogenesis, such as migration of endothelial cells 
(Otani et al., 2002, Wakasugi et al., 2002), and activation of extracellular 
signal-regulated kinase (ERK1/2) and Akt (Tzima et al., 2003).  
 
Tumor growth has been proposed to be dependent on angiogenesis (Alghisi and 
Rüegg, 2006), the up-regulation of TrpRSs by IFN-g might be related to the 
anti-tumor effect of IFN-g, whose up-regulation increases anti-proliferative and 
anti-angiogenic activity (Otani et al., 2002). However, the cells used in our project 
were normal human epithelial cells instead of cancer cell lines. Since the normal 
cellular function of TrpRS is to provide tryptophan-tRNA to allow protein synthesis, 
IFN-g-induced synthesis of these proteins might be involved in the amplification of 
inflammatory responses. In addition, the up-regulation of WARS gene transcript, 
probably dependent on IFN-g, in the influenza A virus-infected mouse lung further 
suggests that the increased TrpRSs might enhance protein synthesis, potentiating the 















Figure 25. Schematic representation of human TrpRS variants. Shaded regions of 
TrpRS represent the NH(2)-terminal appended domain. Numbers on the left and right 
correspond to the NH(2)- and COOH-terminal residues relative to the human 
full-length enzyme, respectively. TrpRS variants active (+) or inactive (-) in 













This project investigated the proteomes of two major airway structural cells, human 
bronchial epithelial cells and lung fibroblasts stimulated with pro-inflammatory 
cytokines TNF-a and/or IFN-g by using a two-dimensional gel electrophoresis 
approach, from which TNF-a and/or IFN-g-regulated protein profiles were mapped 
and the protein spots with statistically significant changes in optical density were 
identified by MALDI-TOF MS or MS/MS.  
 
First of all, our proteomics analysis revealed for the first time that TNF-a can 
up-regulate anti-viral proteins (MxA and ISG15), and airway remodeling proteins 
(LH2a and P4Ha) in normal human lung fibroblasts. More interestingly, DCIP was 
discovered for the first time to be up-regulated by TNF-a in lung fibroblasts and 
airway smooth muscle cells, and by IFN-g in bronchial epithelial cells. We reported 
here a novel function of DCIP in mediating TNF-a pro-inflammatory responses in 
lung fibroblasts and verified the DCIP expression in a LPS-induced and an influenza 
A virus-infected mouse lung injury model. Nevertheless, there are many issues 
remained to be resolved including whether DCIP expression is cell-type specific, 
what are the binding partners of DCIP and how do they interact, and what are the 
downstream substrates of DCIP and their metabolic products in relation to the TNF-a 
signaling cascade. Currently, there are on-going projects in our laboratory trying to 
answer some of these questions. 
 
Secondly, it was surprising that normal human bronchial epithelial cells were resistant 
to pro-apoptotic cytokine TNF-a or IFN-g single treatment up to 72 h. It was also 
surprising that IFN-g showed much more dramatic effects on the proteome alteration 
of human epithelial cells as compared with TNF-a, and most of the up-regultion was 
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elicited by IFN-g alone, whereas adding TNF-a did not further enhance the elevation 
of these proteins. Proteins with protective roles, such as neutrophil proteinase 
inhibitor SERPINB1, and tapasin isoforms for the assembly of peptide–MHC class I 
complexes for antiviral defense have been found increased by IFN-g in epithelial cells 
for the first time. In addition, proteins demonstrated or proposed to possess cell 
proliferation or apoptosis activity like metastasis suppressor NDRG-1 and BH3 
domain-containing protein apoL2 were also for the first time identified to be 
up-regulated in bronchial epithelial cells in response to IFN-g. Interestingly, by using 
RT-PCR we found the transcripts of all apoL family members except apoL5, were 
dramatically up-regulated by IFN-g. Furthermore, we observed significant cell loss in 
human bronchial epithelial cells in response to TNF-a or IFN-g, only when the cells 
were pretreated with apoL2 siRNA, indicating apoL2 might play a role in cell 
proliferation or apoptosis. Lastly, we verified the increased mRNA expression of the 
corresponding mouse orthologues in an influenza A virus-infected mouse lung injury 
model. However, there are still a lot of questions to be answered. Is it cell cycle arrest 
or apoptosis? The intracellular role that apoL2 plays in cell proliferation or apoptosis 
needs further investigation. The significance of up-regulation of apoLs during viral 
infection awaits to be interpreted.  
 
Two-dimensional gel electrophoresis proteomics approach is efficient in picking up 
changes in the expression levels of intracellular proteins. However, cells might secrete 
many important mediators including cytokines and chemokines into the culture 
medium upon stimulation, which is hard to be detected under the current protocol due 
to interference by a large amount of serum proteins especially albumin in culture 
medium, and the low abundancy of targeted proteins. The current serum albumin 
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removal kit which is designed to remove human albumin from very small volume of 
human serum with proteins highly concentrated does not work well for the large 
volume of culture medium with proteins highly diluted. Thus, a new protocol of 
protein precipitation from cell culture medium with subsequent processing, which 
should be compatible with 2-D gel electrophoresis recipe is needed. In addition, the 
sensitivity of 2-DE needs to be increased for the detection of low abundant proteins. 
The new approach like SILAC may circumvent this lack of sensitization problem. 
 
On the other hand, the airway epithelial cells and fibroblasts used in this project were 
both from normal human body, which can never mimic the cells under pathological 
condition, where the airway resident cells might already be transformed, becoming 
more susceptible to any stimulus. In this scenario, the proteome alterations might be 
markedly different. Therefore, conducting proteomic studies to compare the 
individual type of normal airway resident cells with its corresponding diseased cells 
would be strongly recommended, if there were clinical samples obtainable. The data 
could be more meaningful and useful to interpret observed phenomena under real 
pathological condition.  
 
In summary, proteomics is an efficient tool to study the molecular mechanisms 
involved in the pathophysiology after cytokine stimulation in that it is capable of 
identifying multiple regulated proteins in a biological process simultaneously. By 
providing direct profiles of cytokine-regulated protein expression of a particular type 
of cell, these studies could give us a better understanding of cytokine-regulated 
biological responses and signal transduction, and it is also possible to identify new 













Abarca-Heidemann K, Friederichs S, Klamp T, Boehm U, Guethlein LA, Ortmann B. 
Regulation of the expression of mouse TAP-associated glycoprotein (tapasin) by 
cytokines. Immunol Lett 2002; 83: 197-207. 
 
Abraham E. Neutrophils and acute lung injury. Crit Care Med 2003; 31: S195-9. 
 
Aggarwal BB.Comparative analysis of the structure and function of TNF-alpha and 
TNF-beta. Immunol Ser 1992; 56: 61-78. 
 
Ahn WS, Bae SM, Lee JM, Namkoong SE, Han SJ, Cho YL, Nam GH, Seo JS, Kim 
CK, Kim YW. Searching for pathogenic gene functions to cervical cancer. Gynecol 
Oncol 2004; 93: 41-8. 
 
Alghisi GC, Rüegg C. Vascular integrins in tumor angiogenesis: mediators and 
therapeutic targets. Endothelium 2006; 13: 113-35. 
 
Alho HS, Maasilta PK, Harjula AL, Hammainen P, Salminen J, Salminen US. Tumor 
necrosis factor-alpha in a porcine bronchial model of obliterative bronchiolitis. 
Transplantation 2003; 76: 516-23. 
 
Andrew AS, Warren AJ, Barchowsky A, Temple KA, Klei L, Soucy NV, O'Hara KA, 
Hamilton JW. Genomic and proteomic profiling of responses to toxic metals in human 
lung cells. Environ Health Perspect 2003; 111: 825-35. 
 
Antalis TM, La Linn M, Donnan K, Mateo L, Gardner J, Dickinson JL et al. The 
serine proteinase inhibitor (serpin) plasminogen activator inhibitor type-2 protects 
against viral cytopathic effects by constitutive interferon α/β priming. J Exp Med 
1998; 187: 1799-811. 
 
Aravind L, Koonin EV. The HD domain defines a new superfamily of 
metal-dependent phosphohydrolases. Trends Biochem Sci 1998; 23: 469-472. 
 
Araya J, Cambier S, Morris A, Finkbeiner W, Nishimura SL. Integrin-mediated 
transforming growth factor-beta activation regulates homeostasis of the pulmonary 
epithelial-mesenchymal trophic unit. Am J Pathol 2006; 169: 405-15. 
 
Atasoy U, Curry SL, Lopez de Silanes I, Shyu AB, Casolaro V, Gorospe M, Stellato C. 
Regulation of eotaxin gene expression by TNF-alpha and IL-4 through mRNA 
stabilization: involvement of the RNA-binding protein HuR. J Immunol 2003; 171: 
4369-78. 
 
Aviv T, Lin Z, Ben-Ari G, Smibert CA, Sicheri F. Sequence-specific recognition of 
RNA hairpins by the SAM domain of Vts1p. Nat Struct Mol Biol 2006; 13: 168-76. 
 
Baak JP, Janssen EA, Soreide K, Heikkilae R. Genomics and proteomics--the way 
forward. Ann Oncol 2005; 16: ii30-44. 
 
Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor: a paradigm for cytokine 
receptor signaling. Annu Rev Immunol 1997; 15: 563-91. 
 
 141 
Bae SH, Harris AG, Hains PG, Chen H, Garfin DE, Hazell SL, Paik YK, Walsh BJ, 
Cordwell SJ. Strategies for the enrichment and identification of basic proteins in 
proteome projects. Proteomics 2003; 3: 569-79. 
 
Bandyopadhyay S, Pai SK, Gross SC, Hirota S, Hosobe S, Miura K, Saito K, 
Commes T, Hayashi S, Watabe M, Watabe K. The Drg-1 gene suppresses tumor 
metastasis in prostate cancer. Cancer Res 2003; 63: 1731-6.   
 
Bandyopadhyay S, Pai SK, Hirota S, Hosobe S, Takano Y, Saito K, Piquemal D, 
Commes T, Watabe M, Gross SC, Wang Y, Ran S, Watabe K. Role of the putative 
tumor metastasis suppressor gene Drg-1 in breast cancer progression. Oncogene 2004; 
23: 5675-81. 
 
Bandyopadhyay S, Pai SK, Hirota S, Hosobe S, Tsukada T, Miura K, Takano Y, Saito 
K, Commes T, Piquemal D, Watabe M, Gross S, Wang Y, Huggenvik J, Watabe K. 
PTEN up-regulates the tumor metastasis suppressor gene Drg-1 in prostate and breast 
cancer. Cancer Res 2004; 64: 7655-60. 
 
Barnden MJ, Purcell AW, Gorman JJ, McCluskey J. Tapasin-mediated retention and 
optimization of peptide ligands during the assembly of class I molecules. J Immunol 
2000; 165: 322–330 
 
Barrera FN, Poveda JA, Gonzalez-Ros JM, Neira JL. Binding of the C-terminal sterile 
alpha motif (SAM) domain of human p73 to lipid membranes. J Biol Chem 2003; 
278: 46878-85. 
 
Becker KF, Metzger V, Hipp S, Hofler H. Clinical proteomics: new trends for protein 
microarrays. Curr Med Chem 2006; 13: 1831-7. 
 
Benarafa C, Priebe GP, Remold-O'Donnell E. The neutrophil serine protease inhibitor 
serpinb1 preserves lung defense functions in Pseudomonas aeruginosa infection. J 
Exp Med 2007; 204: 1901-9. 
 
Bhatia M, Moochhala S. Role of inflammatory mediators in the pathophysiology of 
acute respiratory distress syndrome. J Pathol 2004; 202: 145-56. 
 
Binz PA, Muller M, Hoogland C, Zimmermann C, Pasquarello C, Corthals G, Sanchez 
JC, Hochstrasser DF, Appel RD. The molecular scanner: concept and developments. 
Curr Opin Biotechnol 2004; 15: 17-23. 
 
Blagoev B, Kratchmarova I, Ong SE, Nielsen M, Foster LJ, Mann M. A proteomics 
strategy to elucidate functional protein-protein interactions applied to EGF signaling. 
Nat Biotechnol 2003; 21: 315-8. 
 
Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF 
superfamily. Trends Biochem Sci 2002; 27: 19-26. 
 
Boehm U, Guethlein L, Klamp T, Ozbek K, Schaub A, Futterer A, Pfeffer K, Howard 
JC. Two families of GTPases dominate the complex cellular response to IFN-gamma. 
J Immunol 1998; 161: 6715-23. 
 142 
 
Bogdanov B, Smith RD. Proteomics by FTICR mass spectrometry: top down and 
bottom up. Mass Spectrom Rev 2005; 24: 168-200. 
 
Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate 
and adaptive immunity. Trends Immunol 2004; 25: 280-288. 
 
Boucherat O, Bourbon JR, Barlier-Mur AM, Chailley-Heu B, D'Ortho MP, Delacourt 
C. Differential expression of matrix metalloproteinases and inhibitors in developing 
rat lung mesenchymal and epithelial cells. Pediatr Res 2007; 62: 20-5. 
 
Bouillet P, Strasser A. BH3-only proteins - evolutionarily conserved proapoptotic 
Bcl-2 family members essential for initiating programmed cell death. J Cell Sci 2002; 
115: 1567-74. 
 
Brasier AR, Spratt H, Wu Z, Boldogh I, Zhang Y, Garofalo RP, Casola A, Pashmi J, 
Haag A, Luxon B, Kurosky A. Nuclear heat shock response and novel nuclear domain 
10 reorganization in respiratory syncytial virus-infected a549 cells identified by 
high-resolution two-dimensional gel electrophoresis. J Virol 2004; 78: 11461-76. 
 
Brown EG. Increased virulence of a mouse-adapted variant of influenza A/FM/1/47 
virus is controlled by mutations in genome segments 4, 5, 7, and 8. J Virol 1990; 64: 
4523-4533. 
 
Bruder D, Srikiatkhachorn A, Enelow RI. Cellular immunity and lung injury in 
respiratory virus infection. Viral Immunol 2006; 19: 147-55. 
 
Buckley CD, Pilling D, Lord JM, Akbar AN, Scheel-Toellner D, Salmon M. 
Fibroblasts regulate the switch from acute resolving to chronic persistent 
inflammation. Trends Immunol 2001; 22: 199-204. 
 
Bykova NV, Rampitsch C, Krokhin O, Standing KG, Ens W. Determination and 
characterization of site-specific N-glycosylation using MALDI-Qq-TOF tandem mass 
spectrometry: case study with a plant protease. Anal Chem 2006; 78: 1093-103. 
 
Cameron MJ, Ran L, Xu L, Danesh A, Bermejo-Martin JF, Cameron CM, Muller MP, 
Gold WL, Richardson SE, Poutanen SM, Willey BM, Devries ME, Fang Y, 
Seneviratne C, Bosinger SE, Persad D, Wilkinson P, Greller LD, Somogyi R, Humar 
A, Keshavjee S, Louie M, Loeb MB, Brunton J, McGeer AJ, Kelvin DJ. 
Interferon-mediated immunopathological events are associated with atypical innate 
and adaptive immune responses in severe acute respiratory syndrome (SARS) patients. 
J Virol 2007; 81: 8692-706. 
 
Canault M, Peiretti F, Kopp F, Bonardo B, Bonzi MF, Coudeyre JC, Alessi MC, 
Juhan-Vague I, Nalbone G. The TNF alpha converting enzyme (TACE/ADAM17) is 
expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice: possible 
contribution to elevated plasma levels of soluble TNF alpha receptors. 
Atherosclerosis 2006; 187: 82-91. 
 
Cargile BJ, Sevinsky JR, Essader AS, Stephenson JL Jr, Bundy JL. Immobilized pH 
 143 
gradient isoelectric focusing as a first-dimension separation in shotgun proteomics. J 
Biomol Tech 2005; 16: 181-9. 
 
Cataldo DD, Gueders M, Munaut C, et al. Matrix metalloproteinases and tissue 
inhibitors of matrix metalloproteinases mRNA transcripts in the bronchial secretions 
of asthmatics. Lab Invest 2004; 84: 418–424. 
 
Cottrell JS. Protein identification by peptide mass fingerprinting. Pept Res 1994; 7: 
115-24. 
 
Cerretti DP.Characterization of the tumour necrosis factor alpha-converting enzyme, 
TACE/ADAM17. Biochem Soc Trans 1999; 27: 219-23. 
 
Cerri C, Chimenti D, Conti I, Neri T, Paggiaro P, Celi A. 
Monocyte/macrophage-derived microparticles up-regulate inflammatory mediator 
synthesis by human airway epithelial cells. J Immunol 2006; 177: 1975-80. 
 
Cha MH, Rhim T, Kim KH, Jang AS, Paik YK, Park CS. Proteomic identification of 
macrophage migration-inhibitory factor upon exposure to TiO2 particles. Mol Cell 
Proteomics 2007; 6: 56-63. 
 
 
Chakir J, Shannon J, Molet S, Fukakusa M, Elias J, Laviolette M, Boulet LP, Hamid 
Q. Airway remodelingassociated mediators in moderate to severe asthma: effect of 
steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression. J 
Allergy Clin Immunol 2003; 111: 1293–1298. 
 
Chan JHP, Liao W, Lau HYA, Wong WSF. Gab2 antisense oligonucleotide blocks rat 
basophilic leukemic cell functions. Int Immunopharmacol 2007, 7, 937-944.  
 
Chan JHP, Lim SH, Wong WSF. Antisense oligonucleotides: from design to 
therapeutic application. Clin Exp Pharmacol Physiol 2006, 33, 533-540. 
 
Chan MC, Cheung CY, Chui WH, Tsao SW, Nicholls JM, Chan YO, Chan RW, Long 
HT, Poon LL, Guan Y, Peiris JS. Pro-inflammatory cytokine responses induced by 
influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. 
Respir Res 2005; 6: 135. 
 
Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, 
Borden EC. Apoptosis and interferons: role of interferon-stimulated genes as 
mediators of apoptosis. Apoptosis 2003; 8: 237-49. 
 
Chelius D, Zhang T, Wang G, Shen RF. Global protein identification and 
quantification technology using two-dimensional liquid chromatography nanospray 
mass spectrometry. Anal Chem 2003; 75: 6658-65. 
 
Chen B, Nelson DM, Sadovsky Y. N-myc down-regulated gene 1 modulates the 




Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 2002; 296: 
1634-5. 
 
Chen J, Anderson JB, DeWeese-Scott C, Fedorova ND, Geer LY, He S, Hurwitz DI, 
Jackson JD, Jacobs AR, Lanczycki CJ, Liebert CA, Liu C, Madej T, Marchler-Bauer 
A, Marchler GH, Mazumder R, Nikolskaya AN, Rao BS, Panchenko AR, Shoemaker 
BA, Simonyan V, Song JS, Thiessen PA, Vasudevan S, Wang Y, Yamashita RA, Yin JJ, 
Bryant SH. MMDB: Entrez's 3D-structure database. Nucleic Acids Res 2003; 31: 
474-7. 
 
Chernushevich IV, Loboda AV, Thomson BA. An introduction to 
quadrupole-time-of-flight mass spectrometry. J Mass Spectrom 2001; 36: 849-65. 
 
Chesler DA, Reiss CS. The role of IFN-gamma in immune responses to viral 
infections of the central nervous system. Cytokine Growth Factor Rev 2002; 13: 
441-54. 
 
Clauser KR, Baker P, Burlingame AL. Role of accurate mass measurement (+/- 10 
ppm) in protein identification strategies employing MS or MS/MS and database 
searching. Anal Chem 1999; 71: 2871-82. 
 
Comhair SA, Xu W, Ghosh S, Thunnissen FB, Almasan A, Calhoun WJ, Janocha AJ, 
Zheng L, Hazen SL, Erzurum SC. Superoxide dismutase inactivation in 
pathophysiology of asthmatic airway remodeling and reactivity. Am J Pathol 2005; 
166: 663-74. 
 
Cooley J, Takayama TK, Shapiro SD, Schechter NM, Remold-O'Donnell E. The 
serpin MNEI inhibits elastase-like and chymotrypsin-like serine proteases through 
efficient reactions at two active sites. Biochemistry 2001; 40: 15762-70. 
 
Cottin V, Doan JE, Riches DW. Restricted localization of the TNF receptor CD120a 
to lipid rafts: a novel role for the death domain. J Immunol 2002; 168: 4095-102. 
 
Cottrell JS. Protein identification by peptide mass fingerprinting. Pept Res 1994; 7: 
115-24. 
 
Cramer R, Saxton M, Barnouin K. Sample preparation of gel electrophoretically 
separated protein binding partners for analysis by mass spectrometry. Methods Mol 
Biol 2004; 261: 499-510. 
 
Cresswell P, Ackerman AL, Giodini A, Peaper DR, Wearsch PA. Mechanisms of 
MHC class I-restricted antigen processing and cross-presentation. Immunol Rev 
2005; 207: 145–147. 
 
Cretich M, Damin F, Pirri G, Chiari M. Protein and peptide arrays: recent trends and 
new directions. Biomol Eng 2006; 23: 77-88. 
 
Dabrowska M, Grubek-Jaworska H, Hoser G, Domagała-Kulawik J, Krenke R, 
Chazan R. Effect of IFN-gamma stimulation on expression of intercellular adhesion 
molecule-1 (ICAM-1) on alveolar macrophages in patients with non-small cell lung 
 145 
cancer. J Interferon Cytokine Res 2006; 26: 190-5. 
 
Dai J, Xie C, Churg A. Iron loading makes a nonfibrogenic model air pollutant 
particle fibrogenic in rat tracheal explants. Am J Respir Cell Mol Biol 2002; 26: 
685-93. 
 
D’Ambrosio D, Mariani M, Panina-Bordignon P, Sinigaglia F. Chemokines and their 
receptors guiding T lymphocyte recruitment in lung inflammation. Am J Respir Crit 
Care Med 2001; 164: 1266-1275. 
 
Dancik V, Addona TA, Clauser KR, Vath JE, Pevzner PA. De novo peptide sequencing 
via tandem mass spectrometry. J Comput Biol 1999; 6: 327-42. 
 
Davies DE, Holgate ST. Asthma: the importance of epithelial mesenchymal 
communication in pathogenesis. Inflammation and the airway epithelium in asthma. 
Int J Biochem Cell Biol 2002; 34: 1520-6. 
 
Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, 
Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, 
Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, 
Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, 
Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson 
A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, 
French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, 
Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, 
Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, 
Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, 
Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne 
S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, 
Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice 
CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, 
Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, 
Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, 
Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray 
PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J. The DNA sequence and 
comparative analysis of human chromosome 20. Nature 2001; 414: 865-872. 
 
Dickinson JL, Bates EJ, Ferrante A, Antalis TM. Plasminogen activator inhibitor 
type-2 inhibits tumor necrosis factor α-induced apoptosis: evidence for an alternate 
biological function. J Biol Chem 1995; 270: 27894-904. 
 
Domazet B, Maclennan GT, Lopez-Beltran A, Montironi R, Cheng L. Laser capture 
microdissection in the genomic and proteomic era: targeting the genetic basis of 
cancer. Int J Clin Exp Pathol 2008; 1: 475-88. 
 
Domon B, Aebersold R. Mass spectrometry and protein analysis. Science 2006; 312: 
212-7. 
 
Douglas DJ, Frank AJ, Mao D. Linear ion traps in mass spectrometry. Mass 
Spectrom Rev 2005; 24: 1-29. 
 146 
 
Duchateau PN, Pullinger CR, Cho MH, Eng C, Kane JP. Apolipoprotein L gene 
family: tissue-specific expression, splicing, promoter regions; discovery of a new 
gene. J Lipid Res 2001; 42: 620-30. 
 
Duchateau PN, Pullinger CR, Orellana RE, Kunitake ST, Naya-Vigne J, O'Connor 
PM, Malloy MJ, Kane JP. Apolipoprotein L, a new human high density lipoprotein 
apolipoprotein expressed by the pancreas. Identification, cloning, characterization, 
and plasma distribution of apolipoprotein L. J Biol Chem 1997; 272: 25576-82. 
 
Edwards CJ, Polosa R. Study of infliximab treatment in asthma. Am J Respir Crit 
Care Med 2007; 175: 196. 
 
Eisenberg D, Marcotte EM, Xenarios I, Yeates TO. Protein function in the 
post-genomic era. Nature 2000; 405: 823-6. 
 
Ekstrom S, Onnerfjord P, Nilsson J, Bengtsson M, Laurell T, Marko-Varga G. 
Integrated microanalytical technology enabling rapid and automated protein 
identification. Anal Chem 2000; 72: 286-93. 
 
Elliott T, Williams A. The optimization of peptide cargo bound to MHC class I 
molecules by the peptide-loading complex. Immunol Rev 2005; 207: 89–99. 
 
Elrick MM, Walgren JL, Mitchell MD, Thompson DC. Proteomics: recent 
applications and new technologies. Basic Clin Pharmacol Toxicol 2006; 98: 432-41. 
 
Ens W, Standing KG. Hybrid quadrupole/time-of-flight mass spectrometers for 
analysis of biomolecules. Methods Enzymol 2005; 402: 49-78. 
 
Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, Neighbour H, 
Zacharasiewicz AS, Turner J, Barnathan ES, Kon OM, Barnes PJ, Hansel TT. The 
effects of a monoclonal antibody directed against tumor necrosis factor-alpha in 
asthma. Am J Respir Crit Care Med 2006; 174: 753-62. 
 
Ewing RM, Chu P, Elisma F, Li H, Taylor P, Climie S, McBroom-Cerajewski L, 
Robinson MD, O'Connor L, Li M, Taylor R, Dharsee M, Ho Y, Heilbut A, Moore L, 
Zhang S, Ornatsky O, Bukhman YV, Ethier M, Sheng Y, Vasilescu J, Abu-Farha M, 
Lambert JP, Duewel HS, Stewart II, Kuehl B, Hogue K, Colwill K, Gladwish K, 
Muskat B, Kinach R, Adams SL, Moran MF, Morin GB, Topaloglou T, Figeys D. 
Large-scale mapping of human protein-protein interactions by mass spectrometry. 
Mol Syst Biol 2007; 3: 89. 
 
Fang Q, Liu X, Al-Mugotir M, Kobayashi T, Abe S, Kohyama T, Rennard SI. 
Thrombin and TNF-alpha/IL-1beta synergistically induce fibroblast-mediated 
collagen gel degradation. Am J Respir Cell Mol Biol 2006; 35: 714-21. 
 
Figeys D, McBroom LD, Moran MF. Mass spectrometry for the study of 
protein-protein interactions. Methods 2001; 24: 230-9. 
 
Fujii M, Tanaka H, Abe S. Interferon-gamma up-regulates expression of cysteinyl 
 147 
leukotriene type 2 receptors on eosinophils in asthmatic patients. Chest 2005; 128: 
3148-55. 
 
Garbi N, Tiwari N, Momburg F, Hammerling GJ. A major role for tapasin as a 
stabilizer of the TAP peptide transporter and consequences for MHC class I 
expression. Eur J Immunol 1999; 33: 264–273. 
 
Guan RJ, Ford HL, Fu Y, Li Y, Shaw LM, Pardee AB. Drg-1 as a 
differentiation-related, putative metastatic suppressor gene in human colon cancer. 
Cancer Res 2000; 60: 749-55. 
 
Givant-Horwitz, V., Davidson, B., Reich, R. Laminin-induced signaling in tumor cells. 
Cancer Lett 2005; 223: 1-10. 
 
Gordien E, Rosmorduc O, Peltekian C, Garreau F, Brechot C, Kremsdorf D. 
Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein. J 
Virol 2001; 75: 2684-91. 
 
Gorg A, Obermaier C, Boguth G, Harder A, Scheibe B, Wildgruber R, Weiss W. The 
current state of two-dimensional electrophoresis with immobilized pH gradients. 
Electrophoresis 2000; 21: 1037-53. 
 
Gorg A, Postel W, Gunther S. The current state of two-dimensional electrophoresis 
with immobilized pH gradients. Electrophoresis 1988; 9: 531-46. 
 
Gorg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for 
proteomics. Proteomics 2004; 4: 3665–3685. 
 
Grandea AG 3rd, Golovina TN, Hamilton SE, Sriram V, Spies T, Brutkiewicz RR, 
Harty JT, Eisenlohr LC, Van Kaer L. Impaired assembly yet normal trafficking of 
MHC class I molecules in Tapasin mutant mice. Immunity 2000; 13: 213-22. 
 
Grant MM, Scheel-Toellner D, Griffiths HR. Contributions to our understanding of T 
cell physiology through unveiling the T cell proteome. Clin Exp Immunol 2007; 149: 
9-15. 
 
Graves PR, Haystead TA. Molecular biologist's guide to proteomics. Microbiol Mol 
Biol Rev 2002; 66: 39-63. 
 
 
Green MK, Johnston MV, Larsen BS. Mass accuracy and sequence requirements for 
protein database searching. Anal Biochem 1999; 275: 39-46. 
 
Gygi SP, Corthals GL, Zhang Y, Rochon Y, Aebersold R. Evaluation of 
two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl 
Acad Sci U S A 2000; 97: 9390-5. 
 
Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA 
abundance in yeast. Mol Cell Biol 1999; 19: 1720-30. 
 
 148 
Hamamdzic D, Phillips-Dorsett T, Altman-Hamamdzic S, London SD, London L. 
Reovirus triggers cell type-specific pro-inflammatory responses dependent on the 
autocrine action of IFN-beta. Am J Physiol Lung Cell Mol Physiol 2001; 280: 
L18-29. 
 
Han DK, Eng J, Zhou H, Aebersold R. Quantitative profiling of 
differentiation-induced microsomal proteins using isotope-coded affinity tags and 
mass spectrometry. Nat Biotechnol 2001; 19: 946-51. 
 
Hayashi J, Stoyanova R, Seeger C. The transcriptome of HCV replicon expressing 
cell lines in the presence of alpha interferon. Virology 2005; 335: 264-75. 
 
Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour 
necrosis factor receptor superfamily: players, rules and the games. Immunology 2005; 
115: 1-20. 
 
Henderson N, Markwick LJ, Elshaw SR, Freyer AM, Knox AJ, Johnson SR. Collagen 
I and thrombin activate MMP-2 by MMP-14-dependent and -independent pathways: 
implications for airway smooth muscle migration. Am J Physiol Lung Cell Mol 
Physiol 2007; 292: L1030-8. 
 
Henricks PA, Nijkamp FP. Reactive oxygen species as mediators in asthma. Pulm 
Pharmacol Ther 2001; 14: 409-20. 
 
Hetzel M, Bachem M, Anders D, Trischler G, Faehling M. Different effects of growth 
factors on proliferation and matrix production of normal and fibrotic human lung 
fibroblasts. Lung 2005; 183: 225-37. 
 
Hirche TO, Crouch EC, Espinola M, Brokelman TJ, Mecham RP, DeSilva N, Cooley 
J, Remold-O’Donnell E, and Belaaouaj A. Neutrophil serine proteinases inactivate 
surfactant protein D by cleaving within a conserved subregion of the carbohydrate 
recognition domain. J Biol Chem 2004; 279: 27688-27698. 
 
Hoffmann A, Baltimore D. Circuitry of nuclear factor kappaB signaling. Immunol 
Rev 2006; 210: 171-186. 
 
Holzinger D, Jorns C, Stertz S, Boisson-Dupuis S, Thimme R, Weidmann M, 
Casanova JL, Haller O, Kochs G. Induction of MxA gene expression by influenza A 
virus requires type I or type III interferon signaling. J Virol 2007; 8: 7776-85. 
 
Hopfgartner G, Varesio E, Tschappat V, Grivet C, Bourgogne E, Leuthold LA. Triple 
quadrupole linear ion trap mass spectrometer for the analysis of small molecules and 
macromolecules. J Mass Spectrom 2004; 39: 845-55. 
 
Horisberger MA. Interferon-induced human protein MxA is a GTPase which binds 
transiently to cellular proteins. J Virol 1992; 66: 4705-9. 
 
Horn DM, Zubarev RA, McLafferty FW. Automated reduction and interpretation of 
high resolution electrospray mass spectra of large molecules. J Am Soc Mass 
Spectrom 2000; 11: 320-32. 
 149 
 
Horrevoets AJ, Fontijn RD, van Zonneveld AJ, de Vries CJ, ten Cate JW, Pannekoek 
H. Vascular endothelial genes that are responsive to tumor necrosis factor-alpha in 
vitro are expressed in atherosclerotic lesions, including inhibitor of apoptosis 
protein-1, stannin, and two novel genes. Blood 1999; 93: 3418-31. 
 
Hoving S, Gerrits B, Voshol H, Muller D, Roberts RC, van Oostrum J. Preparative 
two-dimensional gel electrophoresis at alkaline pH using narrow range immobilized 
pH gradients. Proteomics 2002; 2: 127-34. 
 
Howarth M, Williams A, Tolstrup AB, Elliott T. Tapasin enhances MHC class I 
peptide presentation according to peptide half-life. Proc Natl Acad Sci USA 2004; 
101: 11737–11742. 
 
Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, McConnell W, Beckett P, Al 
Ali M, Chauhan A, Wilson SJ, Reynolds A, Davies DE, Holgate ST. Tumour necrosis 
factor (TNF-alpha) as a novel therapeutic target in symptomatic corticosteroid 
dependent asthma. Thorax 2005; 60: 1012-8. 
 
Hu Y, Peng J, Feng D, Chu L, Li X, Jin Z, Lin Z, Zeng Q. Role of extracellular 
signal-regulated kinase, p38 kinase, and activator protein-1 in transforming growth 
factor-beta1-induced alpha smooth muscle actin expression in human fetal lung 
fibroblasts in vitro. Lung 2006; 184: 33-42. 
 
Huang YF, Huang CC, Hu CC, Chang HT. Capillary electrophoresis-based separation 
techniques for the analysis of proteins. Electrophoresis 2006; 27: 3503-22. 
 
Huck CW, Bakry R, Huber LA, Bonn GK. Progress in capillary electrophoresis 
coupled to matrix-assisted laser desorption/ionization - time of flight mass 
spectrometry. Electrophoresis 2006; 27: 2063-74. 
 
Ishida T, Tsukada H, Hasegawa T, Yoshizawa H, Gejyo F. Matrix metalloproteinase-1 
activation via plasmin generated on alveolar epithelial cell surfaces. Lung 2006; 184: 
15-9. 
 
Isogai S, Athiviraham A, Fraser RS, Taha R, Hamid Q, Martin JG. 
Interferon-gamma-dependent inhibition of late allergic airway responses and 
eosinophilia by CD8+ gammadelta T cells. Immunology 2007; 122: 230-8. 
 
Issaq HJ, Janini GM, Chan KC, Veenstra TD. Sheathless electrospray ionization 
interfaces for capillary electrophoresis-mass spectrometric detection advantages and 
limitations. J Chromatogr A 2004; 1053: 37-42. 
 
James AJ, Penrose JF, Cazaly AM, Holgate ST, Sampson AP. Human bronchial 
fibroblasts express the 5-lipoxygenase pathway. Respir Res 2006; 7: 102. 
 
Jung HH, Lee J, Kim JH, Ryu KJ, Kang SA, Park C, Sung K, Nam DH, Kang WK, 
Park K, Im YH. STAT1 and Nmi are downstream targets of Ets-1 transcription factor 
in MCF-7 human breast cancer cell. FEBS Lett 2005; 579: 3941-6. 
 
 150 
Kanamoto T, Hellman U, Heldin CH, Souchelnytskyi S. Functional proteomics of 
transforming growth factor-beta1-stimulated Mv1Lu epithelial cells: Rad51 as a target 
of TGFbeta1-dependent regulation of DNA repair. EMBO J 2002; 21: 1219-30. 
 
Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, 
Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis 
factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104. 
 
Kegan HM. Intra- and extracellular enzymes of collagen biosynthesis as biological 
and chemical targets in the control of fibrosis. Acta Trop 2000; 77: 147-52. 
 
Kelleher NL. Top-down proteomics. Anal Chem 2004; 76: 197A-203A. 
 
Khatun J, Ramkissoon K, Giddings MC. Fragmentation characteristics of 
collision-induced dissociation in MALDI TOF/TOF mass spectrometry. Anal Chem 
2007; 79: 3032-40. 
 
Kim J, Remick DG. Tumor necrosis factor inhibitors for the treatment of asthma. 
Curr Allergy Asthma Rep 2007; 7: 151-6. 
 
Kim KT, Ongusaha PP, Hong YK, Kurdistani SK, Nakamura M, Lu KP, Lee SW. 
Function of Drg1/Rit42 in p53-dependent mitotic spindle checkpoint. J Biol Chem 
2004; 279: 38597-602. 
 
Kiningham KK, Xu Y, Daosukho C, Popova B, St Clair DK. Nuclear factor 
kappaB-dependent mechanisms coordinate the synergistic effect of PMA and 
cytokines on the induction of superoxide dismutase 2. Biochem J 2001; 353: 
147-156. 
 
Kitatani K, Akiba S, Sato T. Ceramide-induced enhancement of secretory 
phospholipase A2 expression via generation of reactive oxygen species in tumor 
necrosis factor-alpha-stimulated mesangial cells. Cell Signal 2004; 16: 967-74. 
 
Knight DA, Lane CL, Stick SM. Does aberrant activation of the 
epithelial-mesenchymal trophic unit play a key role in asthma or is it an unimportant 
sideshow? Curr Opin Pharmacol 2004; 4: 251-6. 
 
Knight DA, Holgate ST. The airway epithelium: structural and functional properties in 
health and disease. Respirology 2003; 8: 432-46. 
 
Komiya A, Nagase H, Yamada H, Sekiya T, Yamaguchi M, Sano Y, Hanai N, Furuya 
A, Ohta K, Matsushima K, Yoshie O, Yamamoto K, Hirai K. Concerted expression of 
eotaxin-1, eotaxin-2, and eotaxin-3 in human bronchial epithelial cells. Cell Immunol 
2003; 225: 91-100. 
 
Kotenko SV, Pestka S. Jak-Stat signal transduction pathway through the eyes of 
cytokine class II receptor complexes. Oncogene 2000; 19: 2557-65. 
 
Kovacevic Z, Richardson DR. The metastasis suppressor, Ndrg-1: a new ally in the 
fight against cancer. Carcinogenesis 2006; 27: 2355-66. 
 151 
 
Kroger A, Koster M, Schroeder K, Hauser H, Mueller PP. Activities of IRF-1. J 
Interferon Cytokine Res 2002; 22: 5-14. 
 
Krouwels FH. Anti-tumor necrosis factor-alpha in asthma. Am J Respir Crit Care 
Med 2007; 175: 288-9. 
 
Kruithof EK, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen 
activator inhibitor type 2. Blood 1995; 86: 4007-24. 
 
Kumar RK, Herbert C, Webb DC, Li L, Foster PS. Effects of anticytokine therapy in a 
mouse model of chronic asthma. Am J Respir Crit Care Med 2004; 170: 1043-8. 
 
Kumar RK, Webb DC, Herbert C, Foster PS. Interferon-gamma as a possible target in 
chronic asthma. Inflamm Allergy Drug Targets 2006; 5: 253-6. 
 
Kumar S, Baglioni C. Protection from tumor necrosis factor-mediated cytolysis by 
overexpression of plasminogen activator inhibitor type-2. J Biol Chem 1991; 266: 
20960-4 
 
Kunzi MS, Pitha PM. Role of interferon-stimulated gene ISG-15 in the 
interferon-ω-mediated inhibition of human immunodeficiency virus replication. J 
Interferon Cytokine Res 1996; 16: 919-27 
 
Kwon SJ, Choi EY, Choi YJ, Ahn JH, Park OK. Proteomics studies of 
post-translational modifications in plants. J Exp Bot 2006; 57: 1547-51. 
 
Laberge S, El Bassam S. Cytokines, structural cells of the lungs and airway 
inflammation. Paediatr Respir Rev 2004; 5: S41-5. 
 
Lachat P, Shaw P, Gebhard S, van Belzen N, Chaubert P, Bosman FT. Expression of 
NDRG1, a differentiation-related gene, in human tissues. Histochem Cell Biol 2002; 
118: 399-408. 
 
Larsen K, Macleod D, Nihlberg K, Gürcan E, Bjermer L, Marko-Varga G, 
Westergren-Thorsson G. Specific haptoglobin expression in bronchoalveolar lavage 
during differentiation of circulating fibroblast progenitor cells in mild asthma. J 
Proteome Res 2006; 5: 1479-83. 
 
Lee HC, Ziegler SF. Inducible expression of the proallergic cytokine thymic stromal 
lymphopoietin in airway epithelial cells is controlled by NF-kappaB. Proc Natl Acad 
Sci USA 2007; 104: 914-919. 
 
Lee KS, Min KH, Kim SR, Park SJ, Park HS, Jin GY, Lee YC. Vascular endothelial 
growth factor modulates matrix metalloproteinase-9 expression in asthma. Am J 
Respir Crit Care Med 2006; 174: 161-70. 
 




Lee SH, Vidal SM. Functional diversity of Mx proteins: variations on a theme of host 
resistance to infection. Genome Res 2002; 12: 527-30. 
 
Leir SH, Holgate ST, Lackie PM. Inflammatory cytokines can enhance 
CD44-mediated airway epithelial cell adhesion independently of CD44 expression. 
Am J Physiol Lung Cell Mol Physiol 2003; 285: L1305-11. 
 
Letuve S, Lajoie-Kadoch S, Audusseau S, Rothenberg ME, Fiset PO, Ludwig MS, 
Hamid Q. IL-17E up-regulates the expression of pro-inflammatory cytokines in lung 
fibroblasts. J Allergy Clin Immunol 2006; 117: 590-6. 
 
Lezcano-Meza D, Negrete-Garcia MC, Dante-Escobedo M, Teran LM. The 
monocyte-derived chemokine is released in the bronchoalveolar lavage fluid of 
steady-state asthmatics. Allergy 2003; 58: 1125-30. 
 
Li C, Xiao Z, Chen Z, Zhang X, Li J, Wu X, Li X, Yi H, Li M, Zhu G, Liang S.  
Proteome analysis of human lung squamous carcinoma. Proteomics 2006; 6: 547-58. 
 
Li CJ, Ning W, Matthay MA, Feghali-Bostwick CA, Choi AM. MAPK pathway 
mediates EGR-1-HSP70-dependent cigarette smoke-induced chemokine production. 
Am J Physiol Lung Cell Mol Physiol 2007; 292: L1297-303. 
 
Li Y, Huang TT, Carlson EJ, Melov S, Ursell PC, Olson JL, Noble LJ, Yoshimura 
MP, Berger C, Chan PH, Wallace DC, Epstein CJ. Dilated cardiomyopathy and 
neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat 
Genet 1995; 11: 376-81. 
 
Lim LH, Pervaiz S. Annexin 1: the new face of an old molecule. FASEB J 2007; 21: 
968-975. 
 
Liu CY, Lin HC, Yu CT, Lin SM, Lee KY, Chen HC, Chou CL, Huang CD, Chou PC, 
Liu WT, Wang CH, Kuo HP. The concentration-dependent chemokine release and 
pro-apoptotic effects of neutrophil-derived alpha-defensin-1 on human bronchial and 
alveolar epithelial cells. Life Sci 2007; 80: 749-58. 
 
Liu HL, Hsu JP. Recent developments in structural proteomics for protein structure 
determination. Proteomics 2005; 5: 2056-68. 
 
Liu J, Shue E, Ewalt KL, Schimmel P. A new gamma-interferon-inducible promoter 
and splice variants of an anti-angiogenic human tRNA synthetase. Nucleic Acids Res 
2004; 32: 719-27. 
 
Liu M, Yang SC, Sharma S, Luo J, Cui X, Peebles KA, Huang M, Sato M, Ramirez 
RD, Shay JW, Minna JD, Dubinett SM. EGFR Signaling is Required for 
TGF-{beta}1-mediated COX-2 Induction in Human Bronchial Epithelial Cells. Am J 
Respir Cell Mol Biol 2007; 37: 578-588. 
 
Liu Y, Chen Q, Zhang JT. Tumor suppressor gene 14-3-3sigma is down-regulated 
whereas the proto-oncogene translation elongation factor 1delta is up-regulated in 
non-small cell lung cancers as identified by proteomic profiling. J Proteome Res 
 153 
2004; 3: 728-35. 
 
Liu Y, Xiao Z, Li M, Li M, Zhang P, Li C, Li F, Chen Y, Yi H, Yao H, Chen ZC. 
Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung 
adenocarcinoma. J Pathol 2008; [Epub ahead of print] 
 
Liu Z, Lu H, Jiang Z, Pastuszyn A, Hu CA. Apolipoprotein l6, a novel proapoptotic 
Bcl-2 homology 3-only protein, induces mitochondria-mediated apoptosis in cancer 
cells. Mol Cancer Res 2005; 3: 21-31. 
 
Lorenz HM, Kalden JR. Perspectives for TNF-alpha-targeting therapies. Arthritis 
Res 2002; 4: S17-24. 
 
Lou X, Xiao T, Zhao K, Wang H, Zheng H, Lin D, Lu Y, Gao Y, Cheng S, Liu S, Xu N. 
Cathepsin D is secreted from M-BE cells: its potential role as a biomarker of lung 
cancer. J Proteome Res 2007; 6: 1083-92. 
 
Lucignani G. Rubor, calor, tumor, dolor, functio laesa... or molecular imaging. Eur J 
Nucl Med Mol Imaging 2007; 34: 2135-41. 
 
MacEwan DJ. TNF receptor subtype signalling: differences and cellular consequences. 
Cell Signal 2002; 14: 477-92. 
 
Makinde T, Murphy RF, Agrawal DK. The regulatory role of TGF-beta in airway 
remodeling in asthma. Immunol Cell Biol 2007; 85: 348-56. 
 
Malagarie-Cazenave S, Ségui B, Lévêque S, Garcia V, Carpentier S, Altié MF, 
Brouchet A, Gouazé V, Andrieu-Abadie N, Barreira Y, Benoist H, Levade T. Role of 
FAN in tumor necrosis factor-alpha and lipopolysaccharide-induced interleukin-6 
secretion and lethality in D-galactosamine-sensitized mice. J Biol Chem 2004; 279: 
18648-55. 
 
Malmström J, Larsen K, Hansson L, Löfdahl CG, Nörregard-Jensen O, Marko-Varga 
G, Westergren-Thorsson G. Proteoglycan and proteome profiling of central human 
pulmonary fibrotic tissue utilizing miniaturized sample preparation: a feasibility study. 
Proteomics 2002; 2: 394-404. 
 
Malmstrom J, Westergren-Thorsson G, Marko-Varga G. A proteomic approach to 
mimic fibrosis disease evolvement by an in vitro cell line. Electrophoresis 2001; 22: 
1776-84. 
 
Marcus K, Immler D, Sternberger J, Meyer HE. Identification of platelet proteins 
separated by two-dimensional gel electrophoresis and analyzed by matrix assisted 
laser desorption/ionization-time of flight-mass spectrometry and detection of 
tyrosine-phosphorylated proteins. Electrophoresis 2000; 21: 2622-2636. 
 
Marouga R, David S, Hawkins E. The development of the DIGE system: 2D 




Matsuda A, Suzuki Y, Honda G, Muramatsu S, Matsuzaki O, Nagano Y, Doi T, 
Shimotohno K, Harada T, Nishida E, Hayashi H, Sugano S. Large-scale identification 
and characterization of human genes that activate NF-kappaB and MAPK signaling 
pathways. Oncogene 2003; 22: 3307-18. 
 
Matsumoto H, Niimi A, Takemura M, et al. Relationship of airway wall thickening to 
an imbalance between matrix metalloproteinase-9 and its inhibitor in asthma. Thorax 
2005; 60: 277–281. 
 
Matsuo K, Iwasaki T, Asanuma H, Yoshikawa T, Chen Z, Tsujimoto H, Kurata T, 
Tamura SS. Cytokine mRNAs in the nasal-associated lymphoid tissue during 
influenza virus infection and nasal vaccination. Vaccine 2000; 18: 1344-50. 
 
McMichael BK, Kotadiya P, Singh T, Holliday LS, Lee BS. Tropomyosin isoforms 
localize to distinct microfilament populations in osteoclasts. Bone 2006; 39: 694-705. 
 
Medcalf, R.L., Stasinopoulos, S.J., The undecided serpin. The ins and outs of 
plasminogen activator inhibitor type 2. FEBS J 2005; 272: 4858-4867. 
 
Meiler F, Zimmermann M, Blaser K, Akdis CA, Akdis M. T-cell subsets in the 
pathogenesis of human asthma. Curr Allergy Asthma Rep 2006; 6: 91-6. 
 
Merkel JS, Michaud GA, Salcius M, Schweitzer B, Predki PF. Functional protein 
microarrays: just how functional are they? Curr Opin Biotechnol 2005; 16: 447–452. 
 
Meyer-Hoffert U, Lezcano-Meza D, Bartels J, Montes-Vizuet AR, Schroder JM, Teran 
LM. Th2- and to a lesser extent Th1-type cytokines up-regulate the production of both 
CXC (IL-8 and gro-alpha) and CC (RANTES, eotaxin, eotaxin-2, MCP-3 and MCP-4) 
chemokines in human airway epithelial cells. Int Arch Allergy Immunol 2003; 131: 
264-71. 
 
Michel PE, Crettaz D, Morier P, Heller M, Gallot D, Tissot JD, Reymond F, Rossier 
JS. Proteome analysis of human plasma and amniotic fluid by Off-Gel isoelectric 
focusing followed by nano-LC-MS/MS. Electrophoresis 2006; 27: 1169-81. 
 
Michel PE, Reymond F, Arnaud IL, Josserand J, Girault HH, Rossier JS. Protein 
fractionation in a multicompartment device using Off-Gel isoelectric focusing. 
Electrophoresis 2003; 24: 3-11. 
 
Mocellin S, Rossi CR, Traldi P, Nitti D, Lise M. Molecular oncology in the 
post-genomic era: the challenge of proteomics. Trends Mol Med 2004; 10: 24-32. 
 
Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Page N, Olivenstein R, Elias J, 
Chakir J. IL-17 is increased in asthmatic airways and induces human bronchial 
fibroblasts to produce cytokines. J Allergy Clin Immunol 2001; 108: 430-8. 
 
Momburg F, Tan P. Tapasin-the keystone of the loading complex optimizing peptide 




Monajemi H, Fontijn RD, Pannekoek H, Horrevoets AJ. The apolipoprotein L gene 
cluster has emerged recently in evolution and is expressed in human vascular tissue. 
Genomics 2002; 79: 539-46. 
 
Monks NR, Biswas DK, Pardee AB. Blocking anti-apoptosis as a strategy for cancer 
chemotherapy: NF-kappaB as a target. J Cell Biochem 2004; 92: 646-50. 
 
Morandell S, Stasyk T, Grosstessner-Hain K, Roitinger E, Mechtler K, Bonn GK, 
Huber LA. Phosphoproteomics strategies for the functional analysis of signal 
transduction. Proteomics 2006; 6: 4047-56. 
 
Mukhopadhyay S, Hoidal JR, Mukherjee TK. Role of TNFalpha in pulmonary 
pathophysiology. Respir Res 2006; 7: 125. 
 
Munder M, Mallo M, Eichmann K, Modolell M. Direct stimulation of macrophages 
by IL-12 and IL-18 - a bridge built on solid ground. Immunol Lett 2001; 75: 159-60. 
 
Mustafa D, Kros JM, Luider T. Combining laser capture microdissection and 
proteomics techniques. Methods Mol Biol 2008; 428: 159-78. 
 
Myllyharju, J. Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. 
Matrix Biol 2003; 22: 15-24. 
 
Nakamura Y, Esnault S, Maeda T, Kelly EA, Malter JS, Jarjour NN. Ets-1 regulates 
TNF-alpha-induced matrix metalloproteinase-9 and tenascin expression in primary 
bronchial fibroblasts. J Immunol 2004; 172: 1945-52. 
 
Nakamura M, Matute-Bello G, Liles WC, Hayashi S, Kajikawa O, Lin SM, Frevert 
CW, Martin TR. Differential response of human lung epithelial cells to fas-induced 
apoptosis. Am J Pathol 2004; 164: 1949-58. 
 
Nan L, Zhang W, Cao X. Identification of human homologue of mouse IFN-gamma 
induced protein from human dendritic cells. Immunol Lett 2000; 74: 221-224. 
 
Neff-LaFord H, Teske S, Bushnell TP, Lawrence BP. Aryl hydrocarbon receptor 
activation during influenza virus infection unveils a novel pathway of IFN-gamma 
production by phagocytic cells. J Immunol 2007; 179: 247-55. 
 
O'Donnell R, Breen D, Wilson S, Djukanovic R. Inflammatory cells in the airways in 
COPD. Thorax 2006; 61: 448-54. 
 
O’Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol 
Chem 1975; 250: 4007-21. 
 
O’Kane CM, Boyle JJ, Horncastle DE, Elkington PT, Friedland JS. 
Monocyte-dependent fibroblast CXCL8 secretion occurs in tuberculosis and limits 
survival of mycobacteria within macrophages. J Immunol 2007; 178: 3767-3776. 
 
Oliveri C, Polosa R. Etanercept in chronic severe asthma. Thorax 2006; 61: 640. 
 
 156 
Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, Mann M. Global, in 
vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 2006; 
127: 635-48. 
 
Omori M, Ziegler S. Induction of IL-4 expression in CD4(+) T cells by thymic 
stromal lymphopoietin. J Immunol 2007; 178: 1396-404. 
 
Ong SE, Kratchmarova I, Mann M. Properties of 13C-substituted arginine in stable 
isotope labeling by amino acids in cell culture (SILAC). J Proteome Res 2003; 2: 
173-81. 
 
Otani A, Slike BM, Dorrell MI, Hood J, Kinder K, Ewalt KL, Cheresh D, Schimmel P, 
Friedlander M. A fragment of human TrpRS as a potent antagonist of ocular 
angiogenesis. Proc Natl Acad Sci U S A 2002; 99: 178-83. 
 
Padovan E, Terracciano L, Certa U, et al. Interferon stimulated gene 15 constitutively 
produced by melanoma cells induces e-cadherin expression on human dendritic cells. 
Cancer Res 2002; 62: 3453-8. 
 
Page NM, Butlin DJ, Lomthaisong K, Lowry PJ. The human apolipoprotein L gene 
cluster: identification, classification, and sites of distribution. Genomics 2001; 74: 
71-8. 
 
Paludan SR. Synergistic action of pro-inflammatory agents: cellular and molecular 
aspects. J Leukoc Biol 2000; 67: 18-25. 
 
Pappin DJ, Hojrup P, Bleasby AJ. Rapid identification of proteins by peptide-mass 
fingerprinting. Curr Biol 1993; 3: 327-32. 
 
Parsons PE, Matthay MA, Ware LB, Eisner MD; National Heart, Lung, Blood 
Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Elevated 
plasma levels of soluble TNF receptors are associated with morbidity and mortality in 
patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol 2005; 288: 
L426-31. 
 
Patton WF. A thousand points of light: the application of fluorescence detection 
technologies to two-dimensional gel electrophoresis and proteomics. Electrophoresis 
2000; 21: 1123-44. 
 
Patton WF, Schulenberg B, Steinberg TH. Two-dimensional gel electrophoresis; 
better than a poke in the ICAT? Curr Opin Biotechnol 2002; 13: 321-8. 
 
Pavlovic J, Haller O, Staeheli P. Human and mouse Mx proteins inhibit different steps 
of the influenza virus multiplication cycle. J Virol 1992; 66: 2564-9. 
 
Pavlovic J, Zurcher T, Haller O, Staeheli P. Resistance to influenza virus and 
vesicular stomatitis virus conferred by expression of human MxA protein. J Virol 
1990; 64: 3370-5. 
 
Pawliczak R, Logun C, Madara P, Barb J, Suffredini AF, Munson PJ, Danner RL, 
 157 
Shelhamer JH. Influence of IFN-gamma on gene expression in normal human 
bronchial epithelial cells: modulation of IFN-gamma effects by dexamethasone. 
Physiol Genomics 2005; 23: 28-45. 
 
Pedersen SK, Harry JL, Sebastian L, Baker J, Traini MD, McCarthy JT, Manoharan A, 
Wilkins MR, Gooley AA, Righetti PG, Packer NH, Williams KL, Herbert BR. Unseen 
proteome: mining below the tip of the iceberg to find low abundance and membrane 
proteins. J Proteome Res 2003; 2: 303-11. 
 
Peng J, Gygi SP. Proteomics: the move to mixtures. J Mass Spectrom 2001; 36: 
1083-91. 
 
Pérez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F, Nolan DP, Lins L, Homblé F, 
Vanhamme L, Tebabi P, Pays A, Poelvoorde P, Jacquet A, Brasseur R, Pays E. 
Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal 
membranes. Science 2005; 309: 469-72. 
 
Perng DW, Wu YC, Chang KT, Wu MT, Chiou YC, Su KC, Perng RP, Lee YC. 
Leukotriene C4 induces TGF-beta1 production in airway epithelium via p38 kinase 
pathway. Am J Respir Cell Mol Biol 2006; 34: 101-7. 
 
Pettus BJ, Chalfant CE, Hannun YA. Ceramide in apoptosis: an overview and current 
perspectives. Biochim Biophys Acta 2002; 1585: 114-25. 
 
Pollard HB, Eidelman O, Jozwik C, Huang W, Srivastava M, Ji XD, McGowan B, 
Norris CF, Todo T, Darling T, Mogayzel PJ, Zeitlin PL, Wright J, Guggino WB, 
Metcalf E, Driscoll WJ, Mueller G, Paweletz C, Jacobowitz DM. De novo biosynthetic 
profiling of high abundance proteins in cystic fibrosis lung epithelial cells. Mol Cell 
Proteomics 2006; 5: 1628-37. 
 
Pollard HB, Ji XD, Jozwik C, Jacobowitz DM. High abundance protein profiling of 
cystic fibrosis lung epithelial cells. Proteomics 2005; 5: 2210-26. 
 
Pornprasertsuk S, Duarte WR, Mochida Y, Yamauchi M. Lysyl hydroxylase-2b directs 
collagen cross-linking pathways in MC3T3-E1 cells. J Bone Miner Res 2004; 19: 
1349-55. 
 
Postma DS, Timens W. Remodeling in asthma and chronic obstructive pulmonary 
disease. Proc Am Thorac Soc 2006; 3: 434-9. 
 
Qiao F, Bowie JU. The many faces of SAM. Sci. STKE 2005; 286: re7. 
 
Qiu Y, Zhu J, Bandi V, Guntupalli KK, Jeffery PK. Bronchial mucosal inflammation 
and up-regulation of CXC chemoattractants and receptors in severe exacerbations of 
asthma. Thorax 2007; 62: 475-82. 
 
Raineri I, Huang TT, Epstein CJ, Epstein LB. Antisense manganese superoxide 
dismutase mRNA inhibits the antiviral action of interferon-gamma and 
interferon-alpha. J Interferon Cytokine Res 1996; 16: 61-8. 
 
 158 
Ramachandran R, Morice AH, Compton SJ. Proteinase-activated receptor2 agonists 
up-regulate granulocyte colony-stimulating factor, IL-8, and VCAM-1 expression in 
human bronchial fibroblasts. Am J Respir Cell Mol Biol 2006; 35: 133-41. 
 
Ramana CV, Gil MP, Schreiber RD, Stark GR. Stat1-dependent and -independent 
pathways in IFN-gamma-dependent signaling. Trends Immunol 2002; 23: 96-101. 
 
Ranjan P, Boss JM. C/EBPbeta regulates TNF induced MnSOD expression and 
protection against apoptosis. Apoptosis 2006; 11: 1837-49.  
 
Rautsi O, Lehmusvaara S, Salonen T, Hakkinen K, Sillanpaa M, Hakkarainen T, 
Heikkinen S, Vahakangas E, Yla-Herttuala S, Hinkkanen A, Julkunen I, Wahlfors J, 
Pellinen R. Type I interferon response against viral and non-viral gene transfer in 
human tumor and primary cell lines. J Gene Med 2007; 9: 122-35. 
 
Remold-O'Donnell E. A fast-acting elastase inhibitor in human monocytes. J Exp 
Med 1985; 162: 2142-55. 
 
Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, Mahler D, Saadeh C, 
Siler T, Snell P, Korenblat P, Smith W, Kaye M, Mandel M, Andrews C, Prabhu R, 
Donohue JF, Watt R, Lo KH, Schlenker-Herceg R, Barnathan ES, Murray J; COPD 
Investigators. The safety and efficacy of infliximab in moderate to severe chronic 
obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 926-34. 
 
Righetti PG, Castagna A, Antonucci F, Piubelli C, Cecconi D, Campostrini N, 
Antonioli P, Astner H, Hamdan M. Critical survey of quantitative proteomics in 
two-dimensional electrophoretic approaches. J Chromatogr A 2004; 1051: 3-17. 
 
Righetti PG, Castagna A, Herbert B, Candiano G. How to bring the "unseen" proteome 
to the limelight via electrophoretic pre-fractionation techniques. Biosci Rep 2005; 25: 
3-17. 
 
Righetti PG, Castagna A, Herbert B, Reymond F, Rossier JS. Prefractionation 
techniques in proteome analysis. Proteomics 2003; 3: 1397-407. 
 
Ritchie KJ, Hahn CS, Kim KI, Yan M, Rosario D, Li L, de la Torre JC, Zhang DE. 
Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nat 
Med 2004; 10: 1374-8. 
 
Rogers RJ, Monnier JM, Nick HS. Tumor necrosis factor-alpha selectively induces 
MnSOD expression via mitochondria-to-nucleus signaling, whereas interleukin-1beta 
utilizes an alternative pathway. J Biol Chem 2001; 276: 20419-27. 
 
Rubio F, Cooley J, Accurso FJ, and Remold-O’Donnell E. Linkage of neutrophil 
serine proteases and decreased surfactant protein-A (SP-A) levels in inflammatory 
lung disease. Thorax 2004; 59: 318-323. 
 
Sabatini F, Silvestri M, Sale R, Scarso L, Defilippi AC, Risso FM, Rossi GA. 
Fibroblast-eosinophil interaction: modulation of adhesion molecules expression and 
chemokine release by human fetal lung fibroblasts in response to IL-4 and TNF-alpha. 
 159 
Immunol Lett 2002; 84: 173-8. 
 
Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14: 778-809. 
 
Sana TR, Janatpour MJ, Sathe M, McEvoy LM, McClanahan TK. Microarray analysis 
of primary endothelial cells challenged with different inflammatory and immune 
cytokines. Cytokine 2005; 29: 256-69. 
 
Sanders ME, Dias EC, Xu BJ, Mobley JA, Billheimer D, Roder H, Grigorieva J, 
Dowsett M, Arteaga CL, Caprioli RM. Differentiating proteomic biomarkers in breast 
cancer by laser capture microdissection and MALDI MS. J Proteome Res 2008; 7: 
1500-7. 
 
Schindler H, Lutz MB, Rollinghoff M, Bogdan C. The production of IFN-gamma by 
IL-12/IL-18-activated macrophages requires STAT4 signaling and is inhibited by IL-4. 
J Immunol 2001; 166: 3075-82. 
 
Schmelzle K, White FM. Phosphoproteomic approaches to elucidate cellular signaling 
networks. Curr Opin Biotechnol 2006; 17: 406-14. 
 
Schreiber RD, Farrar MA. The biology and biochemistry of interferon-gamma and its 
receptor. Gastroenterol Jpn 1993; 28: 88-94. 
 
Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of 
signals, mechanisms and functions. J Leukoc Biol 2004; 75: 163-89.   
 
Scigelova M, Makarov A. Orbitrap mass analyzer - overview and applications in 
proteomics. Proteomics 2006; 6: 16-21. 
 
Sekiya T, Miyamasu M, Imanishi M, Yamada H, Nakajima T, Yamaguchi M, Fujisawa 
T, Pawankar R, Sano Y, Ohta K, Ishii A, Morita Y, Yamamoto K, Matsushima K, 
Yoshie O, Hirai K. Inducible expression of a Th2-type CC chemokine thymus- and 
activation-regulated chemokine by human bronchial epithelial cells. J Immunol 2000; 
165: 2205-2213. 
 
Sen GC. Viruses and interferons. Annu Rev Microbiol 2001; 55: 255-81. 
 
Shadforth I, Crowther D, Bessant C. Protein and peptide identification algorithms 
using MS for use in high-throughput, automated pipelines. Proteomics 2005; 5: 
4082-95. 
 
Shah MA, Kemeny N, Hummer A, Drobnjak M, Motwani M, Cordon-Cardo C, 
Gonen M, Schwartz GK. Drg1 expression in 131 colorectal liver metastases: 
correlation with clinical variables and patient outcomes. Clin Cancer Res 2005; 11: 
3296-302. 
 
Sheikh MS, Huang Y. Death receptor activation complexes: it takes two to activate 
TNF receptor 1. Cell Cycle 2003; 2: 550-2. 
 
Shevchenko A, Jensen ON, Podtelejnikov AV, Sagliocco F, Wilm M, Vorm O, 
 160 
Mortensen P, Shevchenko A, Boucherie H, Mann M.Linking genome and proteome 
by mass spectrometry: large-scale identification of yeast proteins from two 
dimensional gels. Proc Natl Acad Sci U S A 1996; 93: 14440-5. 
 
Shi ZO, Fischer MJ, De Sanctis GT, Schuyler MR, Tesfaigzi Y. IFN-gamma, but not 
Fas, mediates reduction of allergen-induced mucous cell metaplasia by inducing 
apoptosis. J Immunol 2002; 168: 4764-71. 
 
Siegel DH, Howard R. Molecular advances in genetic skin diseases. Curr Opin 
Pediatr 2002; 14: 419-25. 
 
Siegle JS, Hansbro N, Herbert C, Yang M, Foster PS, Kumar RK. Airway 
hyperreactivity in exacerbation of chronic asthma is independent of eosinophilic 
inflammation. Am J Respir Cell Mol Biol 2006; 35: 565-70. 
 
Simpson JC, Wellenreuther R, Poustka A, Pepperkok R, Wiemann S. Systematic 
subcellular localization of novel proteins identified by large-scale cDNA sequencing. 
EMBO Rep 2000; 1: 287-92. 
 
Smeltz RB. Profound enhancement of the IL-12/IL-18 pathway of IFN-gamma 
secretion in human CD8+ memory T cell subsets via IL-15. J Immunol 2007; 178: 
4786-92. 
 
Sonnemann KJ, Fitzsimons DP, Patel JR, Liu Y, Schneider MF, Moss RL, Ervasti JM. 
Cytoplasmic gamma-actin is not required for skeletal muscle development but its 
absence leads to a progressive myopathy. Dev Cell 2006; 11: 387-97. 
 
Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, Gilliet M, Ho S, 
Antonenko S, Lauerma A, Smith K, Gorman D, Zurawski S, Abrams J, Menon S, 
McClanahan T, de Waal-Malefyt Rd R, Bazan F, Kastelein RA, Liu YJ. Human 
epithelial cells trigger dendritic cell mediated allergic inflammation by producing 
TSLP. Nat Immunol 2002; 3: 673-80. 
 
Spickett CM, Pitt AR, Morrice N, Kolch W. Proteomic analysis of phosphorylation, 
oxidation and nitrosylation in signal transduction. Biochim Biophys Acta 2006; 1764: 
1823-41. 
 
Stein S, Thomas EK, Herzog B, Westfall MD, Rocheleau JV, Jackson RS 2nd, Wang 
M, Liang P. NDRG1 is necessary for p53-dependent apoptosis. J Biol Chem 2004; 
279: 48930-40. 
 
Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, Marius R, 
Reynard J, Poliquin L, Atkins H, Brown EG, Durbin RK, Durbin JE, Hiscott J, Bell 
JC. VSV strains with defects in their ability to shutdown innate immunity are potent 
systemic anti-cancer agents. Cancer Cell 2003; 4: 263-75. 
 
Sugiura H, Liu X, Duan F, Kawasaki S, Togo S, Kamio K, Wang XQ, Mao L, Ahn Y, 
Ertl RF, Bargar TW, Berro A, Casale TB, Rennard SI. Cultured lung fibroblasts from 
ovalbumin-challenged “asthmatic” mice differ functionally from normal. Am J 
Respir Cell Mol Biol 2007; 37: 424-30. 
 161 
 
Sutton CW, Pemberton KS, Cottrell JS, Corbett JM, Wheeler CH, Dunn MJ, Pappin 
DJ. Identification of myocardial proteins from two-dimensional gels by peptide mass 
fingerprinting. Electrophoresis 1995; 16: 308-16. 
 
Syka JE, Coon JJ, Schroeder MJ, Shabanowitz J, Hunt DF. Peptide and protein 
sequence analysis by electron transfer dissociation mass spectrometry. Proc Natl 
Acad Sci U S A 2004; 101: 9528-33. 
 
Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S, McKenzie AN, Nagai H, 
Hotokebuchi T, Izuhara K. Periostin: a novel component of subepithelial fibrosis of 
bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 
2006; 118: 98-104. 
 
Tanaka K, Sano K, Yuba K, et al. Inhibition of induction of myofibroblasts by 
interferon gamma in a human fibroblast cell line. Int Immunopharmacol 2003; 3: 
1273–1280. 
 
Templin MF, Stoll D, Schwenk JM, Potz O, Kramer S, Joos TO. Protein microarrays: 
promising tools for proteomic research. Proteomics 2003; 3: 2155–2166. 
 
Tesfaigzi Y. Roles of apoptosis in airway epithelia. Am J Respir Cell Mol Biol 2006; 
34: 537-47. 
 
Thomas PS.Tumour necrosis factor-alpha: the role of this multifunctional cytokine in 
asthma. Immunol Cell Biol 2001; 79: 132-40. 
 
Tillie-Leblond I, Gosset P, Tonnel AB. Inflammatory events in severe acute asthma. 
Allergy 2005; 60: 23-9. 
 
Tong J, Bandulwala HS, Clay BS, Anders RA, Shilling RA, Balachandran DD, Chen 
B, Weinstock JV, Solway J, Hamann KJ, Sperling AI. Fas-positive T cells regulate the 
resolution of airway inflammation in a murine model of asthma. J Exp Med 2006; 
203: 1173-84. 
 
Trautmann A, Kruger K, Akdis M, Muller-Wening D, Akkaya A, Brocker EB, Blaser 
K, Akdis CA. Apoptosis and loss of adhesion of bronchial epithelial cells in asthma. 
Int Arch Allergy Immunol 2005; 138: 142-50. 
 
Trautmann A, Schmid-Grendelmeier P, Kruger K, Crameri R, Akdis M, Akkaya A, 
Brocker EB, Blaser K, Akdis CA. T cells and eosinophils cooperate in the induction 
of bronchial epithelial cell apoptosis in asthma. J Allergy Clin Immunol 2002; 109: 
329-37. 
 
Tsai ST, Chen CW, Lora LC, Huang MC, Chen CH, Wang YS. Simultaneous mass 
analysis of positive and negative ions using a dual-polarity time-of-flight mass 
spectrometer. Anal Chem 2006; 78: 7729-34. 
 
Tzima E, Schimmel P. Inhibition of tumor angiogenesis by a natural fragment of a 
tRNA synthetase. Trends Biochem Sci 2006; 31: 7-10. 
 162 
 
Ulich TR, Watson LR, Yin SM, Guo KZ, Wang P, Thang H, del Castillo J. The 
intratracheal administration of endotoxin and cytokines. I. Characterization of 
LPS-induced IL-1 and TNF mRNA expression and the LPS-, IL-1-, and TNF-induced 
inflammatory infiltrate. Am J Phathol 1991; 138: 1485-1496. 
 
Uller L, Rydell-Törmänen K, Persson CG, Erjefält JS. Anti-Fas mAb-induced 
apoptosis and cytolysis of airway tissue eosinophils aggravates rather than resolves 
established inflammation. Respir Res 2005; 6: 90. 
 
Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method 
for detecting changes in protein extracts. Electrophoresis 1997; 18: 2071-7. 
 
Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, Nolan DP, Lins L, Van Den 
Abbeele J, Pays A, Tebabi P, Van Xong H, Jacquet A, Moguilevsky N, Dieu M, Kane 
JP, De Baetselier P, Brasseur R, Pays E. Apolipoprotein L-I is the trypanosome lytic 
factor of human serum. Nature 2003; 422: 83-7. 
 
Vanhollebeke B, Pays E. The function of apolipoproteins L. Cell Mol Life Sci 2006; 
63: 1937-44. 
 
van der Vaart H, Koeter GH, Postma DS, Kauffman HF, ten Hacken NH. First study 
of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J 
Respir Crit Care Med 2005; 172: 465-9. 
 
Venkatasubbarao S. Microarrays—status and prospects. Trends Biotechnol 2004; 22: 
630–637. 
 
Wadgaonkar R, Pierce JW, Somnay K, Damico RL, Crow MT, Collins T, Garcia JG. 
Regulation of c-Jun N-terminal kinase and p38 kinase pathways in endothelial cells. 
Am J Respir Cell Mol Biol 2004; 31: 423-31. 
 
Wagner AH, Gebauer M, Pollok-Kopp B, Hecker M. Cytokine-inducible CD40 
expression in human endothelial cells is mediated by interferon regulatory factor-1. 
Blood 2002; 99: 520-5.  
 
Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death 
Differ 2003; 10: 45-65. 
 
Wakasugi K, Slike BM, Hood J, Otani A, Ewalt KL, Friedlander M, Cheresh DA, 
Schimmel P. A human aminoacyl-tRNA synthetase as a regulator of angiogenesis. 
Proc Natl Acad Sci U S A 2002; 99: 173-7. 
 
Waldburg N, Kähne T, Reisenauer A, Röcken C, Welte T, Bühling F. Clinical 
proteomics in lung diseases. Pathol Res Pract 2004; 200: 147-54. 
 
Walker LC, Overstreet MA, Yeowell HN. Tissue-specific expression and regulation of 
the alternatively-spliced forms of lysyl hydroxylase 2 (LH2) in human kidney cells 
and skin fibroblasts. Matrix Biol 2005; 23: 515-23. 
 
 163 
Warner RL, Bhagavathula N, Nerusu KC, Lateef H, Younkin E, Johnson KJ, Varani J. 
Matrix metalloproteinases in acute inflammation: induction of MMP-3 and MMP-9 in 
fibroblasts and epithelial cells following exposure to pro-inflammatory mediators in 
vitro. Exp Mol Pathol 2004; 76: 189-95. 
 
Wasinger VC, Cordwell SJ, Cerpa-Poljak A, Yan JX, Gooley AA, Wilkins MR, 
Duncan MW, Harris R, Williams KL, Humphery-Smith I. Progress with gene-product 
mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis 1995; 16: 
1090-4. 
 
Wasinger VC, Locke VL, Raftery MJ, Larance M, Rothemund D, Liew A, Bate I, 
Guilhaus M. Two-dimensional liquid chromatography/tandem mass spectrometry 
analysis of Gradiflow fractionated native human plasma. Proteomics 2005; 5: 
3397-401. 
 
Weber G, Islinger M, Weber P, Eckerskorn C, Volkl A. Efficient separation and 
analysis of peroxisomal membrane proteins using free-flow isoelectric focusing. 
Electrophoresis 2004; 25: 1735-47. 
 
Wenzel SE, Trudeau JB, Barnes S, Zhou X, Cundall M, Westcott JY, McCord K, Chu 
HW. TGF-beta and IL-13 synergistically increase eotaxin-1 production in human 
airway fibroblasts. J Immunol 2002; 169: 4613-9. 
 
Wilkinson TS, Potter-Perigo S, Tsoi C, Altman LC, Wight TN. Pro- and 
anti-inflammatory factors cooperate to control hyaluronan synthesis in lung 
fibroblasts. Am J Respir Cell Mol Biol 2004; 31: 92-99. 
 
Williams AP, Peh CA, Purcell AW, McCluskey J, Elliott T. Optimization of the MHC 
class I peptide cargo is dependent on tapasin. Immunity 2002; 16: 509–520 
 
Williams K, Mackenzie JS. Influenza infections during pregnancy in the mouse. J 
Hyg (Lond) 1977; 79: 249-257. 
 
Williams DK Jr, McAlister GC, Good DM, Coon JJ, Muddiman DC. Dual 
electrospray ion source for electron-transfer dissociation on a hybrid linear ion 
trap-orbitrap mass spectrometer. Anal Chem 2007; 79: 7916-9. 
 
Willis BC, Borok Z. TGF-beta-induced EMT: mechanisms and implications for 
fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 2007; 293: L525-34. 
 
Wilm M, Shevchenko A, Houthaeve T, Breit S, Schweigerer L, Fotsis T, Mann M. 
Femtomole sequencing of proteins from polyacrylamide gels by nano-electrospray 
mass spectrometry. Nature 1996; 379: 466-9. 
 
Wingender E, Chen X, Fricke E, Geffers R, Hehl R, Liebich I, Krull M, Matys V, 
Michael H, Ohnhauser R, Pruss M, Schacherer F, Thiele S, Urbach S. TRANSFAC and 
its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids 
Res 2001; 29: 281-283. 
 
Woods DE, Cantin A, Cooley J, Kenney DM, Remold-O'Donnell E. Aerosol 
 164 
treatment with MNEI suppresses bacterial proliferation in a model of chronic 
Pseudomonas aeruginosa lung infection. Pediatr Pulmonol 2005; 39: 141-9. 
 
Wu J, Reinhardt DP, Batmunkh C, Lindenmaier W, Far RK, Notbohm H, Hunzelmann 
N, Brinckmann J. Functional diversity of lysyl hydroxylase 2 in collagen synthesis of 
human dermal fibroblasts. Exp Cell Res 2006; 312: 3485-94.  
 
Xiao Z, Conrads TP, Lucas DA, Janini GM, Schaefer CF, Buetow KH, Issaq HJ, 
Veenstra TD. Direct ampholyte-free liquid-phase isoelectric peptide focusing: 
application to the human serum proteome. Electrophoresis 2004; 25: 128-33. 
 
Xu W, Zheng S, Dweik RA, Erzurum SC. Role of epithelial nitric oxide in airway 
viral infection. Free Radic Biol Med 2006; 41: 19-28. 
 
Xu W, Zheng S, Goggans TM, Kiser P, Quinones-Mateu ME, Janocha AJ, Comhair 
SA, Slee R, Williams BR, Erzurum SC. Cystic fibrosis and normal human airway 
epithelial cell response to influenza a viral infection. J Interferon Cytokine Res 
2006; 26: 609-27. 
 
Yakunin AF, Proudfoot M, Kuznetsova E, Savchenko A, Brown G, Arrowsmith CH, 
Edwards AM. The HD domain of the Escherichia coli tRNA nucleotidyltransferase 
has 2’,3’-cyclic phosphodiesterase, 2’-nucleotidase, and phosphatase activities. J Biol 
Chem 2004; 279: 36819-36827. 
 
Yamada M, Kubo H, Kobayashi S, Ishizawa K, Sasaki H. Interferon-gamma: a key 
contributor to hyperoxia-induced lung injury in mice. Am J Physiol Lung Cell Mol 
Physiol 2004; 287: L1042-7. 
 
Yasumatsu R, Altiok O, Benarafa C, Yasumatsu C, Bingol-Karakoc G, 
Remold-O'Donnell E, Cataltepe S. SERPINB1 up-regulation is associated with in 
vivo complex formation with neutrophil elastase and cathepsin G in a baboon model 
of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2006; 291: 
L619-27. 
 
Zarling AL, Luckey CJ, Marto JA, White FM, Brame CJ, Evans AM, Lehner PJ, 
Cresswell P, Shabanowitz J, Hunt DF, Engelhard VH. Tapasin is a facilitator, not an 
editor, of class I MHC peptide binding. J Immunol 2003; 171: 5287–5295. 
 
Zhang XD, Matunis MJ. Ub in charge: regulating E2 enzyme nuclear import. Nat 
Cell Biol 2005; 7: 12-14. 
 
Zhang YQ, Li P, Hou M, Wang X, Fan J, Tan L, Zhu YS. Identification of interaction 
between PAI-2 and IRF-3. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao 
(Shanghai) 2003; 35: 661-5. 
 
Zhao H, Adler KB, Bai C, Tang F, Wang X. Epithelial proteomics in multiple organs 
and tissues: similarities and variations between cells, organs, and diseases. J 
Proteome Res 2006; 5: 743-55. 
 
Zhao Y, Conze DB, Hanover JA, Ashwell JD. Tumor necrosis factor receptor 2 
 165 
signaling induces selective c-IAP1-dependent ASK1 ubiquitination and terminates 
mitogen-activated protein kinase signaling. J Biol Chem 2007; 282: 7777-82. 
 
Zheng S, Xu W, Bose S, Banerjee AK, Haque SJ, Erzurum SC. Impaired nitric oxide 
synthase-2 signaling pathway in cystic fibrosis airway epithelium. Am J Physiol 
Lung Cell Mol Physiol 2004; 287: L374-81. 
 
Zhu Y, Lubman DM. Narrow-band fractionation of proteins from whole cell lysates 
using isoelectric membrane focusing and nonporous reversed-phase separations. 
Electrophoresis 2004; 25: 949-58. 
 
Zhu Z, Zheng T, Homer RJ, Kim YK, Chen NY, Cohn L, Hamid Q, Elias JA. Acidic 
mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. 
Science 2004; 304: 1678-82. 
 
Zou W, Wang J, Zhang DE. Negative regulation of ISG15 E3 ligase EFP through its 





List of Mascot Search Results and MS Spectrum 
Mascot Search Results 
Protein View 
Match to: gi|24119203 Score: 393 Expect: 2.1e-033 
tropomyosin 3 isoform 2 [Homo sapiens] 
 
Nominal mass (Mr): 29243; Calculated pI value: 4.75 
NCBI BLAST search of gi|24119203 against nr 
Unformatted sequence string for pasting into other applications 
 
Fixed modifications: Carbamidomethyl (C) 
Variable modifications: Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 66% 
Matched peptides shown in Bold Red 
 
     1 MAGITTIEAV KRKIQVLQQQ ADDAEERAER LQREVEGERR AREQAEAEVA  
    51 SLNRRIQLVE EELDRAQERL ATALQKLEEA EKAADESERG MKVIENRALK  
   101 DEEKMELQEI QLKEAKHIAE EADRKYEEVA RKLVIIEGDL ERTEERAELA  
   151 ESRCREMDEQ IRLMDQNLKC LSAAEEKYSQ KEDKYEEEIK ILTDKLKEAE  
   201 TRAEFAERSV AKLEKTIDDL EDKLKCTKEE HLCTQRMLDQ TLLDLNEM 
 
Start - End Observed Mr(expt) Mr(calc)  Delta   Miss Sequence 
    13 - 27     1770.92  1769.91  1769.89     0.02     1  R.KIQVLQQQADDAEER.A  (Ions score 
21) 
    13 - 27     1770.92  1769.91  1769.89     0.02     1  R.KIQVLQQQADDAEER.A  (No match) 
    14 - 27     1642.82  1641.82  1641.80     0.02     0  K.IQVLQQQADDAEER.A  (Ions score 
22) 
    14 - 27     1642.82  1641.82  1641.80     0.02     0  K.IQVLQQQADDAEER.A  (No match) 
    14 - 30     1999.01  1998.00  1997.98     0.02     1  K.IQVLQQQADDAEERAER.L  (Ions 
score 25) 
    14 - 30     1999.01  1998.00  1997.98     0.02     1  K.IQVLQQQADDAEERAER.L  (No 
match) 
    41 - 54     1543.81  1542.80  1542.77     0.03     1  R.AREQAEAEVASLNR.R  (No match) 
    43 - 54     1316.67  1315.66  1315.64     0.03     0  R.EQAEAEVASLNR.R  (No match) 
    43 - 55     1472.77  1471.76  1471.74     0.02     1  R.EQAEAEVASLNRR.I  (Ions score 29) 
    43 - 55     1472.77  1471.76  1471.74     0.02     1  R.EQAEAEVASLNRR.I  (No match) 
    55 - 65     1399.78  1398.77  1398.75     0.02     1  R.RIQLVEEELDR.A  (No match) 
    56 - 65     1243.68  1242.67  1242.65     0.03     0  R.IQLVEEELDR.A  (No match) 
    56 - 69     1727.91  1726.91  1726.88     0.02     1  R.IQLVEEELDRAQER.L  (Ions score 34) 
    56 - 69     1727.91  1726.91  1726.88     0.02     1  R.IQLVEEELDRAQER.L  (No match) 
    66 - 76     1228.71  1227.71  1227.69     0.01     1  R.AQERLATALQK.L  (No match) 
    70 - 82     1443.77  1442.77  1442.80    -0.03     1  R.LATALQKLEEAEK.A  (No match) 
    77 - 89     1476.71  1475.70  1475.67     0.03     1  K.LEEAEKAADESER.G  (No match) 
    93 - 100     942.52   941.51   941.57    -0.05     1  K.VIENRALK.D  (No match) 
   117 - 124     940.47   939.47   939.44     0.02     0  K.HIAEEADR.K  (No match) 
   126 - 132     894.49   893.48   893.46     0.02     1  K.YEEVARK.L  (No match) 
   132 - 142    1284.77  1283.77  1283.74     0.02     1  R.KLVIIEGDLER.T  (Ions score 18) 
   132 - 142    1284.77  1283.77  1283.74     0.02     1  R.KLVIIEGDLER.T  (No match) 
   133 - 142    1156.68  1155.68  1155.65     0.03     0  K.LVIIEGDLER.T  (No match) 
   143 - 153    1290.65  1289.65  1289.62     0.03     1  R.TEERAELAESR.C  (No match) 
   154 - 162    1236.56  1235.55  1235.54     0.02     1  R.CREMDEQIR.L  (No match) 
   154 - 162    1252.57  1251.56  1251.53     0.03     1  R.CREMDEQIR.L  Oxidation (M) (No 
match) 
   156 - 162     920.43   919.43   919.41     0.02     0  R.EMDEQIR.L  (No match) 
 167 
   156 - 162     936.42   935.42   935.40     0.01     0  R.EMDEQIR.L  Oxidation (M) (No match) 
   163 - 169     861.47   860.46   860.44     0.02     0  R.LMDQNLK.C  (No match) 
   163 - 177    1749.90  1748.89  1748.84     0.04     1  R.LMDQNLKCLSAAEEK.Y  (No match) 
   182 - 190    1182.65  1181.65  1181.55     0.10     1  K.EDKYEEEIK.I  (No match) 
   216 - 225    1189.65  1188.64  1188.62     0.02     1  K.TIDDLEDKLK.C  (No match) 
   226 - 236    1461.68  1460.67  1460.65     0.02     1  K.CTKEEHLCTQR.M  (No match) 






















































































































































































































Mascot Search Results 
Protein View 
Match to: gi|178045 Score: 154 Expect: 1.6e-009 
gamma-actin [Homo sapiens] 
 
Nominal mass (Mr): 26147; Calculated pI value: 5.65 
NCBI BLAST search of gi|178045 against nr 
Unformatted sequence string for pasting into other applications 
 
Fixed modifications: Carbamidomethyl (C) 
Variable modifications: Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 42% 
Matched peptides shown in Bold Red 
 
     1 ASGRTTGIVM DSGDGVTHTV PIYEGYALPH AILRLDLAGR DLTDYLMKIL  
    51 TERGYSFTTT AEREIVRDIK EKLCYVALDF EQEMATAASS SSLEKSYELP  
   101 DGQVITIGNE RFRCPEALFQ PSFLGMESCG IHETTFNSIM KCDVDIRKDL  
   151 YANTVLSGGT TMYPGIADRM QKKITALAPS TMKIKIIAPP ERKYSVWIGG  
   201 FILASLSTFQ QMWISKQEYD ESGPSIVHRK CF 
 
Start - End  Observed Mr(expt) Mr(calc) Delta   Miss Sequence 
     5 - 34     3183.73  3182.72  3182.61     0.11     0  
R.TTGIVMDSGDGVTHTVPIYEGYALPHAILR.L  (No match) 
    54 - 63     1132.59  1131.58  1131.52     0.06     0  R.GYSFTTTAER.E  (Ions score 32) 
    54 - 63     1132.59  1131.58  1131.52     0.06     0  R.GYSFTTTAER.E  (No match) 
    96 - 111    1790.97  1789.96  1789.88     0.07     0  K.SYELPDGQVITIGNER.F  (Ions score 
22) 
    96 - 111    1790.97  1789.96  1789.88     0.07     0  K.SYELPDGQVITIGNER.F  (No match) 
   149 - 169    2215.16  2214.15  2214.06     0.09     0  K.DLYANTVLSGGTTMYPGIADR.M  
(Ions score 7) 
   149 - 169    2215.16  2214.15  2214.06     0.09     0  K.DLYANTVLSGGTTMYPGIADR.M  
(No match) 
   149 - 169    2231.14  2230.14  2230.06     0.08     0  K.DLYANTVLSGGTTMYPGIADR.M  
Oxidation (M) (No match) 
   186 - 193     923.62   922.61   922.56     0.05     1  K.IIAPPERK.Y  (Ions score 6) 
   186 - 193     923.62   922.61   922.56     0.05     1  K.IIAPPERK.Y  (No match) 
   217 - 229    1516.77  1515.76  1515.70     0.07     0  K.QEYDESGPSIVHR.K  (Ions score 46) 








































































































































































































Mascot Search Results 
Protein View 
Match to: gi|37655183 Score: 229 Expect: 5.2e-017 
N-myc downstream regulated gene 1 [Homo sapiens] 
 
Nominal mass (Mr): 43264; Calculated pI value: 5.49 
NCBI BLAST search of gi|37655183 against nr 
Unformatted sequence string for pasting into other applications 
 
Fixed modifications: Carbamidomethyl (C) 
Variable modifications: Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 39% 
Matched peptides shown in Bold Red 
 
     1 MSREMQDVDL AEVKPLVEKG ETITGLLQEF DVQEQDIETL HGSVHVTLCG  
    51 TPKGNRPVIL TYHDIGMNHK TCYNPLFNYE DMQEITQHFA VCHVDAPGQQ  
   101 DGAASFPAGY MYPSMDQLAE MLPGVLQQFG LKSIIGMGTG AGAYILTRFA  
   151 LNNPEMVEGL VLINVNPCAE GWMDWAASKI SGWTQALPDM VVSHLFGKEE  
   201 MQSNVEVVHT YRQHIVNDMN PGNLHLFINA YNSRRDLEIE RPMPGTHTVT  
   251 LQCPALLVVG DSSPAVDAVV ECNSKLDPTK TTLLKMADCG GLPQISQPAK  
   301 LAEAFKYFVQ GMGYMPSASM TRLMRSRTAS GSSVTSLDGT RSRSHTSEGT  
   351 RSRSHTSEGT RSRSHTSEGA HLDITPNSGA AGNSAGPKSM EVSC 
 
Start - End  Observed Mr(expt) Mr(calc) Delta   Miss Sequence 
     4 - 19     1842.92  1841.92  1841.94    -0.03     0  R.EMQDVDLAEVKPLVEK.G  (No 
match) 
     4 - 19     1858.91  1857.91  1857.94    -0.03     0  R.EMQDVDLAEVKPLVEK.G  Oxidation 
(M) (No match) 
    54 - 70     1965.07  1964.06  1964.00     0.06     0  K.GNRPVILTYHDIGMNHK.T  (Ions 
score 14) 
    54 - 70     1965.07  1964.06  1964.00     0.06     0  K.GNRPVILTYHDIGMNHK.T  (No 
match) 
    54 - 70     1981.06  1980.06  1980.00     0.06     0  K.GNRPVILTYHDIGMNHK.T  
Oxidation (M) (No match) 
    54 - 70     1981.06  1980.06  1980.00     0.06     0  K.GNRPVILTYHDIGMNHK.T  
Oxidation (M) (No match) 
   133 - 148    1580.90  1579.89  1579.84     0.05     0  K.SIIGMGTGAGAYILTR.F  (Ions score 
1) 
   133 - 148    1580.90  1579.89  1579.84     0.05     0  K.SIIGMGTGAGAYILTR.F  (No match) 
   133 - 148    1596.89  1595.88  1595.83     0.05     0  K.SIIGMGTGAGAYILTR.F  Oxidation 
(M) (No match) 
   133 - 148    1596.89  1595.88  1595.83     0.05     0  K.SIIGMGTGAGAYILTR.F  Oxidation 
(M) (No match) 
   199 - 212    1720.85  1719.84  1719.79     0.05     0  K.EEMQSNVEVVHTYR.Q  (Ions score 5) 
   199 - 212    1720.85  1719.84  1719.79     0.05     0  K.EEMQSNVEVVHTYR.Q  (No match) 
   199 - 212    1736.84  1735.84  1735.78     0.05     0  K.EEMQSNVEVVHTYR.Q  Oxidation (M) 
(No match) 
   213 - 234    2567.32  2566.31  2566.25     0.06     0  R.QHIVNDMNPGNLHLFINAYNSR.R  
(No match) 
   213 - 234    2567.32  2566.31  2566.25     0.06     0  R.QHIVNDMNPGNLHLFINAYNSR.R  
(No match) 
   213 - 234    2583.33  2582.32  2582.24     0.07     0  R.QHIVNDMNPGNLHLFINAYNSR.R  
Oxidation (M) (No match) 
   286 - 300    1572.79  1571.79  1571.74     0.04     0  K.MADCGGLPQISQPAK.L  (Ions score 
67) 
   286 - 300    1572.79  1571.79  1571.74     0.04     0  K.MADCGGLPQISQPAK.L  (No match) 
   286 - 300    1588.79  1587.78  1587.74     0.05     0  K.MADCGGLPQISQPAK.L  Oxidation 
(M) (No match) 
 171 
   307 - 322    1825.87  1824.86  1824.80     0.06     0  K.YFVQGMGYMPSASMTR.L  (Ions 
score 4) 
   307 - 322    1825.87  1824.86  1824.80     0.06     0  K.YFVQGMGYMPSASMTR.L  (No 
match) 
   307 - 322    1841.85  1840.85  1840.79     0.05     0  K.YFVQGMGYMPSASMTR.L  Oxidation 
(M) (No match) 
   307 - 322    1857.85  1856.84  1856.79     0.05     0  K.YFVQGMGYMPSASMTR.L  2 
Oxidation (M) (No match) 
   307 - 322    1873.84  1872.83  1872.78     0.05     0  K.YFVQGMGYMPSASMTR.L  3 
Oxidation (M) (No match) 
   328 - 341    1338.70  1337.69  1337.64     0.05     0  R.TASGSSVTSLDGTR.S  (Ions score 26) 
   328 - 341    1338.70  1337.69  1337.64     0.05     0  R.TASGSSVTSLDGTR.S  (No match) 
   364 - 388    2376.18  2375.17  2375.11     0.06     0  
R.SHTSEGAHLDITPNSGAAGNSAGPK.S  (Ions score 47) 
   364 - 388    2376.18  2375.17  2375.11     0.06     0  












































































































































































































Mascot Search Results 
Protein View 
Match to: gi|40354192 Score: 109 Expect: 5.5e-005 
keratin 10 [Homo sapiens] 
 
Nominal mass (Mr): 59020; Calculated pI value: 5.09 
NCBI BLAST search of gi|40354192 against nr 
Unformatted sequence string for pasting into other applications 
 
Fixed modifications: Carbamidomethyl (C) 
Variable modifications: Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 9% 
Matched peptides shown in Bold Red 
 
     1 MSVRYSSSKH YSSSRSGGGG GGGGCGGGGG VSSLRISSSK GSLGGGFSSG  
    51 GFSGGSFSRG SSGGGCFGGS SGGYGGLGGF GGGSFRGSYG SSSFGGSYGG  
   101 SFGGGSFGGG SFGGGSFGGG GFGGGGFGGG FGGGFGGDGG LLSGNEKVTM  
   151 QNLNDRLASY LDKVRALEES NYELEGKIKE WYEKHGNSHQ GEPRDYSKYY  
   201 KTIDDLKNQI LNLTTDNANI LLQIDNARLA ADDFRLKYEN EVALRQSVEA  
   251 DINGLRRVLD ELTLTKADLE MQIESLTEEL AYLKKNHEEE MKDLRNVSTG  
   301 DVNVEMNAAP GVDLTQLLNN MRSQYEQLAE QNRKDAEAWF NEKSKELTTE  
   351 IDNNIEQISS YKSEITELRR NVQALEIELQ SQLALKQSLE ASLAETEGRY  
   401 CVQLSQIQAQ ISALEEQLQQ IRAETECQNT EYQQLLDIKI RLENEIQTYR  
   451 SLLEGEGSSG GGGRGGGSFG GGYGGGSSGG GSSGGGYGGG HGGSSGGGYG  
   501 GGSSGGGSSG GGYGGGSSSG GHGGSSSGGY GGGSSGGGGG GYGGGSSGGG  
   551 SSSGGGYGGG SSSGGHKSSS SGSVGESSSK GPRY 
 
Start - End  Observed Mr(expt) Mr(calc) Delta   Miss Sequence 
   148 - 156    1090.54  1089.53  1089.52     0.01     0  K.VTMQNLNDR.L  (No match) 
   148 - 156    1106.55  1105.54  1105.52     0.02     0  K.VTMQNLNDR.L  Oxidation (M) (No 
match) 
   157 - 165    1064.63  1063.62  1063.60     0.02     1  R.LASYLDKVR.A  (No match) 
   166 - 177    1381.68  1380.67  1380.64     0.03     0  R.ALEESNYELEGK.I  (No match) 
   178 - 184     995.53   994.52   994.51     0.01     1  K.IKEWYEK.H  (No match) 
   323 - 333    1365.65  1364.64  1364.63     0.01     0  R.SQYEQLAEQNR.K  (No match) 
   323 - 334    1493.73  1492.73  1492.73     0.00     1  R.SQYEQLAEQNRK.D  (Ions score 30) 
   323 - 334    1493.73  1492.73  1492.73     0.00     1  R.SQYEQLAEQNRK.D  (No match) 
   335 - 343    1109.50  1108.50  1108.48     0.01     0  K.DAEAWFNEK.S  (Ions score 61) 






















































































































































































Mascot Search Results 
Protein View 
Match to: gi|19861692 Score: 131 Expect: 3.5e-007 
Interferon-induced 35 kDa protein (IFP 35) [Homo sapiens] 
 
Nominal mass (Mr): 31666; Calculated pI value: 5.75 
NCBI BLAST search of gi|19861692 against nr 
Unformatted sequence string for pasting into other applications 
 
Fixed modifications: Carbamidomethyl (C) 
Variable modifications: Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 34% 
Matched peptides shown in Bold Red 
 
     1 MSAPLDAALH ALQEEQARLK MRLWDLQQLR KELGDSPKDK VPFSVPKIPL  
    51 VFRGHTQQDP EVPKSLVSNL RIHCPLLAGS ALITFDDPKV AEQVLQQKEH  
   101 TINMEECRLR VQVQPLELPM VTTIQVSSQL SGRRVLVTGF PASLRLSEEE  
   151 LLDKLEIFFG KTRNGGGDVD VRELLPGSVM LGFARDGVAQ RLCQIGQFTV  
   201 PLGGQQVPLR VSPYVNGEIQ KAEIRSQPVP RSVLVLNIPD ILDGPELHDV  
   251 LEIHFQKPTR GGGEVEALTV VPQGQQGLAV FTSESG 
 
Start - End Observed Mr(expt) Mr(calc)  Delta   Miss Sequence 
    23 - 30     1071.61  1070.60  1070.59     0.02     0  R.LWDLQQLR.K  (No match) 
    23 - 31     1199.71  1198.70  1198.68     0.02     1  R.LWDLQQLRK.E  (No match) 
    39 - 47     1016.60  1015.59  1015.57     0.02     1  K.DKVPFSVPK.I  (No match) 
    72 - 89     1968.10  1967.09  1967.02     0.08     0  R.IHCPLLAGSALITFDDPK.V  (No 
match) 
    90 - 98     1042.61  1041.61  1041.58     0.02     0  K.VAEQVLQQK.E  (No match) 
    99 - 108    1318.57  1317.57  1317.54     0.02     0  K.EHTINMEECR.L  (No match) 
    99 - 108    1334.56  1333.56  1333.54     0.02     0  K.EHTINMEECR.L  Oxidation (M) (No 
match) 
   134 - 145    1315.80  1314.80  1314.78     0.02     1  R.RVLVTGFPASLR.L  (No match) 
   135 - 145    1159.70  1158.69  1158.68     0.02     0  R.VLVTGFPASLR.L  (Ions score 32) 
   135 - 145    1159.70  1158.69  1158.68     0.02     0  R.VLVTGFPASLR.L  (No match) 
   173 - 185    1389.78  1388.77  1388.75     0.02     0  R.ELLPGSVMLGFAR.D  (No match) 
   173 - 185    1389.78  1388.77  1388.75     0.02     0  R.ELLPGSVMLGFAR.D  (No match) 
   173 - 185    1405.77  1404.76  1404.74     0.02     0  R.ELLPGSVMLGFAR.D  Oxidation (M) 
(No match) 
   173 - 185    1405.77  1404.76  1404.74     0.02     0  R.ELLPGSVMLGFAR.D  Oxidation (M) 
(No match) 
   192 - 210    2111.16  2110.16  2110.14     0.02     0  R.LCQIGQFTVPLGGQQVPLR.V  (Ions 
score 27) 


































































































































































Mascot Search Results 
Protein View 
Match to: gi|13489087 Score: 538 Expect: 6.5e-048 
serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 1 [Homo 
sapiens] 
 
Nominal mass (Mr): 42829; Calculated pI value: 5.90 
NCBI BLAST search of gi|13489087 against nr 
Unformatted sequence string for pasting into other applications 
 
Fixed modifications: Carbamidomethyl (C) 
Variable modifications: Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 52% 
Matched peptides shown in Bold Red 
 
     1 MEQLSSANTR FALDLFLALS ENNPAGNIFI SPFSISSAMA MVFLGTRGNT  
    51 AAQLSKTFHF NTVEEVHSRF QSLNADINKR GASYILKLAN RLYGEKTYNF  
   101 LPEFLVSTQK TYGADLASVD FQHASEDARK TINQWVKGQT EGKIPELLAS  
   151 GMVDNMTKLV LVNAIYFKGN WKDKFMKEAT TNAPFRLNKK 
DRKTVKMMYQ  
   201 KKKFAYGYIE DLKCRVLELP YQGEELSMVI LLPDDIEDES TGLKKIEEQL  
   251 TLEKLHEWTK PENLDFIEVN VSLPRFKLEE SYTLNSDLAR LGVQDLFNSS  
   301 KADLSGMSGA RDIFISKIVH KSFVEVNEEG TEAAAATAGI ATFCMLMPEE  
   351 NFTADHPFLF FIRHNSSGSI LFLGRFSSP 
 
Start - End  Observed Mr(expt) Mr(calc) Delta   Miss Sequence 
     2 - 10     1005.51  1004.51  1004.49     0.02     0  M.EQLSSANTR.F  (No match) 
    57 - 69     1602.84  1601.84  1601.76     0.08     0  K.TFHFNTVEEVHSR.F  (Ions score 27) 
    57 - 69     1602.84  1601.84  1601.76     0.08     0  K.TFHFNTVEEVHSR.F  (No match) 
    70 - 80     1305.76  1304.75  1304.68     0.07     1  R.FQSLNADINKR.G  (Ions score 32) 
    70 - 80     1305.76  1304.75  1304.68     0.07     1  R.FQSLNADINKR.G  (No match) 
    97 - 110    1686.95  1685.94  1685.87     0.08     0  K.TYNFLPEFLVSTQK.T  (Ions score 40) 
    97 - 110    1686.95  1685.94  1685.87     0.08     0  K.TYNFLPEFLVSTQK.T  (No match) 
   111 - 129    2053.02  2052.02  2051.92     0.10     0  K.TYGADLASVDFQHASEDAR.K  (Ions 
score 68) 
   111 - 129    2053.02  2052.02  2051.92     0.10     0  K.TYGADLASVDFQHASEDAR.K  (No 
match) 
   111 - 130    2181.13  2180.12  2180.01     0.11     1  K.TYGADLASVDFQHASEDARK.T  (No 
match) 
   130 - 137    1016.64  1015.64  1015.58     0.05     1  R.KTINQWVK.G  (No match) 
   131 - 137     888.54   887.53   887.49     0.05     0  K.TINQWVK.G  (Ions score 39) 
   131 - 137     888.54   887.53   887.49     0.05     0  K.TINQWVK.G  (No match) 
   138 - 158    2219.21  2218.20  2218.10     0.10     1  K.GQTEGKIPELLASGMVDNMTK.L  
(No match) 
   144 - 158    1618.89  1617.88  1617.81     0.07     0  K.IPELLASGMVDNMTK.L  (No match) 
   144 - 158    1634.88  1633.87  1633.81     0.07     0  K.IPELLASGMVDNMTK.L  Oxidation 
(M) (No match) 
   178 - 186    1006.55  1005.54  1005.49     0.06     0  K.EATTNAPFR.L  (Ions score 19) 
   178 - 186    1006.55  1005.54  1005.49     0.06     0  K.EATTNAPFR.L  (No match) 
   197 - 202     860.32   859.31   859.39    -0.08     1  K.MMYQKK.K  2 Oxidation (M) (No 
match) 
   203 - 213    1346.76  1345.75  1345.69     0.06     1  K.KFAYGYIEDLK.C  (No match) 
   204 - 213    1218.66  1217.66  1217.60     0.06     0  K.FAYGYIEDLK.C  (Ions score 54) 
   204 - 213    1218.66  1217.66  1217.60     0.06     0  K.FAYGYIEDLK.C  (No match) 
   245 - 254    1230.75  1229.75  1229.69     0.06     1  K.KIEEQLTLEK.L  (No match) 
   255 - 275    2536.44  2535.44  2535.31     0.12     0  K.LHEWTKPENLDFIEVNVSLPR.F  
(No match) 
 177 
   276 - 290    1785.99  1784.98  1784.89     0.08     1  R.FKLEESYTLNSDLAR.L  (Ions score 
36) 
   276 - 290    1785.99  1784.98  1784.89     0.08     1  R.FKLEESYTLNSDLAR.L  (No match) 
   278 - 290    1510.82  1509.81  1509.73     0.08     0  K.LEESYTLNSDLAR.L  (No match) 
   291 - 301    1207.69  1206.69  1206.62     0.06     0  R.LGVQDLFNSSK.A  (No match) 
   302 - 311     964.51   963.50   963.44     0.06     0  K.ADLSGMSGAR.D  (No match) 
   302 - 311     980.45   979.45   979.44     0.01     0  K.ADLSGMSGAR.D  Oxidation (M) (No 
match) 
   364 - 375    1287.75  1286.74  1286.67     0.07     0  R.HNSSGSILFLGR.F  (Ions score 45) 























































































































































































































Mascot Search Results 
Protein View 
Match to: gi|47419916 Score: 350 Expect: 4e-029 
tryptophanyl-tRNA synthetase isoform a [Homo sapiens] 
 
Nominal mass (Mr): 53480; Calculated pI value: 5.83 
NCBI BLAST search of gi|47419916 against nr 
Unformatted sequence string for pasting into other applications 
 
Fixed modifications: Carboxymethyl (C) 
Variable modifications: Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 48% 
Matched peptides shown in Bold Red 
 
     1 MPNSEPASLL ELFNSIATQG ELVRSLKAGN ASKDEIDSAV KMLVSLKMSY  
    51 KAAAGEDYKA DCPPGNPAPT SNHGPDATEA EEDFVDPWTV QTSSAKGIDY  
   101 DKLIVRFGSS KIDKELINRI ERATGQRPHH FLRRGIFFSH RDMNQVLDAY  
   151 ENKKPFYLYT GRGPSSEAMH VGHLIPFIFT KWLQDVFNVP LVIQMTDDEK  
   201 YLWKDLTLDQ AYSYAVENAK DIIACGFDIN KTFIFSDLDY MGMSSGFYKN  
   251 VVKIQKHVTF NQVKGIFGFT DSDCIGKISF PAIQAAPSFS NSFPQIFRDR  
   301 TDIQCLIPCA IDQDPYFRMT RDVAPRIGYP KPALLHSTFF PALQGAQTKM  
   351 SASDPNSSIF LTDTAKQIKT KVNKHAFSGG RDTIEEHRQF GGNCDVDVSF  
   401 MYLTFFLEDD DKLEQIRKDY TSGAMLTGEL KKALIEVLQP LIAEHQARRK  
   451 EVTDEIVKEF MTPRKLSFDF Q 
 
Start - End Observed Mr(expt) Mr(calc)  Delta   Miss Sequence 
    28 - 41     1404.71  1403.70  1403.69     0.01     1  K.AGNASKDEIDSAVK.M  (No match) 
    97 - 106    1191.69  1190.68  1190.67     0.02     1  K.GIDYDKLIVR.F  (Ions score 24) 
    97 - 106    1191.69  1190.68  1190.67     0.02     1  K.GIDYDKLIVR.F  (No match) 
   112 - 119    1000.60   999.59   999.57     0.02     1  K.IDKELINR.I  (Ions score 35) 
   112 - 119    1000.60   999.59   999.57     0.02     1  K.IDKELINR.I  (No match) 
   123 - 133    1319.71  1318.70  1318.70     0.00     0  R.ATGQRPHHFLR.R  (No match) 
   123 - 133    1319.71  1318.70  1318.70     0.00     0  R.ATGQRPHHFLR.R  (No match) 
   134 - 141    1019.56  1018.55  1018.55     0.00     1  R.RGIFFSHR.D  (Ions score 16) 
   134 - 141    1019.56  1018.55  1018.55     0.00     1  R.RGIFFSHR.D  (No match) 
   135 - 141     863.46   862.45   862.44     0.00     0  R.GIFFSHR.D  (Ions score 23) 
   135 - 141     863.46   862.45   862.44     0.00     0  R.GIFFSHR.D  (No match) 
   142 - 153    1439.67  1438.66  1438.64     0.02     0  R.DMNQVLDAYENK.K  (No match) 
   142 - 153    1455.69  1454.68  1454.63     0.05     0  R.DMNQVLDAYENK.K  Oxidation (M) 
(No match) 
   142 - 162    2565.33  2564.32  2564.24     0.08     1  R.DMNQVLDAYENKKPFYLYTGR.G  
(No match) 
   154 - 162    1144.62  1143.62  1143.61     0.01     0  K.KPFYLYTGR.G  (Ions score 26) 
   154 - 162    1144.62  1143.62  1143.61     0.01     0  K.KPFYLYTGR.G  (No match) 
   163 - 181    2068.15  2067.14  2067.06     0.08     0  R.GPSSEAMHVGHLIPFIFTK.W  (No 
match) 
   254 - 264    1341.69  1340.69  1340.76    -0.07     1  K.IQKHVTFNQVK.G  (No match) 
   257 - 264     972.53   971.52   971.52     0.00     0  K.HVTFNQVK.G  (Ions score 21) 
   257 - 264     972.53   971.52   971.52     0.00     0  K.HVTFNQVK.G  (No match) 
   278 - 298    2325.32  2324.31  2324.20     0.12     0  K.ISFPAIQAAPSFSNSFPQIFR.D  (No 
match) 
   327 - 349    2485.44  2484.43  2484.35     0.08     0  R.IGYPKPALLHSTFFPALQGAQTK.M  
(No match) 
   350 - 366    1784.87  1783.86  1783.83     0.03     0  K.MSASDPNSSIFLTDTAK.Q  (No 
match) 
   375 - 388    1611.79  1610.78  1610.75     0.03     1  K.HAFSGGRDTIEEHR.Q  (No match) 
   382 - 388     899.43   898.43   898.41     0.01     0  R.DTIEEHR.Q  (No match) 
   419 - 432    1513.81  1512.80  1512.75     0.05     1  K.DYTSGAMLTGELKK.A  (No match) 
 179 
   433 - 448    1801.06  1800.05  1800.03     0.03     0  K.ALIEVLQPLIAEHQAR.R  (Ions score 
11) 
   433 - 448    1801.06  1800.05  1800.03     0.03     0  K.ALIEVLQPLIAEHQAR.R  (No match) 
   451 - 464    1693.88  1692.88  1692.84     0.04     1  K.EVTDEIVKEFMTPR.K  (No match) 

















































































































































Mascot Search Results 
Protein View 
Match to: gi|47419918 Score: 316 Expect: 1e-025 
tryptophanyl-tRNA synthetase isoform b [Homo sapiens] 
 
Nominal mass (Mr): 49163; Calculated pI value: 6.03 
NCBI BLAST search of gi|47419918 against nr 
Unformatted sequence string for pasting into other applications 
 
Fixed modifications: Carbamidomethyl (C) 
Variable modifications: Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 39% 
Matched peptides shown in Bold Red 
 
     1 MLVSLKMSYK AAAGEDYKAD CPPGNPAPTS NHGPDATEAE EDFVDPWTVQ  
    51 TSSAKGIDYD KLIVRFGSSK IDKELINRIE RATGQRPHHF LRRGIFFSHR  
   101 DMNQVLDAYE NKKPFYLYTG RGPSSEAMHV GHLIPFIFTK WLQDVFNVPL  
   151 VIQMTDDEKY LWKDLTLDQA YSYAVENAKD IIACGFDINK TFIFSDLDYM  
   201 GMSSGFYKNV VKIQKHVTFN QVKGIFGFTD SDCIGKISFP AIQAAPSFSN  
   251 SFPQIFRDRT DIQCLIPCAI DQDPYFRMTR DVAPRIGYPK PALLHSTFFP  
   301 ALQGAQTKMS ASDPNSSIFL TDTAKQIKTK VNKHAFSGGR DTIEEHRQFG  
   351 GNCDVDVSFM YLTFFLEDDD KLEQIRKDYT SGAMLTGELK KALIEVLQPL  
   401 IAEHQARRKE VTDEIVKEFM TPRKLSFDFQ  
 
Start - End Observed Mr(expt) Mr(calc)  Delta   Miss Sequence 
    11 - 18      824.32   823.31   823.37    -0.06     0  K.AAAGEDYK.A  (No match) 
    56 - 65     1191.74  1190.73  1190.67     0.07     1  K.GIDYDKLIVR.F  (Ions score 27) 
    56 - 65     1191.74  1190.73  1190.67     0.07     1  K.GIDYDKLIVR.F  (No match) 
    71 - 78     1000.64   999.63   999.57     0.06     1  K.IDKELINR.I  (No match) 
    82 - 92     1319.77  1318.77  1318.70     0.07     0  R.ATGQRPHHFLR.R  (No match) 
    82 - 92     1319.77  1318.77  1318.70     0.07     0  R.ATGQRPHHFLR.R  (No match) 
    93 - 100    1019.61  1018.60  1018.55     0.06     1  R.RGIFFSHR.D  (Ions score 17) 
    93 - 100    1019.61  1018.60  1018.55     0.06     1  R.RGIFFSHR.D  (No match) 
    94 - 100     863.50   862.49   862.44     0.05     0  R.GIFFSHR.D  (Ions score 17) 
    94 - 100     863.50   862.49   862.44     0.05     0  R.GIFFSHR.D  (No match) 
   113 - 121    1144.68  1143.67  1143.61     0.06     0  K.KPFYLYTGR.G  (Ions score 19) 
   113 - 121    1144.68  1143.67  1143.61     0.06     0  K.KPFYLYTGR.G  (No match) 
   122 - 140    2068.16  2067.15  2067.06     0.09     0  R.GPSSEAMHVGHLIPFIFTK.W  (No 
match) 
   180 - 190    1265.69  1264.68  1264.61     0.07     0  K.DIIACGFDINK.T  (No match) 
   213 - 223    1341.76  1340.75  1340.76    -0.00     1  K.IQKHVTFNQVK.G  (No match) 
   216 - 223     972.58   971.57   971.52     0.06     0  K.HVTFNQVK.G  (Ions score 58) 
   216 - 223     972.58   971.57   971.52     0.06     0  K.HVTFNQVK.G  (No match) 
   224 - 236    1416.72  1415.71  1415.64     0.07     0  K.GIFGFTDSDCIGK.I  (Ions score 49) 
   224 - 236    1416.72  1415.71  1415.64     0.07     0  K.GIFGFTDSDCIGK.I  (No match) 
   286 - 308    2485.49  2484.48  2484.35     0.13     0  R.IGYPKPALLHSTFFPALQGAQTK.M  
(No match) 
   309 - 325    1784.92  1783.92  1783.83     0.09     0  K.MSASDPNSSIFLTDTAK.Q  (No 
match) 
   392 - 407    1801.12  1800.11  1800.03     0.09     0  K.ALIEVLQPLIAEHQAR.R  (Ions score 
6) 
   392 - 407    1801.12  1800.11  1800.03     0.09     0  K.ALIEVLQPLIAEHQAR.R  (No match) 






































































































































































































Mascot Search Results 
Protein View 
Match to: gi|13325156 Score: 246 Expect: 9.9e-019 
Apolipoprotein L, 2 [Homo sapiens] 
 
Nominal mass (Mr): 37113; Calculated pI value: 6.28 
NCBI BLAST search of gi|13325156 against nr 
Unformatted sequence string for pasting into other applications 
 
Fixed modifications: Carboxymethyl (C) 
Variable modifications: Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 24% 
Matched peptides shown in Bold Red 
 
     1 MNPESSIFIE DYLKYFQDQV SRENLLQLLT DDEAWNGFVA AAELPRDEAD  
    51 ELRKALNKLA SHMVMKDKNR HDKDQQHRQW FLKEFPRLKR ELEDHIRKLR  
   101 ALAEEVEQVH RGTTIANVVS NSVGTTSGIL TLLGLGLAPF TEGISFVLLD  
   151 TGMGLGAAAA VAGITCSVVE LVNKLRARAQ ARNLDQSGTN VAKVMKEFVG  
   201 GNTPNVLTLV DNWYQVTQGI GRNIRAIRRA RANPQLGAYA PPPHVIGRIS  
   251 AEGGEQVERV VEGPAQAMSR GTMIVGAATG GILLLLDVVS LAYESKHLLE  
   301 GAKSESAEEL KKRAQELEGK LNFLTKIHEM LQPGQDQ 
 
Start - End Observed Mr(expt) Mr(calc)  Delta   Miss Sequence 
    15 - 22     1042.50  1041.49  1041.49     0.01     0  K.YFQDQVSR.E  (Ions score 21) 
    15 - 22     1042.50  1041.49  1041.49     0.01     0  K.YFQDQVSR.E  (No match) 
    47 - 53      847.30   846.30   846.37    -0.08     0  R.DEADELR.K  (No match) 
    91 - 97      911.47   910.46   910.45     0.01     0  R.ELEDHIR.K  (Ions score 39) 
    91 - 97      911.47   910.46   910.45     0.01     0  R.ELEDHIR.K  (No match) 
    91 - 98     1039.57  1038.56  1038.55     0.02     1  R.ELEDHIRK.L  (No match) 
   101 - 111    1280.67  1279.67  1279.65     0.01     0  R.ALAEEVEQVHR.G  (Ions score 27) 
   101 - 111    1280.67  1279.67  1279.65     0.01     0  R.ALAEEVEQVHR.G  (No match) 
   232 - 248    1757.98  1756.98  1756.94     0.04     0  R.ANPQLGAYAPPPHVIGR.I  (Ions score 
16) 
   232 - 248    1757.98  1756.98  1756.94     0.04     0  R.ANPQLGAYAPPPHVIGR.I  (No 
match) 
   249 - 259    1174.59  1173.58  1173.56     0.02     0  R.ISAEGGEQVER.V  (Ions score 19) 
   249 - 259    1174.59  1173.58  1173.56     0.02     0  R.ISAEGGEQVER.V  (No match) 
   260 - 270    1144.59  1143.58  1143.57     0.01     0  R.VVEGPAQAMSR.G  (Ions score 42) 
   260 - 270    1144.59  1143.58  1143.57     0.01     0  R.VVEGPAQAMSR.G  (No match) 
   260 - 270    1160.58  1159.57  1159.57     0.01     0  R.VVEGPAQAMSR.G  Oxidation (M) 
(Ions score 6) 
   260 - 270    1160.58  1159.57  1159.57     0.01     0  R.VVEGPAQAMSR.G  Oxidation (M) (No 
match) 
   327 - 337    1295.61  1294.60  1294.60     0.00     0  K.IHEMLQPGQDQ.-  (Ions score 21) 
   327 - 337    1295.61  1294.60  1294.60     0.00     0  K.IHEMLQPGQDQ.-  (No match) 


















































































































Mascot Search Results 
Protein View 
Match to: gi|27436897 Score: 96 Expect: 0.0012 
tapasin isoform 3 precursor [Homo sapiens] 
 
Nominal mass (Mr): 44145; Calculated pI value: 6.35 
NCBI BLAST search of gi|27436897 against nr 
Unformatted sequence string for pasting into other applications 
 
Fixed modifications: Carbamidomethyl (C) 
Variable modifications: Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 21% 
Matched peptides shown in Bold Red 
 
     1 MKSLSLLLAV ALGLATAVSA GPAVIECWFV EDASGKGLAK RPGALLLRQG  
    51 PGEPPPRPDL DPELYLSVHD PAGALQAAFR RYPRGAPAPH CEMSRFVPLP  
   101 ASAKWASGLT PAQNCPRALD GAWLMVSISS PVLSLSSLLR PQPEPQQEPV  
   151 LITMATVVLT VLTHTPAPRV RLGQDALLDL SFAYMPPTSE AASSLAPGPP  
   201 PFGLEWRRQH LGKGHLLLAA TPGLNGQMPA AQEGAVAFAA WDDDEPWGPW  
   251 TGNGTFWLPT VQPFQEGTYL ATIHLPYLQG QVTLELAVYK PPKVSLMPAT  
   301 LARAAPGEAP PELLCLVSHF YPSGGLEVEW ELRGGPGGRS QKAEGQRWLS  
   351 ALRHHSDGSV SLSGHLQPPP VTTEQHGARY ACRIHHPSLP ASGRSAEVTL  
   401 EVAGKSWELC GI 
 
Start - End  Observed Mr(expt) Mr(calc) Delta   Miss Sequence 
    41 - 48      895.59   894.58   894.58     0.00     0  K.RPGALLLR.Q  (Ions score 16) 
    41 - 48      895.59   894.58   894.58     0.00     0  K.RPGALLLR.Q  (No match) 
    85 - 95     1212.53  1211.52  1211.52     0.01     0  R.GAPAPHCEMSR.F  (No match) 
    96 - 104     929.56   928.55   928.54     0.01     0  R.FVPLPASAK.W  (No match) 
   105 - 117    1457.70  1456.70  1456.69     0.01     0  K.WASGLTPAQNCPR.A  (Ions score 15) 
   105 - 117    1457.70  1456.70  1456.69     0.01     0  K.WASGLTPAQNCPR.A  (No match) 
   294 - 303    1058.62  1057.62  1057.60     0.02     0  K.VSLMPATLAR.A  (No match) 
   294 - 303    1074.61  1073.61  1073.59     0.02     0  K.VSLMPATLAR.A  Oxidation (M) (No 
match) 
   354 - 379    2731.34  2730.34  2730.32     0.01     0  
R.HHSDGSVSLSGHLQPPPVTTEQHGAR.Y  (No match) 
   384 - 394    1171.64  1170.63  1170.63     0.01     0  R.IHHPSLPASGR.S  (Ions score 17) 







































































































































































Mascot Search Results 
Protein View 
Match to: gi|27436893 Score: 225 Expect: 1.4e-016 
tapasin isoform 1 precursor [Homo sapiens] 
 
Nominal mass (Mr): 47883; Calculated pI value: 6.50 
NCBI BLAST search of gi|27436893 against nr 
Unformatted sequence string for pasting into other applications 
 
Fixed modifications: Carbamidomethyl (C) 
Variable modifications: Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 22% 
Matched peptides shown in Bold Red 
 
     1 MKSLSLLLAV ALGLATAVSA GPAVIECWFV EDASGKGLAK RPGALLLRQG  
    51 PGEPPPRPDL DPELYLSVHD PAGALQAAFR RYPRGAPAPH CEMSRFVPLP  
   101 ASAKWASGLT PAQNCPRALD GAWLMVSISS PVLSLSSLLR PQPEPQQEPV  
   151 LITMATVVLT VLTHTPAPRV RLGQDALLDL SFAYMPPTSE AASSLAPGPP  
   201 PFGLEWRRQH LGKGHLLLAA TPGLNGQMPA AQEGAVAFAA WDDDEPWGPW  
   251 TGNGTFWLPT VQPFQEGTYL ATIHLPYLQG QVTLELAVYK PPKVSLMPAT  
   301 LARAAPGEAP PELLCLVSHF YPSGGLEVEW ELRGGPGGRS QKAEGQRWLS  
   351 ALRHHSDGSV SLSGHLQPPP VTTEQHGARY ACRIHHPSLP ASGRSAEVTL  
   401 EVAGLSGPSL EDSVGLFLSA FLLLGLFKAL GWAAVYLSTC KDSKKKAE 
 
Start - End  Observed Mr(expt) Mr(calc) Delta   Miss Sequence 
    41 - 48      895.60   894.59   894.58     0.01     0  K.RPGALLLR.Q  (Ions score 23) 
    41 - 48      895.60   894.59   894.58     0.01     0  K.RPGALLLR.Q  (No match) 
    85 - 95     1212.54  1211.54  1211.52     0.02     0  R.GAPAPHCEMSR.F  (Ions score 28) 
    85 - 95     1212.54  1211.54  1211.52     0.02     0  R.GAPAPHCEMSR.F  (No match) 
    85 - 95     1228.54  1227.53  1227.51     0.02     0  R.GAPAPHCEMSR.F  Oxidation (M) (No 
match) 
    96 - 104     929.57   928.56   928.54     0.02     0  R.FVPLPASAK.W  (No match) 
   105 - 117    1457.72  1456.71  1456.69     0.02     0  K.WASGLTPAQNCPR.A  (Ions score 38) 
   105 - 117    1457.72  1456.71  1456.69     0.02     0  K.WASGLTPAQNCPR.A  (No match) 
   294 - 303    1058.63  1057.62  1057.60     0.02     0  K.VSLMPATLAR.A  (No match) 
   294 - 303    1074.62  1073.61  1073.59     0.02     0  K.VSLMPATLAR.A  Oxidation (M) (No 
match) 
   354 - 379    2731.35  2730.35  2730.32     0.03     0  
R.HHSDGSVSLSGHLQPPPVTTEQHGAR.Y  (Ions score 63) 
   354 - 379    2731.35  2730.35  2730.32     0.03     0  
R.HHSDGSVSLSGHLQPPPVTTEQHGAR.Y  (No match) 
   384 - 394    1171.65  1170.64  1170.63     0.02     0  R.IHHPSLPASGR.S  (Ions score 31) 
   384 - 394    1171.65  1170.64  1170.63     0.02     0  R.IHHPSLPASGR.S  (No match) 


















































































































































































List of Reagents and Solutions 
 
 
Rehydration Solution, pH 6-11 (-20oC)  
Urea 7 M 




IPG buffer pH 6-11 0.5% 
1% bromophen blue 0.0005% 
DTT 2.5 % 
Sample Lysis Buffer (2-DE, -20oC)  
Urea 8 M 
Thiourea 2 M 
CHAPS 4% 
Pharmalyte 0.8% 
DTT 65 mM 
Cocktail 20 µl/ml 
RNAase 5 µg/ml 
DNAase 20 µg/ml 
  
Rehydration Solution, pH 4-7 (-20oC)  
Urea 8 M 
CHAPS 2% 
IPG buffer pH 4-7 0.5% 
1% bromophen blue 0.0005% 
DTT 0.28 % 
  
  
Running Gel (2-DE, 12%, 80 ml/gel)  
1.5 M Tris-Cl, pH8.8 20.0 ml 
10% SDS 0.8 ml 
30% Acrylamide (37.5:1) 32.0 ml 
10% APS 0.4 ml 
TEMED 40.0 µl 
Milli-Q H2O 26.8 ml 
  
Equilibration Buffer (-20oC)  
1.5 M Tris-HCl, pH 8.8 50 mM 




10 ´ Electrophoresis Buffer (R.T.)  
Tris-base 250 mM 





Sample Lysis Buffer (Western blotting)  
Tris-HCl, pH 7.5 50 mM 
NaCl 150 mM 
Triton X-100 1% 
SDS 0.1% 
Na3VO4 2 mM 
PMSF 5 mM 
Aprotinin 10 μg/ml 
Leupeptin 10 μg/ml 
 
5 ´ Sample Buffer (-20oC)  




1% Bromophenol blue 0.0625% 
 
Stacking Gel (2.5 ml/gel)  
0.5 M Tris-HCl, pH 6.8 0.625 ml 
10% SDS 0.025 ml 
30% Acrylamide (37.5:1) 0.3125 ml 
10% Glycerol 0.025 ml 
10% APS 0.0075 ml 
TEMED 0.0025 ml 
Milli-Q H2O 1.563 ml 
 
Running Gel (Western blotting, 10%, 5 ml/gel)  
1.5 M Tris-HCl, pH 8.8 1.865 ml 
10% SDS 0.075 ml 
Silver Staining (Prepare in fresh, 250 ml/gel)  
Fixation Ethanol 100 ml 
 Acetic acid, glacial 25 ml 
 Milli-Q H2O 125 ml 
   
Sensitizating Ethanol 75 ml 
 Sodium thiosulfate (5% w/v) 0.5 g 
 Sodium acetate 17 g 
 Milli-Q H2O 175 ml 
   
Silver reaction Silver nitrate (2.5% w/v) 0.625 g 
 Milli-Q H2O 250 ml 
   
Developing Sodium carbonate 6.25 g 
 Formaldehyde (37% w/v) 100 µl 
 Milli-Q H2O 250 ml 
   
Stopping EDTA-Na2 ´ H2O 3.65 g 
 Milli-Q H2O 250 ml 
 190 
30% Acrylamide (37.5:1) 2.465 ml 
10% Glycerol 0.075 ml 
10% APS 0.0385 ml 
TEMED 0.00365 ml 
Milli-Q H2O 3.05 ml 
 
10 ´ Transfer Buffer for PVDF (4oC)  
Tris-HCl, pH 7.5 1 M 
Glycine 1.92 M 
 
10 ´ TBS (Tris-buffered saline)  
Tris-HCl, pH 7.5 1 M 
NaCl 9% 
 
TTBS (Tris-buffered saline-Tween 20)  
10 ´ TBS 1 ´ 
Tween 20 0.05% 
 
AP (Alkaline phosphatase) Substrate Solution (7.5 ml/blot)  
25 ´ AP buffer 300 µl 
BCIP 75 µl 
NBT 75 µl 
Milli-Q H2O 7.05 ml 
 
PBS (Phosphate-buffered saline, pH 7.2, per 1L)  
NaCl 8 g 
Na2HPO4 1.16 g 
KH2PO4 0.2 g 
KCl 0.2 g 
 
Coating Buffer (Mouse TNF ELISA Set)  
0.2 M Sodium phosphate, pH 6.5  
To prepare 1L:  
Na2HPO4 11.8 g 
NaH2PO4 16.1 g 
 
Coating Buffer (Mouse IFN-g ELISA Set)  
0.1 M Sodium carbonate, pH 9.5  
To prepare 1L:  
NaHCO3 7.13 g 
Na2CO3 1.59 g 
 
Assay Diluent (ELISA)  
PBS with 10% FBS (heat-inactivated)  
 
Mouse Sensitization Solution  
OVA (grade V) 20 µg 
Al(OH)3 4 mg 
Saline 0.1 ml 
 
